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Abstract 
Muscular dystrophy is a collective group of genetic disorder that results in 
progressive wasting of skeletal muscle. Dysferlin, the gene responsible for Limb 
Girdle Muscular Dystrophy type 2B (LGMD2B) and Miyoshi Myopathy (MM) was 
found to be a member of a newly identified protein family named the ferlins. 
Recent work has suggested that dysferlin is necessary for efficient calcium 
sensitive membrane resealing therefore is involved in membrane repair, a 
mechanism which if defective results in progressive muscle wasting. In this 
project, the involvement of other genes that could possibly be associated with 
muscular dystrophy is investigated. 
Myoferlin, a member of the feriin protein family is highly homologous to dysferlin 
and is also a plasma membrane protein with six C2 domains and a C-terminus 
transmembrane domain. To date no disease has been associated with 
mutations in the myoferlin gene but its high similarity to dysferlin means that it 
could be a potential muscular dystrophy associated gene. 
Results obtained from this study strongly suggest that myoferlin like dysferlin is 
enriched at plasma membrane disruption sites and during myoblast 
differentiation, two processes which involve the fusion of two opposed bilayers, 
a process vital in membrane repair. 
In addition, a fifth member of the feriin protein family is reported in this project 
and the primary results obtained are consistent with it being a potential 
muscular dystrophy associated gene. 
Finally, a group of MM affected families that were previously excluded for 
mutations in their dysferlin gene were analysed for muscular dystrophy 
associated genes other than dysferlin. 
1 Chapter One, introduction 
1.1 Background 
In 1925 it was first suggested that living cells are coated with a bilayer of 
phospholipids (Gorter & Grendel, 1925). The well known ability of phospholipids 
to reseal and fission into smaller membrane bound vesicles in aqueous 
solutions (following thermodynamic principles by removing hydrophobic 
domains from the aqueous environment therefore resulting in an energetically 
favoured molecule) (Tanford, 1973) suggested that the plasma membrane 
would have self-sealing characteristics (Parsegian et al., 1984), which meant 
that today's sophisticated mechanism of plasma membrane resealing following 
disruptions to its integrity was taken for granted and assumed to be a natural 
consequence of the phospholipids' interaction with water. However, we 
understand today that plasma membrane resealing is a complicated process, in 
which many simultaneous processes are needed for successful membrane 
resealing. 
In 1930, Heilbrunn L.V. (Heilbrunn, 1930) described plasma membrane repair in 
sea urchin eggs as 'reactions of superficial precipitation' when large portions of 
the egg's surface were torn off and showed that egg survival depended on Ca^^ 
initiated events. Heilbrunn showed that this 'surface precipitation' does not 
occur in Ca^Vree extracellular environment and termed this reaction as "Ca^*-
dependent response", in which it is absolutely dependent on near physiological 
levels of Ca^^ in echinoderm eggs (Heilbrunn, 1958). 
Other evidence that plasma membrane resealing was a more complex process 
was seen in 1970 with experiments using Physarum (a plasmodial slime mold). 
Sequential electron micrographs were the first to show rapid vesicle-vesicle 
fusion that served to seal plasma membrane lesions (Komnick et al., 1970). 
Evidence that plasma membrane repair was an active process and part of 
normal cell biology was seen in a series of experiments in the 1980 s for 
example the reseating ability for transacted neurons and skeletal muscle cells 
(Casademonte ta l . , 1988,Yawo & Kuno, 1985). 
This early work suggested that cell membrane repair was a widely observed 
phenomenon, suggesting that it was vital for normal cell physiological function. 
Scientists then turned their attention to what these functions may be. 
1.2 Importance of Cell Membrane Repair 
Cells of a mammalian body undergo cell membrane damage routinely as a 
result of exposure to mechanical forces. In order for cells to survive a plasma 
membrane disruption, developing a rapid resealing mechanism is vital, or 
othenwise small mammalian cells undergo apoptosis if not resealed within - 1 5 
seconds (Miyake & McNeil, 1995,Steinhardt, 1994). 
Cell death as a result of failing to reseal (Lemasters et al., 1987) is thought to 
be due to diffusion mediated Ca^" entry down by a 10" concentration gradient 
(from the extracellular environment to the intracellular environment) that 
results in a rapid but transient increase in intracellular Ca^"" (McNeil et al., 1985) 
in addition to the escape of vital cell components. Skeletal muscle, cardiac 
muscle, epidermal cells, endothelial cells, and gut epithelial cells are ail 
examples of cell types known to undergo cell wounding under normal 
physiological conditions (McNeil, 1993). 
So far all cells with the exception of erythrocytes -which lack cytoplasmic 
organelles-, are thought to exhibit complex membrane repair mechanisms. 
Erythrocytes lack cytoplasmic organelles, as explained later in this chapter; this 
is the source of membrane repair. But the resealing in erythrocytes, like in a 
synthetic lipid bilayer is a simple thermodynamic principle, energy stability. The 
process of resealing removes the hydrophobic domains of the phospholipids 
molecules from the aqueous environment (Miyake & McNeil, 1995). 
Cell wounding is thought to be the highest in muscle cells ranging between 5-
30% in cardiac (Clarke et al., 1995) and skeletal muscle (McNeil & Khakee, 
1992) cells respectively under normal physiological conditions, rising to 
approximately 80% in cardiac muscle cells when stimulated (Clarke et al., 
1995). 
Now that the importance of cell membrane repair has been clarified, in the next 
section the mechanisms suggested to be involved in membrane repair and the 
possible sources of resealing the membrane is investigated. 
1.2.1 The Source of Membrane in Membrane Repair 
The fact that stripped cytoplasm in Komnick's experiment (discussed earlier) 
(Komnick et al., 1970) managed to seal off from the external environment meant 
that the source of the new membrane was coming from inside the cells. But 
where these vesicles came from remained a question. Similar to the Physarum 
experiment, when naked cytoplasm of sea urchin eggs was injected to 
extracellular levels of Ca^"^, but still managed to form a cellular barrier, 
possessing cell membrane properties, merely from homotypic fusion events 
suggested the reserve or yolk granule of the egg to be the key source in sea 
urchin eggs (Terasaki et ai., 1997). 
However, later experiments on other cells showed that once a plasma 
membrane disruption is resealed, normally distributed lipids and protein 
components of the plasma membrane are absent from plasma membrane 
disruption sites, indicating the involvement of internal membrane at these sites 
(McNeil et al., 2000). 
As a matter of common sense the ability of the cells to repair the wound 
depends on the wound size. However, the resealing capacity is dependent on 
the local availability of the cytoplasmic vesicles which as explained later, are 
thought to patch with each other to reseal the plasma membrane which resulted 
in the patch hypothesis (McNeil et al., 2000). 
Internal membrane or so called endomembrane is a vital substrate for 
resealing, such that red blood cells, which lack endomembrane, fail to reseal 
efficiently under physiological conditions in which nucleated cells readily reseal 
(McNeil et a!., 2003). Now that the source of the resealing membrane has been 
clarified, how this membrane attempts to reseal the disruption is clarified in the 
next paragraph. 
1.2.2 Patch Hypothesis 
It is suggested that small membrane disruptions are sealed by exocytotic 
(vesicle-plasma membrane) fusion, but relatively large disruptions need 
homotypic (vesicle-vesicle) fusion to form a barrier (Terasaki et al., 1997) or a 
'patch' of membrane be exocytotically joined to the plasma membrane. Later 
this idea was called the "patch hypothesis" (McNeil et al., 2000). 
The Ca^'^-dependent surface precipitation of sea urchin eggs previously 
suggested, was shown to be true when organelles from echinoderm eggs 
expelled from a micro-needle into Ca^^-depleted sea water, clustered or 
"tethered" to each other only to form a vesicular structure in the presence of 
Ca^* (Terasaki et al., 1997). 
It was concluded that echinoderm egg granules show Ca^^-independent 
tethering prior to Ca^^'-dependent granule fusion in vitro, suggesting a role for 
membrane tethers in the production of the previously predicted 'patch' of 
membrane required for membrane resealing (McNeil, 2005). 
The tethering factor is thought to be a multisubunit complex of at least seven 
high molecular weight proteins in which the depletion of the tethering factor 
complex in vitro inhibited tethering (McNeil, 2005). 
However, once the patch of membrane is formed with the aid of tethering 
factors, how this patch of membrane is attached in a three dimensional model is 
the question. Very recently it has been suggested that a model developed to 
explain vacuole fusion in Saccharomyces cervisiae could be applicable to other 
cells too (Figure 1.1) (McNeil & Kirchhausen, 2005). The 'vertex fusion' model 
suggests that the patching membrane created from homotypic vesicle fusion is 
attached to the plasma membrane through several fusion pores or 'vertices'. 
These vertices are the curvilinear zones of outermost contact between two 
docked membranes where the protein machinery of fusion become 
concentrated. The lateral expansion of these fusion pores results in a 
continuous, sealed membrane. The residual plasma membrane is discarded to 
the extracellular space while the wound site is sealed using the lower part of the 
patch. The resulting concave patched domain is restored by cytoskeletal 
Figure 1.1 This sl<etch demonstrates 'Vertex fusion' as a possible plasma 
membrane reseating mechanism in cel ls other than Saccharomyces 
cervisiae. (a) Calcium influx through a plasma-membrane disruption site, (b) A 
membrane patch is assembled through homotypic vesicle fusion, (c) Several 
fusion pores are designated between the membrane patch and the plasma 
membrane, (d) The fusion pores produce a continuous, resealed membrane via 
lateral expansion, (e) While the wound site is resealed using the lower part of 
the patch membrane resulting in a concave, the upper part is no longer needed 
and is discarded to the extracellular space, (f) The cell's normal architecture is 
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re-modelling (McNeil, 2005). The membrane needed for the patch hypothesis to 
be successful needs to be transported to the site of membrane disruption. One 
mechanism thought to be involved in transporting this membrane is exocytosis 
as explained in the next section. 
1.2.3 E x o c y t o s i s M e c h a n i s m & C a l c i u m 
It is thought that membrane resealing by exocytosis follows a pattern similar to 
neurotransmitter release (Steinhardt, 1994). In this theory, quanta of 
neurotransmitters are released from presynaptic terminals as a result of 
electrical excitation which leads to opening voltage-gated calcium channels 
finally resulting in the exocytotic discharge of the neurotransmitters stored within 
synaptic vesicles (Augustine & Charlton, 1986). Synaptic vesicles within the 
interior of the presynaptic terminal are too far away from the plasma membrane 
to participate immediately in neurotransmitter release during an action potential. 
It has been proposed that these vesicles form a reserve pool that will be 
mobilised following the action potential to replenish vesicles that have 
undergone fusion (Pieribone et al., 1995). It is thought that activity-dependent 
mobilisation of vesicles from the reserve pool is controlled by phosphorylation of 
synapsin (a family of proteins that are peripherally associated with the synaptic 
vesicle membrane) by calcium-regulated kinases such as the type II calcium-
calmodulin-dependent protein kinase. Once these vesicles are mobilised, they 
are docked to the presynaptic plasma membrane (Greengard et al., 1993) in a 
GTP-binding protein dependent manner (Ungermann et al., 1998). It has been 
suggested that docked vesicles undergo ATR-dependent priming reactions prior 
to exocytosis via dissociated complex SNARE proteins. These results are 
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supported by the finding that all SNAP (soluble NSF attachment protein) 
peptides that block Golgi vesicle fusion also inhibit neurotransmitter release. In 
addition injecting SNAP or SNF peptides cause an accumulation of synaptic 
vesicles that are apparently docked to the plasma membrane but can not fuse 
proving that SNARE complex dissociation is crucial for the step that follows 
vesicle docking preceding fusion with the plasma membrane (Augustine et al., 
1999). 
Calcium is thought to trigger exocytosis by catalysing vesicle fusion by binding 
to a presynaptic protein. One presynaptic calcium receptor is Synaptotagmin as 
detailed later (Sudhof & Rizo, 1996). It is not clear how vesicle fusion is 
triggered by calcium bound Synaptotagmin but it is thought that its interaction 
with SNARE proteins could be important (Jaiswal et al., 2004). 
In adipocytes, the insulin stimulated trafficking of GLUT4 has several features in 
common with regulated exocytosis pathway of synaptic vesicles. GLUT4, a 
glucose transporter isoform, is highly expressed in adipose tissue and striated 
muscle, and is known to cycle between the plasma membrane and intracellular 
compartments, some of which overlap with the recycling endosome system 
(Pessin et al., 1999). 
Since plasma membrane repair is thought to follow a pattern similar to 
neurotransmitter release, calcium is needed to initiate resealing by acting as a 
second messenger in response to alterations in Ca^* level as low as 1|JM 
(Andrews, 2005) and it is thought that there is a tight association between 
membrane integrity and the extinction of the signal leading to the resealing. 
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One mechanism in which internal membrane is transported to the external 
environment for resealing is exocytosis. Indeed, blocking fusion events using 
botulinium neurotoxins B and A, which are proteases that are thought to 
specifically target and thereby inactivate members of the SNARE family of 
proteins required for exocytotic events, inhibit wound resealing in both sea 
urchin eggs and fibroblasts proves the necessity of exocytosis for wound 
healing. 
Membrane repair was also inhibited by the block of Ca^Vcalmodulin kinase. 
Ca^Vcalmodulin kinase regulates exocytotic vesicles during synapsis, and is 
also shown to be involved in the regulation of kinesin which is required for 
outward-directed transport of vesicles (Steinhardt, 1994). 
Wound induced exocytosis was also demonstrated in bovine endothelial cells 
and 3T3 fibroblasts. Exocytosed vesicles were predicted to be 
endosome/lysosomes based on labelling by lipophilic fluorescent dye. These 
vesicles were abnormally abundant within seconds surrounding a wound site 
(Miyake & McNeil, 1995). This confirmed that plasma membrane disruptions are 
resealed by an exocytosis based mechanism, in which exocytosis was 
proportionate to the wound induced. In addition, those vesicles released from 
wounded cells in Ca^'^-free media were two times higher that that released from 
cells wounded in Ca^^-medium, resulting in a proportionate cell death (Miyake & 
McNeil, 1995). 
The dependency of successful membrane resealing on Ca^" was also shown 
when sea urchin eggs were subjected to relatively large wounds in the presence 
of membrane impermeable dextran and Ca^"", cells did not show any uptake of 
dextran indicating rapid wound healing (within seconds). In contrast when this 
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process was repeated in the absence of Ca^^ dextran was detected inside the 
cell in addition to continuous leakage of the cytoplasm indicating the failure to 
reseal in the absence of Ca^"^ (Terasaki et al., 1997). 
This proved that Ca^"^ is needed for successful wound induced exocytosis. This 
also proves that wound healing involves Ca^"'-dependent formation of a 
membrane barrier rather than a dense precipitation of proteins and previously 
thought (Terasaki et al., 1997). 
In fact, repeated membrane disruption shows long term potentiation of Ca^"^-
regulated exocytosis, which is directly proportionate to faster membrane repair. 
In 3T3 fibroblasts, if a second wound is induced on the same location of a 
previously resealed wound, the second wound reseals more rapidly resulting in 
approximately twice as much exocytosis (Togo et al., 2003). This response is 
Ca^"^ and PKC (protein kinase C) -dependent. PKC's kinase activity is 
necessary in Golgi vesicle formation, such that a PKC inhibitor (Ro 31-8220), 
results in the inhibition of vesicle formation in the Golgi apparatus. The PKC 
inhibitor, or the addition of BFA (Brefeldin A), a fungal metabolite that inhibits 
the formation of vesicles at the Golgi apparatus, did not disturb membrane 
repair in the first wound, but inhibited membrane repair at the second wound, 
suggesting the newly derived vesicles from the Golgi apparatus are used for the 
repair of multiple wound sites rather than endocytotic compartments (Togo et 
al., 1999). 
This potentiation of exocytosis is shown to be PKA (protein kinase A) 
dependent as well, in the early stages post injury (few minutes) , leading to 
protein synthesis in the intermediate stage post injury (approximately 3 hours) 
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and depends on the activation of cAMP response element binding protein 
(CREB) in the 24 hours post injury (Togo et al., 2003). 
One purpose of vesicle exocytosis during wound resealing is to reduce surface 
tension by the addition of new membrane. When chemicals known to reduce 
surface tension such as cytochalasin D were added to cells, membrane 
resealing was facilitated, although the amount of exocytosed vesicles was 
affected adversely in a slight manner, suggesting the compensation of reduced 
surface tension for exocytosis (Togo et al., 2000). 
It was later shown that exocytosis precedes reduced membrane tension and 
that when cells are wounded twice; the rate of decrease in membrane tension at 
the second wound was approximately 2.3 times faster than that of the initial 
wound, a process inhibited by the induction of BFA. Furthermore, membrane 
tension did not decrease in low Ca^^ solution, thus inhibiting membrane repair 
(Togoe ta l . , 2000). 
1.2.4 L y s o s o m a l E x o c y t o s i s 
The theory of those exocytotic vesicles being endosomes/lysosomes predicted 
by Miyake et al. (Miyake & McNeil, 1995) was shown to be true in fibroblasts 
and epithelial cells during the protozoan parasite Trypanosoma Cruz/ invasion. 
Lysosomes in the host cells were mobilised to the entry site to gradually allow 
fusion with the plasma membrane (Rodriguez et al., 1996). Further more, CHO 
cells with increased cell surface expression of rat lysosomal membrane 
glycoprotein Lamp-1 made them up to five times more susceptible to parasite 
invasion, but a mutation in critical residues in the lysosome-targeting motif of 
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Lamp-1 abolished the facilitated invasion of the parasite. In addition this 
facilitated invasion was nnicrotubule dependent, such that pre-treatment of cells 
with microtubule destabilising agents such as nocodazole reduced the 
susceptibility to parasite invasion considerably (Kima et a!., 2000). 
This process is Ca^^'-dependent lysosomal exocytosis. It is Ca^*-dependent 
since depleting the intracellular Ca^^ in the host cell blocks parasite entry. 
Lysosomal exocytosis was shown in several ways by 1) measuring the release 
of the lysosomal enzyme (3- hexosaminidase, 2) lysosomal tracers released into 
the culture medium , 3) the release of the lysosomal marker Cathepsin D into 
the culture medium and 4) the surface appearance of Lamp-1 in cells with 
elevated intracellular Ca^* induced by the use of ionomycin treatment and 
permeablisation using SLO (Streptolysin O) (Rodriguez et al., 1995). SLO 
permeablisation allows an intracellular and extracellular equilibrium of Ca^^ 
concentration enabling the determination of Ca^* -induced exocytosis threshold. 
Later on this Ca^'^-dependent lysosomal exocytosis was shown to be true in 
other non-secretory cells such as NRK fibroblasts and muscle cells (Reddy et 
al., 2001) and is thought to be temperature and ATP dependent (Rodriguez et 
al., 1997). However, the Ca^'' induced exocytosis of Golgi, ER, early and late 
endosomal vesicles in response to a calcium ionophore has been ruled out 
(Ja iswale ta l . , 2002). 
The process of exocytosis and endocytosis has to be in proportion in order for 
the cell to have a reasonably constant surface area. Since it is known for Ca^* 
to be the control factor of exocytosis, it comes to no surprise that it is indeed 
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needed for endocytosis too (Gerasimenko et al., 1998) although its role is not 
yet fully understood. 
Microinjection of NRK cells with Lamp-1 under normal intracellular Ca^"^ , 
induced the formation of highly homogenous aggregates of individual 
lysosomes which retain their individual dimensions despite being highly 
compact, suggesting they cross-linked through the anti-Lamp-1 tail (Bakker et 
al., 1997). 
However, when intracellular Ca^^ was elevated by Ca^^'-ionophore, ionomycin 
and thapsigargin, an inhibitor of the ER Ca^"" ATPase that triggers a rapid 
release of intracellularly stored Ca^* into the cytoplasm, large Lamp-1-positive 
vesicles were detected, from the fusion of approximately 3-15 individual 
lysosomes (Bakker et al., 1997). 
However, to what extent lysosomes are involved in membrane repair remains a 
question. A recent study suggested that lysosomes only undergo partial release 
of lumenal contents and none of the lysosomal membrane proteins diffuse into 
the plasma membrane and instead remain near the site e f fus ion. This process 
is dependent on the presence of Syt VII, as detailed in the next section (Jaiswal 
e ta l . , 2004). 
Another study showed that pre-treatment of cells with a new, unnamed drug 
that specifically blocked exocytosis of lysosomes did not affect wound healing 
(Meldolesi, 2003). This is supported by the fact that ionomycin induced 
lysosomal exocytosis takes approximately one minute or more, while plasma 
membrane repair takes seconds (Togo et al., 2003). In addition, a special clone 
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of PC 12 cells that are deficient in lysosomal exocytosis can still reseal plasma 
membrane disruptions(Borgonovo et al., 2002). 
Vacuolin-1 is a member of vacuolins, molecules known to induce homotypic 
fusion of endosomes and lysosomes to form vacuoles in different cells. 
Cerny et al (Cerny et al., 2004) showed that the induction of vacuolin-1 halted 
the release of p-hexosaminidase and blocked the Ca^^-dependent surface 
appearance of Lamp-1 in response to ionomycin treatment, while a more recent 
paper challenges these results and suggests that vacuolin-1 does not hinder 
lysosomal exocytosis despite morphological alteration in response to wounding 
or treatment with a calcium ionophore (Huynh & Andrews, 2005). 
However, the inhibitory effect of vacuolin-1 on Ca^'^-dependent lysosomal 
exocytosis reported by Cerny et al (Cerny et al., 2004) did not affect the 
exocytosis of enlargosomes (novel vesicles expressing the protein AHNAK, see 
dysferlin associated proteins), or the resealing efficiency of those cells. 
This data suggests the possible involvement of lysosomes in membrane repair 
and that they are not the only source of membrane during resealing, leaving the 
field open to other players such as novel vesicles named enlargosomes (as 
explained later). 
Synaptotagmin VII, a member of the Synaptotagmin family is ubiquitously 
expressed and is localised on the membrane of lysosomes and is thought to 
have a role in lysosomal exocytosis as explained in the following section. 
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1.2.5 S y n a p t o t a g m i n s 
Synaptotagmins (Syt) have at least 12 identified isoforms, characteristically 
sharing a unique NH2- terminal ecto domain and highly conserved cytosolic 
domain containing two Ca^^-binding C2 domains , C2A and C2B (Schiavo et al., 
1998) 
Some synaptotagmins are expressed in neuronal tissue, they are found in the 
transmembrane protein of synaptic vesicles of the brain (Syt I & II & III) (Sugita 
et al., 1996) and secretory granules of pancreatic (3-cells (Syt III) or ubiquitously 
expressed in several tissues (Syt VI, VII, VIII) (Craxton & Goedert, 1999,Li et 
al., 1995). 
Syt VII in particular shows Ca^'^-dependent syntaxin binding in a relatively low 
micromolecular range (Li et al., 1995) making it a suitable candidate for 
involvement of lysosomal exocytosis. In NRK cells, Syt VII was found to be in 
mature lysosomes targeted to vesicles with the luminal domain of Lamp-1 at 
plasma membrane disruption sites. Functional exocytosis assay suggest that 
the C2A domain of Syt VII has a role in calcium regulated exocytosis (Martinez 
et al., 2000). This, in turn, suggests its involvement in plasma membrane repair 
since plasma membrane disruptions in fibroblasts or squid giant axons fail to 
reseal if cells are treated with competitive peptide fragments or neutralizing 
antibodies of Syt VII (Reddy e ta l . , 2001). 
In the presence of Syt VII during exocytosis, the opening of the lysosomal 
fusion pore is restricted geometrically and temporally and lysosomal membrane 
proteins do not diffuse into the plasma membrane; instead they remain near the 
fusion site. This is thought to aid in membrane resealing (Jaiswal et al., 2004). 
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In contrast, in the absence of Syt VII, cells from Syt VII knockout mice for 
example, lysosomes fuse completely and diffuse without restrictions into the 
plasma membrane leaving cells defective in lysosomal exocytosis, membrane 
resealing and less susceptible to T. Cruzi invasion (Chakrabarti et al., 2003). 
These findings have led to the belief that Syt VII acts as a calcium sensor to 
regulate Ca^'^-dependent lysosomal exocytosis rather than a Ca^'^-dependent 
trigger (Jaiswal et al., 2004). 
In the following section, the cytoskeleton and its role in plasma membrane 
repair as a possible transport network for resealing vesicles is investigated. 
1.2.6 C y t o s k e l e t o n 
The cytoskeleton is an extremely complex system. Studies carried out on 
microtubules, intermediate and actin filaments indicate that these filaments 
have a controlling role in cell shape, embryonic development and cell division, 
cell motility and most notably wound healing (Wakatsuki et al., 2001). 
It is thought that the actin cytoskeleton, consisting of constant shifting G-actin 
and F-actin, help to distribute and support contractile stresses from inside or 
outside the cells (Gronewold et al., 1999). This has led to the believe that 
cytoskeletal elements are anchored to the plasma membrane in order to provide 
the necessary support needed (Wakatsuki et al., 2001) in addition to acting as 
rapid transport system needed for resealing (Miyake et al., 2001). 
In resting cells, a layer of filamentous actin forming a cortical barrier is present 
underneath the plasma membrane. Once a cell is wounded, the calcium influx 
results in a local depolymerisation of actin to facilitate membrane fusion events 
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needed for resealing. However, once the membrane integrity is restored, actin 
polymerisation at the wound site is possibly needed for restitution and 
reconstruction of the plasma membrane. This theory was the result of a series 
of experiments carried out in which cells fixed within 15 seconds of inducing 
plasma membrane disruptions were observed to be depleted of F-actin staining 
at the wound site. However, cells fixed after plasma membrane repair (1<T<30 
minutes) characteristically displayed a reproducible intense F-actin staining 
bordering the wound site. The addition of actin-depolymerising agent, DNase l , 
enhanced resealing, while the addition of actin stabilizing agents inhibited 
resealing (Miyake e ta l . , 2001). 
In addition to F-actin, kinesin and myosin are thought to be required for vesicle 
transport too. As expected the inhibition of kinesin and myosin inhibits 
membrane resealing by the lack of delivery of vesicles to the site of membrane 
disruption (Steinhardt, 1994). In sea urchin eggs, confocal studies have 
confirmed the involvement of kinesin and myosin motors in exocytotic-
dependent membrane repair in a two step manner (Bi et al., 1997). 
Microtubules, another component of the cellular cytoskeleton, are also thought 
to have a significant role in overall cellular structure, mobility, vesicle trafficking 
and an involvement in ER and Golgi systems (Cole & Lippincott-Schwar, 1995). 
Another anticipated role for the actin cytoskeleton is the active remodelling 
during the process of exocytosis events carried out in unwounded cells. GFP 
tagging of the F-actin showed that post-lysosomal vesicles stained by dextran 
chasing tend to be weakly associated with actin, and this association in itself 
does not initiate exocytosis. Once the vesicle is docked to the plasma 
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membrane, an actin polymerisation followed by fusion and release of the vesicle 
contents is initiated. This is followed by further polymerisation of actin, and a 
contraction of the actin cytoskeleton associated with the vesicle membrane. 
However, what happens to the vesicle membrane afterwards is still unclear. 
This data has strongly led to the belief that actin polymerisation starts as a pre-
fusion event followed by post-fusion contraction and disassembly (Lee & 
Knecht, 2002). 
This finding in fact supports the previous findings by Miyake et al (Miyake et al., 
2001) indirectly. The post-resealing heavy F-actin polymerisation seen at the 
wound site in wounded cells (Miyake et al., 2001) is explained by the 
polymerisation seen once the vesicle contents have been released i.e. vesicle is 
firmly attached to the membrane therefore the wound has been resealed(Lee & 
Knecht, 2002). However, the F-actin depolymerisation seen by Miyake et al 
(Miyake et al., 2001) immediately before resealing might be explained as an 
emergency response to the induced wound in order to facilitate resealing. 
1.3 Plasma Membrane Repair & Muscular Dystrophy 
The emergence of fine details regarding plasma membrane repair and its 
complex mechanisms only highlights the importance of retaining plasma 
membrane integrity naturally and finding therapeutic methods to do so in 
diseases that fail to restore plasma membrane lesions. One disease falling 
under this category of particular interest is muscular dystrophy, to be more 
specific dysferlin deficient muscular dystrophy, MM and LGMD2B. 
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Skeletal muscle cells in mammals are large cells that are frequently subjected 
to plasma membrane disruptions as a result of the mechanical activity of the 
organism. Myogenesis, the process of new muscle formation consists of two 
stages; primary and secondary (as reviewed by (Ontell et al., 1988)). In studies 
of embryonic mouse development, newly formed myofibres were observed as 
early as 14 days post conception, followed by growth through fusion of newly 
formed myoblasts to existing myotubes. This is termed primary myogenesis 
followed by secondary myogenesis using previously formed myotubes as a 
back-bone (Ontell et al., 1988). 
The maintenance of muscle after embryonic development exploits a different 
process. A pool of undifferentiated myogenic precursor cells named satellite 
cells located beneath the basal lamina that surrounds the myofibre are the 
progenitor cells in adult muscle which undergo asymmetrical division to produce 
myoblasts to proliferate following a muscle injury (Mauro, 1961,Schmalbruch & 
Lewis, 2000). This activation and proliferation of satellite cells is thought to be 
largely, if not entirely, responsible for the remarkable capacity for efficient repair 
and regeneration of damaged skeletal muscle, with the generation of large 
numbers of new myoblasts which then either undergo myoinitiation or 
myoaugmentation (the process of myoinitiation and myoaugmentation is 
explained in section 1.6.3) (Pena et al., 1995). 
The terminal differentiation of mammalian muscle cells involves dramatic 
changes in sub-cellular architecture and cell morphology. One key change is 
microtubule reorganisation, resulting, in turn, in the reorganisation and 
redistribution of the Golgi complex and other cellular organelles (Bugnard et al., 
2005). 
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The levels of ceil wounding in skeletal muscle ceils are the highest between the 
rest of the cells studied, for example the epithelial, endothelial, cardiac, etc 
reaching up to 30% under normal physiological conditions, correlating with the 
level of mechanical stress imposed on these cells (McNeil & Steinhardt, 1997). 
At this rate of plasma membrane disruptions replacing skeletal muscle cells as 
a result of injury as opposed to repairing them is not an option because simply it 
is too costly for the organism in terms of energy. 
Cell wounding is defined as a survivable plasma membrane disruption, marked 
by uptake of a membrane impermeable substance (McNeil, 2002). There are 
some cases were the extent of damage to the cells is simply un-repairable and 
cell death is inevitable. An example of this case is seen in Duchenne muscular 
dystrophy (DMD). In this type of muscular dystrophy, as well as mdx mice (mdx 
mice are dystrophin deficient and is a model for DMD) , the muscle cells are 
fragile and easily injured by normal contractions of the muscle as a result of the 
lack of dystrophin protein (Hoffman & Kunkel, 1989) in the dystrophin-
dystroglycan complex (DGC). Dystrophin is a mechanical stabiliser of the 
myofibre plasma membrane and regulator of intracellular calcium homeostasis 
(Clarke et al., 1993). Therefore cells lacking dystrophin have an unstable DGC. 
The role of DGC is to transmit forces generated inside the muscle cell by sub-
sarcolemmal cytoskeleton to the collagen fibres of tendons i.e. the extracellular 
environment (Clarke et al., 1993). Upon failure to do so because of the unstable 
DGC, muscle cell loss outweighs cell repair and a vicious cycle of muscle 
wasting is seen (McNeil & Terasaki, 2001). 
On the other hand, dysferlinopathic muscle seen in two distinct types of 
muscular dystrophy, Miyoshi myopathy (MM) and limb-girdle muscular 
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dystrophy 2B {LGMD2B) as a result of a mutation in the dysferlin gene possess 
a stable DGC suggesting a different mechanism to that of DMD/ mdx mice. In 
dysferlinopathic muscle it has been shown that muscle wasting is a result of 
defective membrane repair (Bansal et al., 2003). As detailed later in this 
chapter, dysferlin deficient muscle fibres are defective in calcium dependent 
sarcolemmal resealing, associated with sub-sarcolemmal accumulation of 
vesicles at the wound site when compared to wild type muscle fibres which 
reseal effectively in the presence of calcium and show dysferlin enriched 
membrane patches in response to injury as explained in details later in this 
chapter (Bansal et al., 2003). Therefore, defective membrane repair is another 
mechanism leading to muscle wasting i.e. muscular dystrophy. 
1.4 Miyoshi Myopathy 
1.4.1 Background 
Miyoshi Myopathy (MM), a distal progressive muscular dystrophy inherited as 
an autosomal recessive disorder, was first described in Japan by Miyoshi et. al. 
(Miyoshi et al., 1986) and after that most cases were reported in Japan. But 
since then it has been found to be more frequent outside Japan than previously 
thought. 
MM has an early adult onset between ages 15-25, (Barohn et al., 1991,Miyoshi 
et al., 1986) with the first prominent symptom of atrophy of the calf muscles 
resulting in patients unable to stand tip-toe, in addition to up to 150 times 
creatine kinase elevation above the normal level (Barohn et al., 1991). 
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Muscle biopsies from MIVl patients tend to show a wide range of abnormalities, 
such as changes in fibre size, nucleation, degeneration and regeneration, 
fibrosis and architectural change (Linssen et al., 1997). 
MM was locus mapped to chromosome 2p12-14 (Bejaoui et al., 1998) at the 
same location to which the gene for a proximal limb-girdle muscular dystrophy 
termed LGMD2B (Passos-Bueno et al., 1995) and a distal myopathy with 
anterior tibial onset termed DMAT . MM, LGMD2B and DMAT share most 
symptoms except that MM affects the distal muscles, LGMD2B affects the 
proximal muscles and DMAT starts in the anterior tibial muscles and rapidly 
progresses to the proximal muscles (Ilia et al., 2001,Liu et al., 1998). 
In two large families both clinical phenotypes MM and LGMD2B occurred in 
siblings carrying the same haplotypes (Weiler et al., 1996). This was later 
shown to be true when native relatives of a Canadian family with the exact 
same missense mutation in dysferlin gene, which probably had the same origin, 
expressed both MM and LGMD2B, suggesting the involvement of modifier 
genes in the phenotypic expression of these two types of muscular dystrophy 
rather than an allelic diversity (Weiler et al., 1999). 
The MM/ LGMD2B gene was cloned by constructing a 3Mb PAC (P1 derived 
Artificial Chromosome) contig spanning the entire candidate region (Liu et al., 
1998) to which candidate genes were mapped prior to mutational analysis (Liu 
e ta l . , 1998). 
As a result, five skeletal muscle ESTs mapped to this narrowed down region 
corresponding with five candidate genes (Liu et al., 1998). Analysing one of the 
ESTs with a strong skeletal muscle signal on a Northern blot led to identifying 
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a 6.243 Kb ORF sequence corresponding to the dysferlin gene (Liu et a!., 
1998). 
Further genetic analysis revealed that identical mutations in dysferlin in one 
family resulted in both the MM and LGMD2B phenotype (Liu et al., 1998). So far 
multiple mutations have been detected in the dysferlin gene and there appears 
to be no mutation hotspots in the gene nor genotype-phenotype correlations 
(Aoki e ta! . , 2001). 
Following the cloning of the dysferlin gene a study carried out by Linssen et al 
(Linssen et al., 1998) was conducted investigating the genetic heterogeneity of 
MM in four Dutch families displaying the MM phenotype and large enough to 
conduct linkage analysis. Haplotype analysis using microsatellite markers 
mapping to the dysferlin locus revealed no evidence of linkage in three of the 
four families to the dysferlin locus. Therefore a genome wide screen was 
undertaken in these families and in two of these families (F I and F II) showed a 
tentative linkage to the chromosome 10 marker, D10S2325. Additional 
chromosome 10 markers (D10S189, D10S1412, D10S172, D10S547, 
D10S570, D10S674, D10S191 and D10S1423) were used to confirm this result 
(giving lod scores of 2.578 at 9=0) (Linssen et al., 1998). This potential second 
locus for MM was designated MMD2 locus spanning a 23cM region on 
chromosome 10 (containing approximately 151 genes as estimated by NCBI 
Map viewer program). The fourth family appears not to be linked to either 
chromosome 2 or 10. 
This genetic heterogeneity seems to coincide with the clinical heterogeneity 
seen in MM patients in general in terms of onset and muscular atrophy although 
non-dysferlin-linked MM shows identical clinical features as the dysferlin linked 
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MM such as predominant involvement of the distal musculature and high level 
of serum creatine kinase (Linssen et al., 1998). 
However, these studies were carried out on unrelated families with only two 
affected subjects in each family in addition to the lack of samples from the 
deceased subjects which might have contributed to not obtaining very 
significant statistical scores. As a result the results obtained from this study 
needs to be further investigated. 
1.4.2 Animal Models of Dysferlinopathy 
SJL mice are known to be natural models for autoimmune diseases, 
inflammatory muscle disease in 100% of the population in addition to other 
abnormalities (Bernard & Carnegie, 1975,Rosenberg et al., 1987,Weller et al., 
1997). 
Further studies on SJL mice showed that they are natural models for 
progressive muscular dystrophy in which histopathological examinations 
showed muscle degeneration and regeneration accompanied by fibrosis, fat 
replacement and inflammation of the proximal muscle groups affected more 
severely than distal muscles. These symptoms turned into full-scale myopathy 
by 6-8 months of age and were inherited as an autosomal recessive trait 
(Bittner et al., 1999). Genetic studies confirmed the mutation of the SJL-
dysferlin gene located on the mouse chromosome 6, the mouse homologue to 
the human dysferlin gene mutated in MM and LGMD2B (Bittner et al., 1999) 
Genetic studies showed that in SJL mice, a 141 bp deletion in the genomic 
sequence (Bittner et al., 1999) results in exon skipping, leaving the cDNA with a 
171 bp (57 amino acids) inframe RNA deletion, resulting in partial removal of the 
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fifth C2 domain (C2E) (Vafiadaki et al., 2001). The C2E domain is highly 
conserved in different ferlins suggesting its functional significance. Therefore, its 
deletion is thought to have a huge impact on the proteins' stability (Vafiadaki et 
al., 2001). 
Like the human dysferlin gene, the mouse dysferlin also has six C2 domains, 
which share a high homology at the C2E (100% identical) and the C2F (96% 
identical) (Vafiadaki et al., 2001). 
The SJL-dysferlin mutation was also confirmed by immunocytochemical studies, 
where dysferlin expression using NCL-Hamlet (explained later) antibody in SJL 
mice was reduced by approximately 85% compared to control mice and human 
samples (Bittner et al., 1999). SJL mice are reported to have up-regulated S100 
Ca^'^-binding protein (Suzuki et al., 2005) and MHC-I expression (Kostek et al., 
2002) and down-regulated intracellular protein traffic-associated proteins 
(Suzuki e ta l . , 2005). 
In a recent study, two additional mouse models of dysferlin muscular dystrophy 
were characterised. One mutant was generated by targeted gene inactivation at 
the C2E domain, and other mutant is a naturally occurring inbred strain, with a 
retrotransposon insertion in the fourth intron of the dysferiin gene, named A/J 
mice (Ho et al., 2004). A/J mice are natural models for lung cancers and 
different immunology-related diseases (Resting, 1969). 
Despite differences in the dysferlin disruption, both strains of mice showed 
typical symptoms of dysferlin deficiency at histopathological level, in addition to 
phenotypic differences, elevated CK, loss of sarcolemmal integrity, thickening of 
basal lamina, sub-sarcolemmal vesicle accumulation similar to those seen in 
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human dysferlinopathic muscle. The most notable difference between A/J, 
dysferlin -/- and SJL mice was the lack of severe aggression observed in SJL 
mice (Ho et al., 2004). 
As explained earlier, MM and LGMD2B is a result of mutations in the dysferlin 
gene. Dysferlin belongs to a newly identified protein named the ferlins. In the 
coming section, this protein family, its subgroups and few interacting proteins is 
studied in deta i l 
1.5 The Ferlins 
The ferlin protein family is a new protein family that is still expanding with new 
members being added. The first member to be discovered was dysferlin (Bashir 
et al., 1998,Liu et al., 1998) and its C-elegans homologue fer-1 (Bashir et al., 
1998), followed by otoferlin (Yasunaga et al., 1999), myoferlin (Britton et al., 
2000,Davis et al., 2000), and fer1L4 (Doherty & McNally, 2003). Later on the 
discovery of a fifth ferlin protein named fer l L5 is reported. 
All the ferlins characteristically share multiple C2 domains and a C-terminal 
transmembrane domain, which seems to be highly conserved (Figure 1.2) 
(Bansal & Campbell, 2004). 
Proteins with C2 domains mostly are involved in signal transduction or 
membrane trafficking, since C2 domains are known to bind calcium and 
phospholipids. C2 domains consist of two four-stranded p-sheets, where 3 
loops at the top and 4 loops at the bottom connect the 8 P-strands. Calcium 
binding is thought to occur at the top three loops depending on their ability to 
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Figure 1.2 This figure shows the ferlin protein family alignment. 
Figure taken from Mc Neil et al (McNeil & Kirchhausen, 2005) 
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act as electrostatic switches without needing major conformational changes. C2 
domains exist in two topologies, with the major difference in the localisation of 
the C and N-termini, top or bottom. It is not clear why different topologies exist 
but it is thought that the topology affects the relative orientation of a C2 domain 
in respect to the neighbouring domains (Rizo & Sudhof, 1998). 
The human and mouse dysferlin genes are 90% identical especially in the last 
two C2 domains (Britton et al., 2000). Dysferlin is 27% identical and 57% similar 
to the C-elegans fer-1 protein (Liu et al., 1998). In C-elegans spermatogenesis, 
the process of haploid spermatid maturation involves the fusion of the large 
vesicular membranous organelles with the spermatids plasma membrane to 
achieve directed surface membrane flow with the aid of extended 
pseudopodium. When the gene fer-1 is mutated, although mutant spermatids 
appear normal they are defective for membranous organelle fusion and fail to 
orient correctly at the plasma membrane, which led to the suggestion that 
dysferlin might have a role in plasma membrane fusion events (Achanzar & 
Ward, 1997). 
1.6 The Ferlin sub-groups 
Renting et al (Renting et al., 2001) used the Prospero algorithm to perform self-
comparisons of all the predicted Drosophila melanogaster gene products to 
search for similarities across repetitive amino acid sequences. This resulted in 
discovering a domain of unknown function that was homologous to two domains 
in dysferlin. This domain was named the DysF domain. The two copies in 
dysferlin are not tandemly repeated but rather inserted within each other, a rare 
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evolutionary case which might reflect constraints on binding sites (Ponting et al., 
2001). Consequently the DysF domain was divided into two parts: the N-
terminal region, named DysF-N region and the C-terminal DysF-C region 
characterised by a stretch of arginine rich sections (NCBI). 
The DysF domain is also present in fungal, worm and rodent genomes. One 
example is the Pex23p yeast protein (Brown et al., 2000). 
According to the possession of the DysF domain, the ferlin protein family has 
been divided into two subcategories, the DysF ferlins consisting of dysferlin, 
myoferlin and FER1L5 and the non-DysF ferlins consisting of otoferlin and 
FER1L4 as detailed later. 
1.6.1 Dysferlin 
The dysferlin gene encodes a protein of 2080 amino acids producing in a 230 
KDa protein consisting of six C2 domains. 
The dysferlin gene has a single C-terminal transmembrane domain and is a 
type II transmembrane protein, in which the N-terminus end and most of the 
protein is located within the cytoplasm. This was later confirmed by immunogold 
cytochemistry that indeed 78% of the dysferlin antibody epitope located inside 
the cell (Anderson et al., 1999). 
The dysferlin monoclonal antibody, NCL-Hamlet, was designed to an epitope 
near the C-terminal transmembrane domain (amino acids 1999-2016). It detects 
a signal on western blots from skeletal muscle of all mammals studied but not 
from birds (Anderson et al., 1999). Dysferlin tends to show ubiquitous 
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expression in different tissues and is reported in foetal tissue as early as 5-6 
weeks gestation. 
In wild type muscle fibres , dysferlin is localised in the sarcolemma and thought 
to be in cytoplasmic vesicles (Piccolo et al., 2000). Expression in the basal 
lamina, nuclear membrane and endoplasmic reticulum has not been detected 
(Anderson et al., 1999). A recent study has suggested dysferlin localisation in 
transverse tubule elements and the T-tubule system (Hernandez-Deviez, 2006). 
However, Immunoblotting of human muscle fractions detected distinct dysferlin 
bands in the microsomal, nuclear, mitochondrial and homogenate fractions. No 
signal was detected in the cytosolic fraction, all of which were clearly eliminated 
by immunoadsorption (Matsuda e ta l . , 1999). 
ER/SR's major function is folding, processing and exporting newly synthesised 
proteins. A disturbance in calcium homeostasis is one reason in functional 
disruption or so called stress of the ER/SR. As a response to this stress the ER 
is thought to derive pathological organelles named tubular aggregates (TAs) to 
help in maintaining intra-sarcoplasmic calcium homeostasis. Therefore cells 
possessing TAs are thought to be under stress. 
In a recent study, dysferlin was shown to be expressed in all TAs without 
exception suggesting its localisation in the SR as well as the sarcolemma at 
least in pathological conditions (Ikezoe et al., 2003). 
1.6.1.1 Dysferlin in Myopathies 
As explained earlier, dysferlin deficiency leads to three distinct types of 
muscular dystrophy. 
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Western blot analysis of dysferlinopathy patients revealed a 95% reduction in 
dysferlin expression compared to control and non-dysferlinopathy patients. In 
addition, all control samples had multiple smaller bands below the 230 KDa 
marker, which are thought to be metabolic fragments of the dysferlin protein as 
a result of the long time taken to synthesis such a large protein (Anderson et al., 
1999). These small bands were also missing from dysferlinopathy patients in 
addition to some cytoplasmic staining of dysferlin. 
Dysferlin null mice start to show symptoms of muscular dystrophy as early as 2 
months of age but by 8 months all the pathological characteristics of muscular 
dystrophy were observed such as split fibres and fat replacement. Based on 
experiments carried out on these mice it is suggested that injury and disease 
progression occur at single muscle fibre levels. In addition, in these muscle 
fibres sarcolemmal disruptions are associated with sub-sarcolemmal 
accumulation of dysferlin. Vesicular accumulation of dysferlin in the cytoplasm 
in MM patients and extreme reduction of dysferlin at the sarcolemma support 
these findings (Piccolo et al., 2000). 
It has been shown that successful membrane repair requires the accumulation, 
followed by fusion of vesicles at the wound site (McNeil, 2002,Miyake & McNeil, 
1995,Steinhardt, 1994). Wild type muscle fibres wounded in the presence of 
calcium showed membrane patches enriched with dysferlin at sites of plasma 
membrane disruption and resealed efficiently, while wild type muscle fibres 
wounded in the absence of calcium failed to reseal. Dysferlin null muscle fibres 
showed sub-sarcolemmal accumulation of vesicles at the site of plasma 
membrane disruption and failed to reseal in the presence or absence of calcium 
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(Bansal et al., 2003). The accumulation of vesicles in response to plasma 
membrane disruptions is also reported in fer-1 mutants of C-elegans (Bashir et 
al., 1998). All findings to date suggest that dysferlin is involved in membrane 
repair probably acting as a calcium-dependent sensor that facilitates the fusion 
of readily accumulated vesicles in response to plasma membrane disruption to 
the sarcolemma (Bansal et al., 2003). 
In addition to its similarity to fer-1 and dysferlin's C2 domains being highly 
homologous to the C2A domain of rat synaptotagmin III (Britton et al., 2000), 
these findings lead to the hypothesis that dysferlin is involved in membrane 
repair (Bansal et al., 2003). 
Muscle microarray profiling of dysferlinopathies showed an over-expression of 
genes involved in myogenisis, proteolysis and intracellular protein trafficking, a 
sign of active cycles of regeneration and degradation (Campanaro et al., 2002). 
It has been suggested that patients with dysferlinopathy show an increased 
expression of MHC class I , increased counts of macrophages and T 
lymphocytes tightly adhered to the sarcolemma, which in turn with the basal 
lamina are unusually multilayered and thick, in addition to numerous electron 
dense aggregates of small vesicles thought to be derived from the Golgi 
apparatus (Cenacchi et al., 2005). 
1.6.1.2 Dysferlin Associated Proteins 
In order to understand dysferlin's cellular function, and that of myoferlin-since 
they are highly similar- studying associated or interacting protein can be a 
useful tool. In the next section, some of the proteins known to interact with 
dysferlin in one way or another are detailed. 
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Calpain3 
Calpain3 is the muscle specific member of the Ca^*-activated proteases, and it 
appears to control the expression of muscle specific transcription factors (Prelle 
e ta l . , 2003). 
Dysferlin has been associated with calpain3 in LGMD2A (Cohn & Campbell, 
2000). However, calpainS expression in addition to other DGC proteins like the 
a, p, y, 6, and e- sarcoglycans and dystrophin are thought to be expressed at 
normal levels in dysferlin-deficient muscle suggesting the integrity of the DGC 
(Bansal et al., 2003,Matsuda et al., 1999) and confirming that dysferlin is not an 
integral component of the DGC as suggested in the early days of dysferlin 
(Piccolo et al., 2000). However, in some cases a secondary calpain3 reduction 
has been reported in association with dysferlinopathy (Anderson et al., 2000). 
Caveolin 3 
Caveolins are membrane proteins present in caveolae which are components of 
lipid rafts (Razani & Lisanti, 2001). Lipid rafts are membrane domains rich in 
cholesterol and saturated polar lipids (usually sphingolipids) in a liquid ordered 
state (Megha & London, 2004). Caveolae are named so due to their 
resemblance to 'little caves' on TEM microscopes as a result of their electron 
density (Razani & Lisanti, 2001). Caveolin 3 is a component of caveolae and is 
characteristically expressed in sarcolemma of muscle cells of all types. 
Caveolin 3 expression is elevated during myoblast fusion (Tang et al., 1996). 
Caveolin 3 is also concentrated in the T-tubule system of developing muscle but 
expressed at lower levels in the T-tubules of mature muscle (Parton et al., 
1997). Caveolin 3 is thought to function as a scaffolding protein in the formation 
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of caveolae membranes by interacting and organising lipid and protein 
components of caveolae (Tang et al., 1996). Caveolin 3 null mice are deficient 
in sarcolemmal caveolae but do not show evident clinical symptoms of 
LGMD1C even at old age as seen in humans as a result of Caveolin 3 mutation, 
but they reveal variably sized muscle fibres, necrotic fibres and myopathic 
changes, indicating that Caveolin 3 is needed in skeletal muscle cells for 
caveolar biogenesis (Razani & Lisanti, 2001). Caveolin 3 mutation causes an 
autosomal dominant form of Limb Girdle muscular dystrophy, LGMD1C (Minetti 
et al., 1998). This mutation acts in a dominant negative way, by forcing both 
wild type and mutant caveolin 3 proteins to aggregate in the Golgi apparatus 
(Galbiati et al., 1999). In addition, caveolin 3 expression is normal in 
dysferlinopathy but caveolin 3 deficiency results in the secondary reduction of 
dysferlin (Matsuda et al., 2001). One explanation for this result might be that 
caveolin 3 is well attached to the plasma membrane, therefore not affected by 
dysferlin deficiency, while vice versa is not true for dysferlin (Matsuda et al., 
2001). 
A very recent study has shown that dysferlin and caveolin 3 are both targeted to 
the sarcolemma in mature muscle fibres, although they do not completely co-
associate and in C2C12 myotubes dysferlin and Caveolin3 seem to partially 
colocalise (Hernandez-Deviez, 2006). It was also observed that caveolin 3 or 
caveolin 1 mutants result in the retention of dysferlin in the Golgi complex of 
muscle and non-muscle cells or more dramatically the absence of caveolin 3/1 
impairs plasma membrane targeting of dysferlin. This suggests a vital role for 
Caveolins in post-Golgi trafficking of dysferlin (Hernandez-Deviez, 2006). 
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Annexins 
Dysferlin also interacts in a Ca^* dependent fashion with annexins A l and A2 
whose genes are located on chromosome 9q21.3 and 4q31.3 respectively. 
Annexins in general are calcium and phospholipid binding proteins, predicted to 
have a role in fusion and aggregation of intracellular vesicles in response to 
plasma membrane disruptions, a role in membrane trafficking and 
transmembrane channel activity. But annexin A l and A2 have been shown to 
act as calcium dependent lipid-raft and vesicle aggulators (Lennon et al., 2003). 
Dysferlin was shown to colocalise with both annexins at the sarcolemma in wild 
type muscle fibres by immunohistochemistry but this association was not 
observed in dysferlinopathic muscle. While dysferlin is associated with annexin 
A l in uninjured cells but not in injured ones, annexin A2 seems to be associated 
in both wounded and unwounded cells (Lennon et al. , 2003). Annexins A1 and 
A2 are strong candidates for non-dysferlin linked muscular dystrophy (Lennon 
e ta l . , 2003). 
Afflxin 
Affixin is also named as p-parvin and is a focal adhesion protein that was 
identified through a search for proteins that interact with integrin-linked kinase 
(ILK). The integrin-linked kinase (ILK) is a multi-domain focal adhesion protein. 
It is thought to be involved in regulating cellular signalling, fibronectin matrix 
assembly, survival, and differentiation (Khyrul et al., 2004). Affixin is 
ubiquitously expressed but is especially upregulated in heart and skeletal 
muscles (Matsuda et al., 2005). In normal skeletal muscle, affixin is expressed 
in the cytoplasm and sarcolemma, but co-localises with ILK only at the 
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sarcolemma. A secondary affixin reduction is reported at the sarcolemma of 
dysferlinopathic muscle in humans suggesting close association. But the overall 
protein content was not changed. It is thought that a part of affixin localises to 
the sarcolemma through binding to dysferlin. The C-terminal intracellular region 
of amino acids 1977-1988 (EKKILAGKLEMT) on the dysferlin molecule is 
thought to be the affixin-binding site. However, a change in the overall 
distribution of affixin in some non-dysferlinopathic, dystrophic muscle has been 
reported (Matsuda et al., 2005). 
AHNAK 
Another protein recently raising interest in connection with dysferlin is AHNAK. 
AHNAK was first co-purified with desomosomal component of keratinocytes 
during bovine muzzle epidermis fractionation and was also named desmoyokin 
(Hieda & Tsukita, 1989). Later studies showed that AHNAK is not associated 
with desmosomes (Gentil et al., 2003,Masunaga et al., 1995) and its human 
counterpart is located on the human chromosome 11q12. AHNAK is a large 
protein of approximately 700 KDa composed of a single exon (Shtivelman et al., 
1992). It is composed of a short N-terminus and a nuclear localisation 
phosphorylation site for PKC/PKB and an export signal on its C-terminus 
(Hashimoto et al., 1995,Nie et al., 2000,Shtivelman et al., 1992,Sussman et al., 
2001). 
The intracellular distribution of AHNAK is unique and does not overlap with 
known vesicles. AHNAK's function is not fully understood despite its expression 
in different tissues. It was suggested that in resting cells, AHNAK is localised to 
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the lumen of specific vesicles. These novel vesicles were named enlargosomes 
(Borgonovo et a!., 2002). 
AHNAK lacks a transmembrane domain, therefore its long exposure at the cell 
surface in response to elevated intracellular calcium, differentially induced 
expression and slow post-exocytosis recycling seems to suggest that it is 
dependent on specific interactions with other vesicle components and their 
involvement in cell surface enlargement (Borgonovo et al., 2002) and the 
structural support of the plasma membrane (Gentil et al., 2003) although its 
function is not clearly understood. 
AHNAK can be localised to the nucleus or to the plasma membrane depending 
on extracellular Ca^^ concentration (Hashimoto et al., 1995,Nie et al., 2000). 
AHNAK was found to be predominantly expressed in muscle and cells with 
contractile properties in addition to some epithelial cells, but absent from 
epithelial cells with secretory or absorptive function (Gentil et al., 2003). 
In adult mouse tissue (e.g. muscle and epithelial cells), AHNAK is mainly 
localised to the plasma membrane. Adult mouse tissue AHNAK expressing cells 
are terminally differentiated and do not go through proliferation, indicating that 
AHNAK is anchored to the plasma membrane and might be involved in growth 
arrest of epithelial cells and that membrane targeting of AHNAK is regulated by 
cell density and the formation of cell to cell contacts (Sussman et al., 2001) 
which explains the down regulation of AHNAK in neuroblastoma cells and few 
other tumours (Shtivelman et al., 1992). In cardiomyocytes AHNAK is thought 
to be involved in the regulation of ion-channel activity (Hohaus et al., 2002). 
AHNAK binds S100B (an EF-hand Ca^^-binding protein) in a strictly Ca^^-
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dependent manner, suggesting a regulatory role in Ca^* homeostasis (Gentll et 
al., 2001). 
AHNAK null mice and ES cells showed no difference to wild type mice and 
cells, leading to the conclusion that AHNAK by itself had minimal or no affect on 
cell adhesion, tumorigenisis, proliferation and differentiation or overall mouse 
development leaving the possibility for a compensatory protein with a similar 
function (Kouno et al., 2004). 
AHNAK in epithelial cells in vivo is targeted to the plasma membrane in a Ca^"^ 
dependent fashion. This process is reversible and the disruption of E-cadherin -
mediated cell to cell contacts by low extracellular Ca^"^ results in the dissociation 
of AHNAK from plasma membrane. However, if Ca^"" levels are increased 
AHNAK is targeted again to newly formed cell-cell contact points (Benaud et al., 
2004). AHNAK interacts with annexin2/S100A10 complex at the C-terminus 
domain of AHNAK in epithelial cells. Annexin 2 is thought to play a role in the 
organisation of cholesterol rich membrane microdomains, the connection of lipid 
rafts and actin cytoskeleton and cholesterol mediated adherent junctions form 
S100A10 mediates interaction between AHNAK and annexin 2. The 
AHNAK/annexin2/S100A10 complex is thought to be involved in the regulation 
of the actin cytoskeleton organisation (Benaud et al., 2004). 
Very recently Komuro et al (Komuro et al., 2004) found another similar protein 
to AHNAK expressed in AHNAK-null mice, named AHNAK 2, which needs to be 
investigated further. 
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1.6.2 Otoferl in 
Otoferlin was the second of the ferlin protein family to be identified through 
cDNA derived from total human foetal RNA (Yasunaga et al., 1999). Northern 
blot analysis revealed a signal in heart, placenta, liver, pancreas, skeletal 
muscle, kidney and two variable length transcripts in the brain (Yasunaga et al., 
1999). Otoferlin is thought to exist as two isoforms, long and short. The long 
isoform has six C2 domains with 1997 amino acids producing a 227 KDa 
protein and is expressed in human brain and inner ear hair cells in which a 
mutation causes some cases of an autosomal recessive form of prelingual 
sensorineural deafness, DFNB9 (Yasunaga et al., 1999). The short isoform is 
expressed exclusively in humans with only three C2 domains, as a result of 
alternative splicing and its mutation causes most cases of DFNB9 (Yasunaga et 
al., 1999). Shorter truncated forms of dysfertin and myoferlin have also been 
reported (Davis et al., 2000). 
1.6.3 Myoferl in 
Two years after the discovery of dysferlin, the third member of the ferlin protein 
family was Identified, named myofertin (Davis et al., 2000) or FER1L3 (Britton et 
al., 2000). It was named myoferlin due to its high homology to dysferlin (68% 
similar and 58% identical) and its high expression in cardiac and skeletal 
muscle detected by a specific antibody to myoferlin although low expression 
was also detected in the lung, kidney, placenta and the brain (Davis et al., 
2000). Myoferlin, a 230 KDa protein, maps to chromosome 10q23.3 and also 
contains six C2 domains at amino acid positions 1-85 (C2A), 200-281 (C2B), 
359-458(C2C), 1113-1218(C2D), 1525-1625(C2E) and 1777-1890(C2F) in 
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addition to one hydrophobic C-terminus transmembrane domain (Britton et a!., 
2000). All except one Ca^* binding residue in the C2D and C2E domain in 
dysferlin and myoferlin are identical (Britton et al., 2000). In addition myoferlin 
has an SH3 domain that is thought to mediate interactions with other proteins. 
This domain is not found in dysferlin (Davis et al., 2000). 
The role of myoferlin is unknown. But myoferlin's expression was found to be 
upregulated up to 274% in mdx mice, mdx mice are dystrophin deficient, 
therefore possess an unstable DGC. This suggests a role for myoferlin in 
membrane regeneration or repair or a compensatory role (Davis et al., 2000). 
A recently generated breed of myoferlin null mice showed defects in 
myogenesis, greatly reduced area of individual muscle fibres, resulting in overall 
reduction in cross-sectional area of the whole muscle. In addition these mice 
had reduced muscle mass, resulting in smaller sized mice compared to control 
mice, meaning that myoferl in-null mice are less efficient in myoblast-myotube 
fusion or so called 'myoaugmentation'. Myoaugmentation has been described 
by Doherty et al (Doherty et al., 2005) as the second stage of myoblast fusion in 
which myoblasts fuse with existing myotubes. Myoaugmentation is preceded by 
'myoinitiation' where individual myoblasts start to fuse with each other. Impaired 
skeletal muscle regeneration after cardiotoxin injury, in addition to disorganised 
muscle architecture with fat replacement in post injury muscle, is also seen in 
myoferlin null mice (Doherty et al., 2005). Dysferlin expression did not change in 
injured, control, wild type or myoferlin null muscle. 
During the first 24 hours of differentiation, dysferlin expression is equivalent in 
myoferlin null cells when compared to wild type. Then, it is up-regulated by X1.6 
in myoferlin-null cells after 4 days of differentiation. However, dysferlin is not 
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upregulated in adult muscle fibres (when all of the fusion events have been 
completed) in response to myoferlin deficiency. This might be due to the fact 
that myoferlin is already expressed at low levels in healthy adult mouse tissue 
(Doherty e ta l . , 2005). 
This finding suggests that dysferlin or other ferlins might be able to compensate 
for the loss of myoferlin in the early stages of fusion. 
The fact that loss of myoferlin hinders myogenisis rather than completely 
blocking it and that myoferlin is present in low levels of healthy adult muscle in 
addition to the belated upregulation of dysferlin in maturing myotubes suggests 
that myoferlin through its Ca^^-sensitive phospholipid binding may have a role in 
myoblast-myotube fusion. Both muscle membrane resealing and myoblast 
fusion involve the use of specialised vesicles suggesting the involvement of 
ferlins in muscle fusion events (Doherty et al., 2005). 
1.6.3.1 Myoferlin Cell Biology 
Immunocytochemical studies using the myoferlin antibody, Myof1 showed that 
similar to dysferlin, myoferlin is also localised to the plasma membrane in 
muscle fibres, in addition nuclear localisation is also detected. This unique 
expression might explain the need for two highly similar proteins in the same 
tissues (Davis et al., 2000). Although Matsuda et al. (Matsuda et al., 1999) have 
reported a nuclear and mitochondrial signal in muscle cell fractions by western 
blots using a polyclonal antibody against dysferlin. 
A difference in the level of protein expression and mRNA expression between 
skeletal and heart muscle was detected using Myof1 antibody. This may 
indicate that mRNA expression is not directly proportionate to protein 
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expression and/or that post-translational regulation of myoferlin protein may 
happen (Davis et al., 2000). 
Cell fractionation of skeletal muscle cells into nuclei, light microsomes and 
heavy microsomes revealed that myoferlin was preferentially found in the 
nuclear fraction. Further fractionation showed that myoferlin is heavily 
associated with nuclear membrane and has been associated with plasma 
membranes too (Davis et al., 2000). Later on, Davis et al (Davis et al., 2002) 
reported a vesicular staining in the perinuclear region in addition to general 
cytoplasmic staining. 
Very recently it was shown that myoblasts cultured in vitro show increased 
expression of myoferlin prior and during myoblast fusions in which myoferlin is 
concentrated at cell to cell contact points. In addition, myoferlin is highly up-
regulated after muscle fibres were injured using cardiotoxin (polypeptides that 
cause the depolarisation and degradation of the plasma membrane (Doherty et 
al., 2005). 
In conclusion: 1) myoferlin is highly similar to dysferlin (Davis et al., 2000), and 
dysferlin in known to be a crucial component in membrane repair (Bansal et al., 
2003), 2) myoferlin is highly similar to the C-elegans protein FER-1 (Davis et al., 
2000), and FER-1 is required for the fusion of specialised vesicles, called 
membranous organelles, with the sperm plasma membrane during C-elegans 
spermatogenesis (Washington & Ward, 2006), 3) myoferlin possess a SH3 
domain, thought to be involved in mediating interactions with other proteins 
(Davis et al., 2000), 4) myoferlin is up-regulated in dystrophin deficient mice 
(Davis et al., 2000), 5) myoferlin's C2A domain is highly homologous to the C2A 
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domain of rat synaptotagmin III (Britton et al., 2000) and Synaptotagmins are 
known to be calcium sensors (Jaiswal et al., 2004), 6) a point mutation to the 
C2A domain of myoferlin disrupts calcium induced phospholipid binding 
(Doherty et al., 2005), 7) myofertin is upregulated in differentiating myoblasts 
(Doherty et al., 2005), and finally 8) myofertin null muscle is defective in muscle 
regeneration following an injury (Doherty et al., 2005). 
So far, nothing more is known about myofertin, especially its function, but 
following this evidence presented here leads to the suggestion that myofertin 
has a role in calcium dependent membrane fusion. 
1.6.4 F E R 1 L 4 
Fer1L4 is the newest member of the fertin protein family (Doherty & McNally, 
2003) (although its sequence has not been published yet) . It maps to human 
chromosome 20q11.22 (NCBI). It is thought to consist of 1953 amino acids, five 
C2 domains and a C-terminus transmembrane domain. Initial studies show that 
it is widely expressed and subjected to alternative splicing which as a result 
might produce multiple isoforms. So far its function is unknown (Doherty & 
McNally, 2003). 
1.6.5 F E R 1 L 5 
The characterisation of a fifth member of the ferlin protein family assigned by 
Dr. Bashir's laboratory as FER1L5 is reported here later in the thesis. FER1L5 
maps to the human chromosome 2q11.2. It is thought to consist of six C2 
domains in addition to the conserved C-terminus transmembrane domain and 
shares the highest homology to myofertin as discussed in chapter 3. 
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1.7 Hypothesis 
As explained earlier in this chapter, Dysferlin, myoferlin and FER1L5 are 
members of the DysF subgroup of a moderately new protein family named the 
Ferlins. The ferlins are characterised by their homology to the C-elegans sperm 
vesicle fusion protein FER-1. 
Myoferlin is one of the least well studied proteins of this protein family compared 
to dysferlin. It has not been linked with any human disease yet and not much is 
known about its function. 
The fact that 1) myoferlin and dysferlin are 68% similar and 58% identical 
(Davis et al., 2000), 2) myoferlin is upregulated in dystrophin-deficient mdx mice 
(Davis et al., 2000), 3) dysferlin is upregulated in mature myotubes of myoferlin-
deficient cells (Doherty et al., 2005), and 4) dysferlin is involved in membrane 
repair (Bansal et al., 2003), leads to the hypothesis that 1) the study of 
myoferlin and related proteins would provide a better understanding of 
the cell and molecular biology of myopathy, 2) myoferlin might have a 
role a s a modifier gene in dysferlinopathies, 3) myoferlin might act as a 
compensatory protein in dysferlin deficiencies, 4) myoferlin will have a 
very similar response pattern to plasma membrane disruptions to that of 
dysferlin, 5) myoferlin might have a role in vesic le fusion similar to that of 
dysferlin, and might therefore be essential in membrane repair and other 
cellular functions of muscle cells s u c h as differentiation. 
In addition, ferlins are a highly conserved, expanding protein family mostly with 
unknown functions. This leads to believe in the existence of other un-
identified ferlin proteins. 
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Finally, the genetic heterogeneity of MM and the identification of several MM 
families not linked to the chromosome 2 locus lead to the hypothesis that there 
is at least one more gene responsible for non-chromosome 2-linked MM. 
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2 Chapter Two, Materials and Methods 
2.1 Tissue Culture 
2.1.1 Ce l l Cu l ture 
All tissue culture products were purchased from GIBCO, Invitrogen and all 
procedures were earned out at room temperature unless otherwise indicated. 
C2C12 cells (mouse C3H muscle myoblast, (Yaffe and Saxel 1977)) and HDF 
(Human Dermal Fibroblasts, (Markiewicz, Dechat et al. 2002)) cell line were a 
generous gift from Prof. C.J. Hutchinson (School of Biological Sciences, 
University of Durham). The NRK (Normal Rat Kidney Fibroblasts, (Due-Nguyen 
1966) cell line was a kind gift from GlaxoSmithKline. All cells were cultured in 
DMEM (Dulbecco's Modified Eagles Medium, 1x liquid, with 4500 mg/L D-
glucose, 110 mg/L sodium pyruvate, glutaMAX 1 (L- Alanyl-L-Glutamine 862 
mg/L) ) supplemented with 10% v/v heat inactivated FBS (Foetal Bovine Serum) 
and 1 % v/v 5000 u/ml penicillin/ streptomycin and usually cultured in 75 cm^ 
filter capped flasks (Gnener) unless stated othenwise at 37°C in a humidified 5% 
CO2 incubator. 
The cells were passaged when 80% confluent by washing twice in 10 ml PBS 
for 1 minute then incubating with trypsin-EDTA (Ethylenediaminetetraacetic acid 
,1x liquid, 0.05% v/v Trypsin, 0.53 mM EDTA) for 45 seconds at 37°C. Cells 
were passaged at 1:5 ratios. 
SJL/J myoblasts (passage 1) and the controls, Fw+10j (passage 3 mouse 
myoblasts, extracted from 10 days old female wild type mice) were a kind gift 
from Genethon III, Gene Therapies Research and Applications Centre, France. 
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These cells were cultured in 8 0 . 1 % v/v F-10 nutrient mixture (Ham) media (1x 
liquid, with L-glutamine), 8.9% v/v DMEM supplemented with 10% v/v heat 
inactivated FBS and 1 % v/v 5000 u/ml penicillin/ streptomycin in 25 cm^ filter 
cap flasks (Greiner) at 37°C in a humidified 5% CO2 incubator. 
All cells needed for immunolabelling were cultured overnight on heat sterilised 
13 mm glass coverslips (SLS) in 12 well plates (Griener) at an average density 
of 4x10"* cells per coverslip in 1 ml of culture media. 
2.1.2 Myob las t differentiation 
C2C12 Cells were passaged at a 1:3 ratio and allowed to grow overnight on 
13 mm glass coverslips (SLS) in 12 well plates (Griener) in 1 ml of culture 
media. 
The next day, cells were gently rinsed once with differentiation media (D-MEM 
supplemented with 2% v/v horse serum, 1 % v/v 5000 u/ml penicillin/ 
streptomycin) to remove any traces of FBS, then incubated with 1 ml of 
differentiation media as normal. The cultures were thereafter maintained up to 
14 days by changing the media every 48 hours. 
2 .2 Cell Membrane Wounding Assays 
2.2.1 Ce l l Membrane W o u n d i n g 
C2C12 cells were injured using either a needle or glass beads. These methods 
are standard for wounding cells in published papers and injured cells are 
recognised by their dextran intake (McNeil and Steinhardt 1997). Under normal 
circumstances dextran is membrane impermeable and would only enter the 
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cytosol via endocytosis. When the integrity of the membrane is disturbed i.e. 
wounded, fluorescein dextran uptake is visible under UV light. Therefore 
dextran uptake is an indicator of cell wounding. 
C2C12 cells grown to 80% confluence on coverslips were rinsed once in 3 ml 
PBS for 10 seconds and wounded in the presence or absence of fluorescein 
dextran, using the tip of a 25 Gauge needle (5/8 , VWR) in a grid like pattern 
(Figure 2.1). 
The excess impermeablised dextran was removed by aspiration and cells were 
fixed (see below). Two different fluorescent dextrans were used depending on 
the nature of the subsequent secondary antibody to be used. Cells were always 
wounded in the presence of 5 mg/ml fluorescent Oregon green dextran (10 
KDa, lysine fixable, Molecular Probes, Invitrogen) if cells were to be 
immunolabelled with fluorophore labelled Goat anti rabbit Alexa 546 as a 
secondary antibody, or in the presence of 5 mg/ml fluorescent Texas red 
dextran (10 KDa, lysine fixable. Molecular Probes, Invitrogen) if the cells were 
to be immunolabelled with fluorophore labelled Goat anti mouse Alexa 488 as a 
secondary antibody. 
All secondary antibodies were purchased from Molecular Probes, Invitrogen. 
An alternative method of inducing injury was treating the cells with acid washed 
glass beads (425-600 Mm, sigma). C2C12 cells on coverslips were rinsed once 
in 3 ml PBS for 10 seconds. 500 |jl of 5 mg/ml of fluorescent dextran in 1.0 mM 
Ca^* PBS was then overlaid on them. Approximately 100 mg (400 beads) of 
acid washed glass beads were evenly sprinkled from an Eppendorf tube held 2 
cm above the cells. The dish was gently rocked four times to roll the beads on 
the cells. The cells were then washed with PBS to remove glass beads and 
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Figure 2.1 Induced cell wounding using a needle 
The sketch shows the needle wounding method used to induce injury in this 
study. Cells were scratched using a 25 Gauge needle in cross sections in the 




dextran, followed by formaldehyde fixation, washing, immunolabelling and 
confocal analysis. 
2.2.2 Myotube W o u n d i n g 
Differentiating myoblasts at the phase of interest were wounded using the tip of 
a 25 Gauge needle (5/8 , VWR) in a grid like pattern in the presence of 
membrane impermeable dextran. 
2.2.3 Ce l l Membrane R e s e a l i n g A s s a y 
C2C12 cells were wounded with glass beads as described above in the 
presence of Oregon green dextran except that after injury the cells were rapidly 
washed with 37°C PBS three times (<1 min) and transferred to 37°C cell culture 
media to allow recovery for 5 minutes at 37°C in 5% CO2. After 5 minutes the 
recovery media was removed and cells were incubated for a further 2 minutes 
in media containing 5 mg/ml fluorescent Cascade Blue dextran (lysine fixable, 
10 KDa, Molecular Probes, Invitrogen) followed by formaldehyde fixation. 
Alternatively some cells were not allowed to recover and were exposed to the 
second dextran immediately (1<T<15 sec) before fixation. Using confocal 
microscopy the percentage of cells that had taken up the first dextran and those 
showing the uptake of the second dextran were calculated at 0 and 5 minutes in 
15 microscopic fields (x40 oil lens) where at least 40% of the cells in each field 
were along the injury line. The exclusion of the second dextran reflected wound 
healing (Cerny, Feng et al. 2004). This experiment was repeated twice and the 
average was displayed as a percentage. 
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2.2.4 l o n o m y c i n Induced E x o c y t o s i s 
A rabbit polyclonal antibody was developed against the KIS epitope 
(CKISMPDVDLHLKGPK) of AHNAK (Gentil, Delphin et al. 2003). 
C2C12 cells grown on coverslips were transferred to HMEM at 37°C then 
treated or not with 5 pM ionomycin (free acid, streptomyces conglobatus, 
Calbiochem) in HMEM (HEPES-buffered minimal essential medium) for 5 
minutes at 37°C in 5% CO2 followed by formaldehyde fixation as explained 
previously. Permeablised or non-permeablised cells were then immunolabelled 
with myoferlin and AHNAK antibodies and analysed by confocal microscopy. 
2.3 Immunocytochemistry & Confocal Microscopy 
For Immunocytochemistry, after the desired treatment cells were fixed using 2% 
v/v formaldehyde in PBS, pH 7.4 for 10 minutes, followed by three; two minute 
washes in 3 ml PBS then permeablised in 0.2% v/v Triton x-100 (sigma) in PBS 
for 5 minutes at 4°C, followed by three, five minute washes in PBS. 
Alternatively, cells were fixed in ice-cold (-20°C) neat methanol (VWR) for 10 
minutes followed by three fifteen minute washes in 3 ml PBS. Cells fixed using 
methanol were not permeablised. 
To block non-specific binding, cells were then incubated in blocking buffer (10% 
v/v FBS in PBS) for one hour. Blocking buffer was used for washes, as well as 
diluting primary (if necessary) and secondary antibodies in subsequent steps. 
After one hour incubation in the desired concentration of primary antibody, cells 
were washed for three, fifteen minute washes and finally incubated for one hour 
in the suitable secondary antibody followed by another three, fifteen minute 
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washes. Coverslips were then inverted and mounted on microscope slides 
(Sigma) using IVIowial (appendix 1) containing 2 mg/ml DAP! (4', 6-Diamidino-2-
phenylindole Dihydrochloride, Sigma) and allowed to set at 4°C overnight 
before confocal analysis and imaging. All confocal imaging was carried out 
using a Zeiss 510 confocal scanning microscope x60 oil immersion lens and its 
analysis using Zeiss Meta 510 with scale bar of 20 pm unless otherwise stated. 
Each immunocytochemistry experiment was repeated three times and cells 
were selected for imaging randomly. 
2.4 Gene Expression Assays 
2.4.1 mRNA Extraction 
C2C12 cells were grown on nine 25 cm^ filter capped flasks. The first three 
flasks were harvested the following day at 80% confluence and treated as 
explained later in this section. The remaining six f lasks were induced to 
differentiate by withdrawing growth media and replacing It with differentiation 
media. After 24hrs in the differentiation media three flasks were harvested and 
treated (D1 samples) while the remaining three continued to differentiate for five 
days before harvesting (D5 samples). For each sample the media was removed 
from the flasks and cells were lysed following the recommended procedure for 
attached cell cultures in GenElute Mammalian Total RNA Kit from Sigma. 
In brief, the culture media was completely removed and cells were lysed by 
incubating the cells for two minutes at RT with 500 pi lysis solution (provided) 
supplemented with 1:100 added 2-mercaptoethanol (2-ME) with two intervals of 
shaking. The collected lysates were then filtered using the GenElute filtration 
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column provided and centrifuged at 15000g in Eppendorf 5415R centrifuge for 2 
minutes. 500 pi of 70% (v/v) ethanoi was added to the filtered lysate, briefly 
vortexed and loaded to GenElute binding column, centrifuged at 15000g in 
Eppendorf 5415R centrifuge for 15 seconds. The bound RNA was then washed 
with 500 pi of wash solution 1, centrifuged for 15 seconds at 15000g in 
Eppendorf 5415R centrifuge, then washed with solution 2 and centrifuged for 15 
seconds at 15000g in Eppendorf 5415R centrifuge followed by a second wash 
in solution 2 and centrifuged for 2 minutes at 15000g in Eppendorf 5415R 
centrifuge. 50 pi of Elution buffer was used to elute the bound RNA and 
centrifuged for 1 minute at maximum speed. The last step was repeated twice 
and the concentration of the total RNA was determined using a 
spectrophotometer. 
mRNA was Isolated following the recommended procedure for GenElute mRNA 
Miniprep Kit from Sigma. In brief, 40 pi of DEPC- treated water, 250 pi 2X 
Binding Solution was added to 500 pg of total RNA and vortexed. Then 15 pi of 
oligo (dT) beads were added to the tube and heated for 3 minutes at 70°C, then 
left at RT for 10 minutes and centrifuged at maximum speed for 2 minutes. The 
pellet is then washed in 500 pi of wash solution and transferred to GenElute 
spin filter collection tube and centrifuged at 15000g in Eppendorf 5415R 
centrifuge for 2 minutes. A second wash was performed in the same manner. 
50 pi of pre-heated (70°C) Elution solution is added to the spin filter in a clean 
collection tube and allowed to stand at 70°C for 5 minutes followed by 
centrifugation at 15000g in Eppendorf 5415R centrifuge for one minute. This 
step was repeated one more time. The mRNA was then used for RT-PCR 
reactions as explained in the next section. 
58 
2.4.2 cDNA Generation 
Single stranded cDNA was synthesised from mRNA using Promega Reverse 
Transcription Systenn Kit. For each of the three stages investigated (DO, D1 , 
D5), two random primer and two oligo (dT) primer reactions were generated. 
The final concentration of each reaction component was; 1X Reverse 
Transcription buffer with MgCb, 1 mM each dNTP, 1 U/pl Recombinant Rnasin 
Ribonuclease Inhibitor, 15 U/pg AMV Reverse Transcriptase, 0.5 pg primer 
(Oligo(dT) or random) per pg RNA, 50 ng/pl mRNA, made up to a total of 20 pi 
in DEPC-treated water. The oligo (dT) primer reactions were incubated at 42°C 
for 15 minutes, followed by 95°C for 5 minutes and finally at 4°C for 5 minutes. 
While the random primer reactions were incubated at RT for 10 minutes 
preceding the reverse transcription reaction. The product cDNA was normalised 
using primers designed to amplify the mouse glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) gene. cDNA used in dysferlin, myoferlin, and otoferlin 
expression profiling were provided and normalised using primers designed to 
amplify the mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene 
by G. Marlow from Dr. R. Bashir's group (University of Durham, UK). 
2.4.3 Primer Design 
The Primer 3 programme (Whitehead Institute for Biomedical Research, USA) 
which combines a primer design algorithm with a web-based interface for 
analysis was used to generate primers for mouse genes and primers were 
supplied by MWG Oligonucleotides. The FER1L5 primers were designed within 
the EST sequence while the dysferlin, myoferlin and otoferlin primers were 
designed to the 3 UTR region of the genes. A complete list of primers to 
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dysferlin, myoferlin, otoferlin and FER1L5 is stated in appendix 2. These 
primers were used for subsequent PGR amplifications of these genes. 
2.4.4 PGR and Agarose Gel Electrophoresis 
PGR mix was set up containing 100 ng of DNA (or cDNA), 1X Reaction Buffer, 
1.5/1.8 mM MgGl2, 200 pM of dNTP mixture, 0.25 pM of both fonward and 
reverse primers and 0.5 units of Taq polymerase made up to 30 pi in dH20. All 
reagents were supplied by Promega. The PGR reactions were carried out using 
the Hybaid Omn-E thermal cycler using the following programme: 94°G for 4 
minutes for 1 cycle followed by 35 cycles of 94°G for 30 seconds, 48-50°G for 1 
minute, 72°G for 1 minute and finally at 72°G for 10 minutes for 1 cycle. 
PGR reactions were then analysed by agarose gel electrophoresis. A 1.5% w/v 
agarose powder (Bioline) was dissolved in hot I X TAB buffer and allowed to 
cool. At 60-55°G, 1 pg/ml ethidium bromide was added and thoroughly mixed. 
The gel was poured in a Biorad pre-cast gel trays with a comb and allowed to 
set at room temperature for 30-45 minutes. The gels were then submerged in 
I X TAE buffer. 10 pi of the desired sample (or 5 pi of the 100 bp or 1 Kb DNA 
ladder (Promega)) was mixed with 5 pi loading buffer (appendix 1) and loaded 
into each well. The gel was run at 65 volts (constant power) for approximately 
30 minutes and the DNA was visualized using BioRad Gel-Doc Ultra Violet 
Transilluminator. Samples which demonstrated successful PGR amplification 
were stored at 4°G for subsequent SSGP analysis. 
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2.5 Protein Expression Assays 
2.5.1 Sub-cellular Fractionation 
G2G12 cells for sucrose gradient fractionation were grown to 80% confluence 
(approximately 1 x 10^ cells per dish) in five 10 cm^ round Petri dishes 
(Griener). Gulture media was aspired and each dish was rinsed once in 5 ml of 
PBS, then the cells in the first plate were scraped using a cell scraper (Greiner) 
in the presence of 5ml of HES buffer (appendix 1) supplemented with freshly 
added Gomplete Mini Protease Inhibitors (1 tablet per 10 ml, Roche Molecular 
Biochemicals) and then added to the next plate. After all five plates were 
scraped the cells were transferred to a homogeniser (Borosilicate glass tube, 
stainless steel pestle shaft, VWR) and homogenised by hand by 15 turns of the 
pestle. The homogenate was centrifuged at 19,000g for 20 minutes at 4°G 
(12,500 rpm) in a Beckman centrifuge JA-20 rotor. The pellet obtained from this 
centrifugation (P I ) was retained on ice for the preparation of a plasma 
membrane fraction while the supernatant was used to prepare intracellular 
fractions by centrifugation at 40,000g (18.25 rpm) for 20 minutes at 4°G in the 
Beckman JA-20 rotor. This yields a pellet of high density microsomes (HDM), 
while the supernatant was centrifuged again at 180,000g (33,000 rpm) for 75 
minutes at 4°C in a Beckman Ultracentrifuge in a SW-41 rotor to isolate the low 
density microsomes (LDM). The pellet from the first centrifugation (P I ) is re-
suspended in 0.8 ml HES buffer and layered on to 10 ml of 1.12 M sucrose in 
HES buffer and centrifuged at 100,000g (26,000 rpm) for 60 minutes at 4°G in 
the SW-41 rotor. The pellet from this centrifugation spin yielded the 
endoplasmic reticulum and nuclear (ERN) fraction, while the plasma membrane 
fraction was recovered from the interface between the sucrose layers of the 
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supernatant and washed with 25 ml of HES buffer by centrifugation at 40,000 g 
(18,250 rpm) for 20 minutes at 4°C in a Beckman JA-20 rotor. This pellet is the 
plasma membrane (PL). All membrane fractions were re-suspended in 100 pi of 
HES buffer and snap frozen in liquid nitrogen (Method adapted from (Howland 
1973)). 
2.5.2 Protein Extractions 
For western blots differentiation of myoblasts was carried out in 75 cm^ filter 
capped flasks for larger samples. Cells were harvested at time points of 
interest, DO, D1 , D3, D5, D7 and D14 as follows. Media was removed from the 
cells and rinsed 3 times with ice-cold PBS. 500 pi of RlPA 
(RadiolmmunoPrecipitation Assay, appendix 1) buffer supplemented with 
freshly added Complete Mini Protease Inhibitors (1 tablet per 10 ml, Roche 
Molecular Biochemicals) was added to the flask and cells were scraped using a 
cell scraper (Griener), transferred to a centrifuge tube and allowed to stand on 
ice for 20 min with occasional shaking. The samples were then centrifuged for 
10 min at 13,000 rpm (16,000g) in Eppendorf 5415R centrifuge at 4°C. The 
supernatant was then transferred to a clean tube and protein concentration was 
determined using the Bio-rad assay. 
2.5.3 Protein Quantification 
The protein concentration in each sample was determined using Bradford 
assay as described (Bradford 1976) using BSA (stock solution 0.1 mg/ml) as 
standard. 
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In brief, 1.5 pi of each sample of unknown concentration was mixed with 
798.5 pi d H 2 0 , 200 pi Bradford reagent (Sigma) and incubated at room 
temperature for 20 minutes. The samples were then transferred to polystyrene 
cuvettes (2 ml capacity, light path 10 mm, VWR) and readings were taken using 
an Eppendorf Biophotometer spectrophotometer set at 595 nm (A595). Protein 
concentrations of each fraction were determined and then normalised. 
2.5.4 Western Blotting 
The desired samples were mixed with 5x sample buffer (appendix 1) in the ratio 
of 1:4 v/v and heated at 95°C for 5 minutes. A final concentration of 15 pg of 
protein from the sub-cellular fractionation and 100 pg of protein from the 
myoblast differentiation profile was loaded into slots of a 6% discontinuous 
SDS-PAGE gel. 
A discontinuous SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel 
electrophoresis) gel formed in a mini-Protean 3 gel system (Biorad). Biorad pre-
stained protein size markers were used as standards. The concentration of the 
resolving gel depended on the size of the protein of interest. For analysis of 
myoferlin and FER1L5, a 6% resolving gel (50% polyacrylamide, Prosieve 50 
gel, Cambrex) was used while all other proteins were run on 12% resolving gel 
(50% polyacrylamide, Prosieve 50 gel, Cambrex). A 5% stacking gel (50% 
polyacrylamide) was used throughout (Table 2.1), 
Gels were then immersed in 1x tank buffer (appendix 1) then loaded and run 
with a Biorad power pak 300 at 80V (constant power) for one hour followed by 
100V (constant power) for another hour. The gels were removed from the plates 
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and stained with Coomassie Blue stain (Sigma) by immersing in water for 3 
times, five minutes each then stained with Coomassie blue stain for one hour at 
room temperature and de-stained in water for one hour at room temperature. 
Alternatively the gels were removed from plates and rinsed in transfer buffer 
(appendix 1) for 15 minutes with the nitrocellulose membrane (Protran pore size 
0.45 [im, Schleicher and Schuell Bioscience) and placed into a Biorad Mini 
Trans-Blot Electrophoretic Transfer Cell. A sandwich was formed from the 
cathode in the following order: 1 fibre pad, 2 Whatman 3MM filter paper, gel, 
nitrocellulose membrane, 2 Whatman 3MM filter paper, 1 fibre pad. The 
transfer was carried out at 50\ / (constant power) for two hours in transfer buffer 
and ice pack. After transfer, blots were blocked overnight at 4°C in blocking 
buffer (appendix 1). The next day blots were incubated for one hour in 6 ml of 
the appropriate concentration of the primary antibody (neat or diluted in wash 
buffer, appendix 1). The wash buffer was used for subsequent washes and 
secondary antibody dilution (Table 2.2). 
After washing two times for 5 minutes, one time for 15 minutes, and one time 
for 5 minutes, the blots were incubated in the appropriate concentration of the 
secondary antibody, followed by another two 5 minute washes, one 15 minute 
wash and one 5 minute wash. 
For immunoblotting of FER1L5, gel electrophoresis and transfer were carried 
out as described previously with the following changes. The blots were blocked 
for one hour at RT in blocking buffer composed of 5% (w/v) skimmed MP (milk 
powder) in TBS at pH8. These blots were then washed three times in TBS for 5 
min each and were incubated overnight at 4°C in 6 ml of the FER1L5 D84 
serum, 1:500 diluted in 3% (w/v) MP TBS. The next day blots were rinsed three 
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times in TBS for 5 min each and incubated in 6 ml HRP (Horse Redish 
Peroxidase) conjugated Donkey anti-rabbit, IgG diluted 1:5000 in 3% (w/v) MP, 
0 . 1 % (v/v) Tween20 and TBS for one hour at RT and finally rinsed three times 
for 5 min each in TBS. 
The blots were then treated with mixed equal volumes (2 ml of each) of ECL 
(Enhanced Chemiluminescence) western blot detection reagent (Amersham 
Biosciences) for 10 seconds, and exposed to Amersham Hyperfilm ECL 
autoradiography films (18 x 24 cm, Amersham). The length of exposure was 
empirically determined for each blot but 1 minute exposure was commonly 
used. The fi lms were then hand developed for 30 seconds and fixed for four 
minutes using GBX hand developing kit (Sigma), washed with water and 
allowed to air dry. 
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Table 2.1 S D S - P A G E gel recipes 
This table shows the different components of SDS-PAGE gels. 6% resolving gel 
was used for high molecular weight proteins, e.g. dysferlin, myoferlin while the 
12% resolving gel was proteins with lower molecular weights. In all gels a 5% 
stacking gel was used. 
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Table 2.1 
Gomponents 6% resolving gel 12% resolving gel 5% stacking gel 
Deionlsed water 6.1 ml 4.9 ml 3.75 ml 
Prosieve 50 gel 1.2 ml 2.4 ml 0.5 ml 
1.5 MTrls-HGI, pH 8.8 2.5 ml 2.5 ml -
1.0MTr is-HGI, pH 6.8 - - 0.65 ml 
10% SDS 100 pi 100 pi 50pl 
10% APS 100 pi 100 pi 50pl 
TEMED 4 pi 4 pi 5pl 
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Table 2.2 Antibodies used In this study 
A) A brief summary of the primary antibodies used in this study. (B) A brief 
summary of the secondary antibodies used and their working concentration. 
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Target Antibody 
S p e c i e s / 
clonality 
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Immunocytochemistry 1:100 Serotec 
B) 
Antibody Assay Dilution source 
Alexa 488 goat-anti-mouse immunocytochemistry 1:500 Molecular probes 
Alexa 546 goat-anti-rabbit immunocytochemistry 1:500 Molecular probes 
FITG goat-anti-rat immunocytochemistry 1:100 Dr. A. Smertenko 
Donkey-anti-mouse HRP Immunoblotting 1:5000 Jackson Immunoresearch 
Donkey-anti-rabbit HRP Immunoblotting 1:5000 Jackson Immunoresearch 
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2.5.5 FER1L3 Antibody Immunoadsorption 
The gel electrophoresis and blot transfer were carried out as explained 
previously. 200pl of the 1 mg/ml FER1L3 peptide (C-
GDEPPPERRDRDNDSDDVE, Dr. L Anderson, University of Newcastle Upon 
Tyne) was added to 2 ml FER1L3 antibody diluted in blocking buffer (1:50 
dilution) to bind overnight at 4°C. The antibody / peptide solution (or antibody 
alone in the case of control) was then added to the membrane for one hour at 
RT, followed by secondary antibody and exposure as explained previously. This 
experiment was carried out by Dr. M. Hill (University of Durham, UK). 
2.5.6 FER1L5 Assembly & Analysis 
The locus XM_937145 (GenelD: 90342) maps to the human chromosome 
2q11.2. Using the web based programme SMART (Simple Modular 
Architecture Research Tool, http://smart.embl-heidelberg.de) this protein is 
predicted to have six C2 domains (C2A: 1-98, C2B: 168-264, C2C: 326-423, 
C2D: 1236-1397, C2E: 1717-1816, C2F: 1952-2081 and a C-terminal 
transmembrane domain: 2192-2211) in addition to a nested DysF domain 
(DysFN: 913-963, DysFC: 1040-1078 & 1103-1135). Using the BLAST 
program, FER1L5 was found to be 37.5% identical and 55% similar to myoferlin 
and 37.5% identical and 53% similar to dysferlin. 
The mouse FER1L5 gene is thought to be located on chromosome 1, locus 
XM_136730. It is predicted to have five C2 domains (C2A: 208-327, C2B: 397-
493, C2C: 554-651, C2D: 1828-1927, C2E: 2000-2192), a transmembrane 
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domain (a. a 2305-2327) and a nested DysF domain using the SMART 
programme. 
2.5.7 FER1L5 Antibody Immunoadsorption 
The FER1L5 antibody was raised to peptides TRIEKHQNRQKYGLC and 
LAPLPRPCMSIDFRD (derived from human FER1L5 sequence) in rabbits 
supplemented by a sepharose beads column that had adsorbed 5mg of the 
FER1L5 peptides by CovalAb, UK. 
The FER1L5 affinity purified antibody did not work by immunocytochemistry, 
and gave a very dirty background when used for immunoblotting. As an 
alternative the Day 84 serum was tested for peptide specificity by 
immunoadsorption and used for immunoblotting. 
Day 84 serum was diluted 1:100 in PBS and left in the sepharose beads-
peptide bound column 1 hour at 37°C followed by overnight incubation at 4°C. 
The unbound serum was used for peptide blocking analysis. 
RlPA lysed C2C12 cells were loaded into a 6% discontinuous SDS-PAGE gel in 
the following order: lanes 1 & 4 (23 pg), 2 & 5 (35 pg) and 3 & 6 (57 pg). Gel 
electrophoresis, blot transfer and blocking were carried out as explained 
previously. For primary antibody incubation lanes 1, 2 and 3 were incubated 
with day 84 FER1L5 serum (1:100) while lanes 4, 5 and 6 were incubated with 
unbound FER1L5 serum (1:100) from the incubation in sepharose beads-
peptide bound column followed by incubation in 6 ml HRP (Horse Redish 
Peroxidase) conjugated Donkey anti-rabbit, IgG diluted 1:5000 in 3% (w/v) MP, 
0 . 1 % (v/v) Tween20 and PBS for one hour at RT and finally rinsed three times 
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for 5 min each in PBS. This entire experiment was carried out by Dr. K. Saleki 
(University of Durham, UK). 
2.6 Sub-cellular Localisation Studies 
2.6.1 Latrunculin B Treatment 
C2C12 cells were cultured at a 1:3 ratio and allowed to grow overnight on 
13 mm glass coverslips (SLS) in 12 well plates (Griener) in 1 ml of culture 
media. 
Latrunculin B (LA-B) was a generous gift from Dr. Anderi Smertenko (University 
of Durham, UK). A working stock solution of LA-B was made to 1 | J M diluted In 
culture media. C2C12 cells were then incubated with a wide range of LA-B 
concentrations and time points using concentrations from published data as a 
guideline (Gronewold, Sasse et al. 1999; Wakatsuki, Schwab et al. 2001). 
Cells were incubated with 0 nM, 50 nM, 100 nM, 150 nM, 200 nM and 250 nM 
of LA-B diluted in culture media for 2 hours at 37°C. Treated and control cells 
were then fixed by neat methanol at -20°C for 10 minutes and re-hydrated as 
explained previously. Treated and control cells were then immunolabelled with 
F-actin antibody (1:30) or Myof2 antibody (1:300) and analysed by confocal 
microscopy. 
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2.6.2 Nocodazole Treatment 
1 mg of Nocodazole (Sigma) was solubilised in 1 ml of DMSO. A working stock 
concentration of 1 pg/ml diluted in culture media was used for experiments. 
C2C12 cells were then treated with 0 ng/ml, 15 ng/ml, 25 ng/ml, 35 ng/ml, 50 
ng/ml of nocodazole for 15 minutes at 37°C. The treated cells were then fixed 
with neat methanol as explained previously, immunolabelled with tubulin 
antibody (1:100) and Myof2 antibody (1:300) and examined by confocal 
microscopy. 
2.6.3 ATP Depletion 
C 2 C 1 2 cells cultured overnight on 1 3 mm glass coverslips (SLS) in 1 2 well 
plates (Griener) in 1 ml of culture media were treated for ATP depletion as 
follows. Cells were treated with a mixture of 0 . 0 2 5 % - 0 . 2 % (w/v) sodium azide 
(NaNa) and 2 5 M M - 2 0 0 [IM 2-deoxyglucose (2-DG) for 3 0 minutes (Reits, 
Benham et al. 1 9 9 7 ) . NaNa and 2-DG were both kind gifts from Dr. A. Benham 
(University of Durham, UK). 
To study which concentration of NaNa and 2-DG successfully depleted the cells 
from ATP therefore inhibited endocytosis, Oregon green dextran ( 5 mg/ml) 
(Wubbolts, Fernandez-Borja et al. 1 9 9 6 ; Reits, Benham et al. 1 9 9 7 ) was added 
to the NaNa / 2-DG media for 3 0 minutes followed by rapid washing and fixing 
by methanol. Although dextran was used previously as an indicator of induced 
plasma membrane disruptions when exposed to cells for seconds (during injury) 
it is used here as an endocytosis marker when exposed to cells for longer time 
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i.e. minutes. The lowest effective dose to inhibit endocytosis for C2C12 cells 
was 0.1% NaNa and 100 | J M 2 -DG, where no endocytosis was detected. 
Control C2C12 cells or cells treated with 0.1% NaNa (w/v) and 100 pM 2 - D G for 
30 minutes at 37X were then wounded using a needle in the presence of 
dextran as explained previously. These cells were then fixed by methanol, and 
immunolabelled with Myof2 antibody for confocal analysis. 
2.7 Single-Strand Conformation Polymorphism (SSCP) 
Analysis 
2.7A Gene analysis & Primer design 
The two Dutch families (1 & II) from the genetic heterogeneity in Miyoshi 
myopathy study by Linssen et al (Linssen, de Visser et al. 1998) that were 
excluded for dysferlin-llnked MM based on genetic analysis in addition to 
showing provisional linkage to a 23cM region on chromosome 10 (Linssen, de 
Visser et al. 1998) were used in this study. Genomic DNA extracted from 
leukocytes of patients' blood samples was provided by Dr. R. Bashir's lab. 
These two families (Fi & Fil) were genotyped with several chromosome 10 
microsatellite markers, their order and segregation of alleles investigated by Dr. 
Bashir's group. From each of these two families, two affected individuals and 
one carrier (affected: lb, Ig, Mb and llh; carrier: id and lie) was chosen for 
SSCP analysis in six genes that lay in the 23cM region on chromosome 10 in 
addition to one sample from a healthy donor used as a control sample. 
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Figure 2.2 Pedigrees of the two families selected for SSCP screening. 
These two families have been excluded for dysferlin-linked MM. Open symbols: 
unaffected subjects, solid symbols: affected subjects, half-solid symbols: carrier 
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The primers were designed using Primer 3 programme and were supplied by 
MWG Oligonucleotides. The list of all the primers is detailed in appendix 3. 
Caveolin 3 was also screened on a panel of 19 MM patients that were 
previously excluded by Dr. R. Bashir's group for mutations on chromosomes 2 
and 10. 
2.7.2 SSCP Gel Electrophoresis 
The SSCP gels (30 ml Hydrolink-MDE (AT Biochem, USA), 3.6 ml 10x TBE, 6 
ml 50% glycerol, 360 pi 10% APS, 55 pi TEMED, 20.4 ml H 2 O ) were cast in 
PROTEAN II xi system (Bio-Rad) and allowed to set for one hour at room 
temperature. 7.5 pi of PGR samples were then aliquoted out and mixed with 7.5 
pi of SSCP loading buffer (95% v/v formaldehyde, 5% v/v 20 mM EDTA, 0.05% 
xylene, 0.05% bromophenol blue) and denatured at 94°C for 4 minutes and 
transferred immediately to ice. The set gels were then transferred into the 
electrophoresis tank and immersed in 0.6x TBE (appendix 1). The wells were 
thoroughly washed and the PCR-loading buffer mixture was loaded into each 
well. The system was connected to cold water supply for cooling and samples 
were allowed to run overnight at 80V (Biorad power pac 300 at constant power). 
The next day the 1mm thick gels were removed from gel plates and carefully 
transferred into a plastic tray. The gel was fixed by incubating in SSCP solution 
1 (appendix 1) for 3 minutes with gentle shaking. After 3 minutes the solution 
was discarded and gels re-incubated in SSCP solutioni for a further 3 minutes. 
The gels were then incubated in SSCP solution 2 (appendix 1) for 15 minutes 
with gentle shaking followed by two 15 second washes in distilled water. Finally 
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gels were incubated in SSCP solution 3 (appendix 1) for 20 minutes with gentle 
shaking. Gels were then rinsed with distilled water and scanned for further 
analysis. 
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3 Chapter Three, Subcellular Localisation of Myoferlin 
3.1 Introduction 
The aims of this chapter were to confirm the specificity of an uncharacterised 
myoferlin monoclonal antibody, FER1L3 by studying the subcellular localisation 
of myoferlin in wild type muscle cells, dysferlin deficient muscle cells and two 
other cell lines. 
Once the subcellular localisation of myoferlin using the FER1L3 antibody was 
confirmed, myoferlin localisation in response to plasma membrane disruptions 
was investigated to study whether myoferlin is enriched at plasma membrane 
disruption sites following cell membrane wounding. 
For these studies C2C12 myoblasts were primarily used. This cell line is the 
most common cell line used for muscle research since it can be induced to 
undergo differentiation from mononucleate myoblasts to multinucleate 
myotubes upon the withdrawal of serum from the growth media. 
The first step was to characterise the specificity of FER1L3 antibody to confirm 
that it was reactive with myoferlin and not other, similar ferlin family members. 
Then, the localisation and mobilisation of myoferlin was also investigated during 
cell wounding and membrane resealing. 
Cell membrane wounding was induced by standard techniques used for 
membrane repair research such as scratching using a fine needle or glass bead 
wounding (McNeil & Warder, 1987,Swanson, 1987). However, how efficient 
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these methods were in inducing injury at the conditions used in this thesis was 
investigated. Since most vesicles needed for plasma membrane repair post 
wounding are not pre-docked at the wound site, it is necessary for successful 
plasma membrane repair to remove any physical barrier sitting between 
vesicles needed for repair and the injured membrane. One such barrier is the 
filamentous actin (F-actin) docked below the plasma membrane. Its temporary 
depolymerisation in the seconds preceding membrane repair is an absolute 
necessity. However, its polymerisation post resealing is reported (Miyake et al., 
2001) and can be used as a good indicator of wounded cells or the wound site 
in particular. 
Myoferlin trafficking was also investigated following elevations of intracellular 
calcium using calcium ionophore. Calcium ionophore is a valuable tool in 
establishing the link between the concentration of calcium and the rate of 
exocytosis. Enlargosomes, like lysosomes, undergo a calcium-dependent 
exocytotic fusion with the plasma membrane (Borgonovo et al., 2002). 
Therefore wounding cells physically or treating with lonomycin, induced Ca^ "^ -
dependent exocytosis. This method is used to test whether myoferlin 
enrichment at the wound site in Ca '^^ -dependent or not. 
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3.2 Results 
3.2.1 Specificity of FER1L3 Antibody 
3.2.1.1 Peptide Blocking Results 
To ensure the specificity of the FER1L3 antibody, western blots of C2C12 cells 
were probed with the antibody. As seen in Figure 3.1, a band of correct 
molecular weight was identified. This interaction was proved to be antigen 
specific by the complete abrogation of antibody binding. This experiment was 
carried out by Dr. M. Hill (University of Durham, UK) and provided supporting 
evidence that experiments using the FER1L3 antibody would characterise the 
presence or absence of myoferlin. 
3.2.1.2 Myoferlin Distribution by Immunoblotting 
To further clarify the intracellular localisation of myoferlin, C2C12 cells were 
fractioned to light and dense microsomes, ER-nuclei and plasma membrane 
fraction as described in materials and methods chapter. An antibody to the 
nuclear membrane protein Lamin A tail, Jol4 (Dyer et al., 1997) was used to 
determine the purity of the fractions and the degree of nuclear contamination in 
the high density and low density microsomes and the plasma membrane 
fraction. Only the nuclear fraction could be recognised by the antibody even at 
very long exposure times (Figure 3.2C) indicating that there was no detectable 
contamination of the other fractions with the nuclear components. 
Immunoblotting of these fractions with FER1L3 antibody showed that myoferlin 
is preferentially in the ER-nuclear fraction and the weak signal in the light and 
dense microsomes in addition to the plasma membrane has been reported 
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using Myof1/2. Myoferlin was clearly absent from the cytosol fraction (Figure 
3.2B) (Davis et al., 2000). 
These fractions were also probed with dysferlin antibody. Although dysferlin is 
not associated with the nuclear membrane fraction, this fractionation technique 
does not separate the nuclei from the endoplasmic reticulum. Therefore, 
although dysferlin is not associated with the nuclear membrane fraction but 
dysferlin's presence in this fraction could indicate its presence in the ER not 
nuclei. Similar to myoferlin, dysferlin was also clearly absent from the cytosol 
(Figure 3.2A). Given the structural similarity between dysferlin and myoferlin, 
there is a formal possibility that antibodies to myoferlin could cross-react with 
dysferlin. Western blots are unable to discriminate between the two as the 
molecular weights of these two proteins are very similar, i.e. 230 KDa (2080 
amino acids for dysferlin and 2061 amino acids for myoferlin). In order to 
address this, the expression of these gene products in normal and dysferlin 
deficient cells was examined. 
3.2.1.3 Reactivity to Dysferlin Deficient Cells 
SJL/J cells are deficient in dysferlin (Bittner et al., 1999), but to date no 
mutations in their myoferlin gene is reported. 
Since the pattern of staining of dysferlin in immunoflorescence has been 
characterised previously (Matsuda et al., 2001), the reactivity of FER1L3 was 
assessed in SJL/J and control cells (Fw+IOj) by confocal microscopy. The 
pattern of immunoflorescence was very similar when compared between the 
control and dysferlin deficient cells (Figure 3.3), a result consistent with FER1L3 
antibody being specific for myoferlin. To support this, the nuclear membrane 
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and peri-nuclear region staining seen in Figure 3.3 is characteristic of myoferlin 
(Davis et al., 2000). In order to examine this further, the colocalisation of 
immunoflorescence of FER1L3 antibody with another antibody to myoferlin, 
Myofi, was examined. 
3.2.1.4 Colocalisation with Myofi Antibody 
Myofi, is a polyclonal antibody specific for myoferlin, and was the first antibody 
developed to myoferlin peptide SEDGSRIRYGGRDYSLD (amino acids 1692-
1708). Cross reactivity with dysferlin has been reported as being undetectable 
(Davis et al., 2000). In order to confirm that the new FER1L3 antibody 
demonstrated similar patterns of reactivity compared to Myofi, C2C12 cells 
were double labelled for Myofi and FER1L3 antibodies and subjected to 
confocal analysis. As can be seen from Figure 3.4 , the pattern of staining of the 
two antibodies was indistinguishable from one another, confirming that FER1L3 
was at least as good as Myofi as a confocal tool, and supporting the evidence 
that FER1L3 was specific for myoferlin. 
Having determined the suitability and specificity of the antibody, the expression 
pattern of myoferlin in normal and wounded cells was assessed by confocal 
microscopy. 
In addition to Myofi, a second polyclonal antibody named Myof2 that was 
developed to myoferlin peptide TEFTDEVYQNESRYPGGD (amino acids 928-
945) by Davis et al (Davis et a!., 2000) was also used in experiments of this 
project. 
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Figure 3.1 FER1L3 antibody binding is blocked by the cognate antigenic 
peptide 
Western blots of C2C12 myoblasts were probed with FER1L3 antibody in the 
presence or absence of the specific peptide. Lanes 1 and 3 shows the control 
(unblocked signal) while lanes 2 and 4 clearly show that the peptide has 
resulted In the total abolishment of signal. The molecular weight is indicated 
(KDa). This procedure was performed by M. Hill (School of Biological Sciences, 




Figure 3.2 Expression of dysferlin, myoferlin and Lamin A in cell fractions 
of C2C12cells. 
C2C12 cells were subjected to differential centrifugation and the membrane 
fractions analysed by western blot. Lanel; High density microsomes (HDM), 
Lane2; Low density microsomes (LDM), Lane 3; ER-nuclear fraction (ERN), 
Lane 4; Plasma membrane (PL), Lane 5; cytosol. A) anti-Dysferlin, B) anti-
Myoferlin, C) anti-Lamin A. Molecular weight marker in KDa. Protein stained 
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Figure 3.3 FER1L3 reactivity to dysferlin deficient cells 
Confocal images of SJL cells (Lane 1) and control cells, Fw+10j (Lane 2) 
stained by immunocytochemistry using FER1L3 antibody. Both groups showed 




Figure 3.4 FER1L3/Myof1 coiocalisation 
C2C12 cells were double labelled by immunocytochemistry with FER1L3 and 
Myofi antibodies to Investigate their colocalisation. A) Myof1 staining, B) 
FER1L3 staining, C) merged images. The first set of images shows a group of 










3.2.2 Myoferlin Localisation 
3.2.2.1 Myoferlin Localisation in Normal Cells 
As explained earlier myoferlin staining has been previously described using 
Myof2 antibody. It was reported that myoferlin shows a nuclear and plasma 
membrane expression in addition to high vesicular expression in the peri-
nuclear region (Davis et al., 2002). 
C2C12 cells stained with FER1L3 were compared to C2C12 cells stained with 
Myof2 (Figure 3.5A). In both cases the staining pattern seems to be very 
similar. This experiment was repeated on HDP and NRK cells. 
In HDP cells the peri-nuclear staining was less prominent (Figure 3.5B), while in 
NRK cells the overall expression was very similar to C2C12 (Figure 3.5C). 
3.2.2.2 Myoferlin Localisation in Wounded Cells 
C2C12 cells wounded in the presence of Texas red dextran, and 
immunolabelled with FER1L3 showed an enrichment of myoferlin in wounded 
cells identified by dextran uptake (Figure 3.6A & B). Enrichment of dysferlin in 
injured muscle fibres has been reported previously (Bansal et al., 2003). These 
results were consistent when repeated with Myof2 antibody (Figure 3.6 C & D). 
Using both antibodies, no cells that had taken up dextran failed to show 
myoferlin enrichment and the opposite is true. 
F-actin (Filamentous actin) polymerisation at the wound site was used as a 
wound site indicator. F-actin rapidly goes through repeated cycles of 
polymerisation and de-polymerisation inside the cell but in general a cortical 
barrier consisting in part of F-actin is present in normal cells. Once the cell is 
injured, Ca "^^  influx from the extracellular environment induces F-actin de-
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polymerisation locally at the wound site. Depolymerised F-actin facilitates 
vesicle-vesicle and vesicle-plasma membrane fusion required for wound 
healing. Shortly after membrane resealing (T>1 min) a thick layer of 
polymerised F-actin is formed lining the injury site which is thought to be 
required for repair of the monolayer injury (Miyake et al., 2001). Therefore F-
actin polymerisation is an indicator of the injury site. C2C12 cells wounded in 
the presence of Cascade blue dextran and double labelled for myoferlin and F-
actin show enrichment of myoferlin at the wound site confirmed by F-actin 
polymerisation and dextran uptake (Figure 3.7). 
As a control and to prove that increased levels of myoferlin at the wound site is 
specific and not artefacts as a result of injury or a fluorescence channel spill 
over, C2C12 cells were injured in the presence of Oregon green dextran and 
immunolabelled with caveolin 3 antibody. All injured cells that had taken up the 
dextran did not show any enrichment or increased levels of caveolin 3 at the 
wound site (Figure 3.8). In addition, the possibility of myoferlin enrichment seen 
in wounded cells being a fluorescence channel spill over from dextran was 
eliminated by analysing and imaging cells immunolabelled for myoferlin and 
wounded in the absence of dextran or wounding cells in the presence of 
dextran not immunolabelled for myoferlin. In both cases, no fluorescence spill 
over was detectable. 
3.2.2.3 Myoferlin Localisation Post Membrane Resealing 
As detailed in materials and methods chapter, the number of cells that had 
taken up the first and second dextran at 0 and 5 minutes were counted in 15 
microscopic fields where at least 40% of the cells were wounded in each field 
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Figure 3.5 IViyoferlin expression in different cells 
Confocal images of A) C2C12, B) HDF, C) NRK cells stained with Myof2 and 
FER1L3 antibody by immunocytochemistry. In general cells stained with theses 
two antibodies show a very similar staining pattern with slightly intense staining 
around the nuclear membrane and some cytoplasmic staining. 
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Figure 3.5 (A) 
Myof2 FER1L3 
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Figure 3.5 (B) 
Myof2 FER1L3 
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Figure 3.5 (C) 
Myof2 FER1L3 
Figure 3.6 IVIyoferlin expression in wounded cells 
C2C12 cells wounded in the presence of dextran and labelled by 
immunocytochemistry for myoferlin. A) Group of cells wounded in the presence 
of Texas red dextran and stained with FER1L3 antibody. B) A close-up image of 
wounded FER1L3 stained cells. C) Group of cells wounded in the presence of 
Oregon green dextran and stained with Myof2 antibody. D) A close-up image of 
wounded Myof2 stained cells. Wounded cells are characterised by myoferlin 
enrichment at the wound site confirmed by dextran uptake compared to control 
(uninjured) cells in the background. 
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Figure 3.6 (A) 
Myoferiin Dextran 
1 0 9 
Figure 3.6 (B) 
Myoferlin Dextran 
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Figure 3.6 (C) 
Myoferiin Dextran 
Figure 3.6 (D) 
Myoferlin Dextran 
Figure 3.7 Wound site indication by F-actin polymerisation 
C2C12 cells wounded in the presence of cascade blue dextran were double 
labelled for myoferlin and F-actin using Myof2 and anti-actin antibodies 
respectively. Myoferlin enrichment is noted in wounded cells confirmed by 
dextran uptake. While actin polymerisation in wounded cells also acts as an 






Figure 3.8 Control experiments to myoferlin enrichment at plasma 
membrane disruption sites 
Caveolin 3 expression was investigated by immunolabelling of C2C12 cells with 
caveolin 3 antibody. A) Un-injured C2C12 caveolin stained cells imaged by 
confocal microscopy in a group of cells and a close-up. B) Cells wounded in the 
presence of Oregon green dextran and immunolabelled with caveolin 3 (group 
and close-up) show no enrichment of caveolin neither at the wound site nor in 
wounded cells in contrast to myoferlin. C) The possibility of myoferlin 
enrichment seen in wounded cells being a fluorescence channel spill over from 
dextran was eliminated by analysing and imaging cells immunolabelled for 
myoferlin and wounded in the absence of dextran or wounding cells in the 
presence of dextran not immunolabelled for myoferlin. In both cases, no 
fluorescence spill over was detectable. 
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Figure 3.8 (A) 
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Figure 3.8 (B) 
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Figure 3.9 Myoferlin expression post membrane reseating 
C2C12 cells injured in the presence of Oregon green dextran were allowed to 
recover for 5 minutes then incubated in Cascade blue dextran for a further 2 
minutes (A). Alternatively another group was not allowed to recover and 
transferred to blue dextran immediately and incubated for 2 minutes (B). All 
cells were then immunolabelled with Myof2 antibody and analysed by confocal 
microscopy. 
In 15 (x40 oil lens) microscopic fields where at least 40% of cells were along the 
injury line, the number of cells that had increased myoferlin staining was 
counted. In the same field the number of these cells that had taken up the first 
and second dextran was counted at 0 and 5 minutes post recovery. This 
experiment was repeated twice and the average of the readings was converted 
to a percentage. As seen from section C of this figure, when cells were not 
allowed to recover (i.e. T=0) the percentage of cells along the injury line with 
enriched myoferlin is relatively close to the percentage of cells that had taken 
up the first and second dextran. While, when cells were allowed to recover for 5 
minutes, cells that had taken up the first dextran during the wounding process 
healed and failed to uptake the second dextran which reflected successful 
wound healing, however myoferlin enrichment was still visible. 
112 














Figure 3.9 (C) 
• Cells along injury line 
showing increased 
myoferlin expression 
• Oregon Green Dextran 
uptake 
• Cascade Blue Dextran 
uptake 
T=0 min T=5 min 
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(Figure 3.9). When analysed and imaged by confocal microscopy, myoferlin 
enricliment in thie injured cells was visible. After 5 minutes recovery most of the 
cells that had taken up the first dextran were excluded for the second dextran 
uptake, a result consistent with membrane resealing. However, although the 
plasma membrane may have successfully resealed, elevated levels of myoferlin 
at the wound site was still clearly detected. These results suggest that 
myoferlin's high levels induced by a plasma membrane disruption do not return 
to normal levels immediately or until few minutes after membrane resealing 
(Figure 3.9). 
3.2.2.4 Myoferlin Localisation Post lonomycin Induced Exocytosis 
As explained earlier, in order to confirm myoferlin mobilisation to the surface in 
response to the Ca "^^  increase inside the cell, ionomycin, a calcium ionophore 
that has been shown to trigger intracellular calcium increase has been used. 
The mobilisation of enlargosomes detected by AHNAK antibody to the cell 
surface in response to this concentration of ionomycin has been reported 
previously (Cerny et al., 2004). 
C2C12 cells treated with ionomycin were checked for viability by trypan blue 
uptake and no toxic effect as a result of ionomycin treatment was detected on 
these cells. 
Next, C2C12 cells were treated with ionomycin and immunolabelled for total 
and surface expression of myoferlin and enlargosomes inside the cells. In 
resting cells, no expression of enlargosomes was detected at the cell periphery, 
while some intracellular expression was detected. After treatment with 
ionomycin (5 uM, 5 min), the enlargosomes' marker AHNAK shifts towards the 
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cell periphery and appears at the surface, reflecting the Ca^'^-regulated 
exocytosis. This pattern of expression has been reported previously (Cerny et 
al., 2004). Alternatively when resting C2C12 cells were surface stained with 
Myof2 no myoferlin was detected at cell surface when compared to total 
myoferlin staining. After ionomycin treatment the surface staining of myoferlin 
was strongly detectable at the peri-nuclear region, in both total and surface 
staining. When compared to AHNAK, this shows calcium induced exocytosis of 
myoferlin in response to elevated calcium a similar pattern to that observed in 
wounded cells in response to plasma membrane disruptions (Figure 3.10). 
3.2.2.5 Myoferlin Co-localisation with Lysosomes & Enlargosomes 
Lysosomes are known to be important membrane providing vesicle populations 
during the process of wound healing. When WT and injured C2C12 cells were 
double labelled for myoferlin and an antigen associated with lysosomes, 
Lamp-I, myoferlin did not appear to be substantially associated with lysosomes. 
However, in injured cells both myoferlin and lysosomes could be seen at the 
injury site but in an independent manner, not co-localising (Figure 3.11). This 
was not true for Enlargosomes, another vesicle population known to mobilise to 
the cell surface in response to elevated calcium levels (Borgonovo et al., 2002) 
(e.g. plasma membrane disruption). The function of enlargosomes is still not 
properly understood but they are thought to have a role in cyto-architecture. In 
normal cells myoferlin and AHNAK have a distinct and different expression 
pattern. However, in injured cells both myoferlin and AHNAK seem to mobilise 
to the injury site and do show some partial co-localisation (Figure 3.12). 
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Figure 3.10 Enlargosomes and myoferlin response to induced exocytosis 
In impermeablised resting cells, AHNAK was not detected at the cell surface. In 
permeablised resting cells both AHNAK was expressed in its normal expression 
pattern. When treated with ionomycin, the enlargosomes' marker AHNAK shifts 
towards the cell periphery and appear at the surface, reflecting the Ca "^^ -
regulated exocytosis (A). 
Myoferlin surface staining of resting cells was nil while myoferlin total staining of 
resting cells reflected the normal expression pattern shown previously. After 
ionomycin treatment myoferlin was strongly detectable at the peri-nuclear 
region, in both total and surface staining (B) compared to resting cells. 
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Figure 3.10(A) 






Figure 3.10 (B) 






Figure 3.11 Myoferlin colocalisation with lysosomes 
C2C12 cells were double labelled for myoferlin (Myof2) and lysosomes (Lamp-
1) and imaged. In uninjured cells myoferlin and lysosomes clearly sustain a 
distinguished and different cellular localisation (A). Wounded cells show the 
enrichment of myoferlin and the mobilisation of lysosomes to the wound site (B). 
However, they do not colocalise at any stage. 
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Figure 3.12 Myoferlin colocalisation with enlargosomes 
C2C12 cells double labelled with myoferlin (FER1L3) and enlargosomes 
(AHNAK) imaged show distinct and different expression in control cells (A). 
However, contrary to lysosomes, myoferlin and AHNAK show some 
colocalisation (B), indicated by yellow staining at plasma membrane disruption 
sites. 
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In this chapter the specificity of a new monoclonal antibody, FER1L3 to 
myoferlin was investigated. This was achieved by 1) a peptide block experiment 
performed by a colleague, 2) studying the subcellular localisation of myoferlin 
using the FER1L3 antibody on fractionated cell membranes by western blots 
and comparing it to the subcellular localisation of dysferlin 3) studying FER1L3 
reactivity in dysferlin deficient cells and comparing it to control cells 4) studying 
the colocalisation of FER1L3 antibody with another known myoferlin antibody, 
Myo f i . 
The signal from the FER1L3 antibody was completely abolished by the peptide, 
confirming that the signal is specific to the peptide while Western blots 
performed on subcellular membrane fractions of C2C12 cells, labelled with 
FER1L3 did specifically label the band at 230 KDa in most fractions and not the 
other bands seen on the protein blot (data not shown). 
More bands were labelled in the ER and nuclear fraction when probed with 
FER1L3 antibody but this pattern has been reported previously in dysferlin 
which were thought to be metabolic fragments of the dysferlin protein as a result 
of the long time taken to synthesis such a large protein (Anderson et al., 1999). 
In addition, the subcellular localisation of myoferlin labelled by FER1L3 was 
very similar to that of dysferlin. The labelling of fractions by lamin A antibody 
confirms the identity of the nuclear fraction. Given the structural similarity 
between dysferlin and myoferlin, there is a formal possibility that antibodies to 
myoferlin could cross-react with dysferlin. Western blots are unable to 
discriminate between the two as the molecular weights of these two proteins are 
very similar, i.e. 230 KDa (2080 amino acids for dysferlin and 2061 amino acids 
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for myoferlin). In order to address this, the staining pattern of FER1L3 antibody 
in normal and dysferlin deficient cells was examined. 
Immunolabelling of dysferlin deficient cells with FER1L3 strongly suggests the 
specificity of this antibody to myoferlin since the staining pattern observed in 
dysferlin deficient cells is highly similar to that of the control cells expressing 
dysferlin. 
In addition, results obtained from Myof1 and FER1L3 immunocytochemistry 
yielded a very similar staining pattern. In conclusion, these experiments strongly 
suggest that FER1L3 is a myoferlin specific antibody and was therefore used in 
subsequent experiments. 
In the next section of this chapter the subcellular distribution of myoferlin was 
investigated. Myoferlin staining pattern by immunolabelling has been published 
in C2C12 cells using Myof2 antibody (Davis et al., 2002) therefore its 
subcellular localisation was investigated in two other cell lines (NRK, HDF) 
using Myof2 and FER1L3 antibodies. Since myoferlin is 6 8 % similar and 58% 
identical to dysferlin (Davis et al., 2000), and dysferlin is known to be enriched 
at plasma membrane disruption sites, myoferlin's response to plasma 
membrane disruption was investigated. 
Results obtained from this set of data strongly suggested that myoferlin like 
dysferlin is enriched at plasma membrane disruption sites. Control experiments 
such as caveolin 3 expression in response to plasma membrane disruption and 
fluorescence channel spill were performed and results were consistent with 
myoferlin's specific response to plasma membrane disruptions. 
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In order to study the relationship between myoferlin enrichment at plasma 
membrane disruption sites and calcium influx from the extracellular environment 
as a result of plasma membrane disruption, an intracellular calcium increase 
was induced using ionomycin and compared to other vesicles known to 
exocytose in response to an increase in intracellular calcium levels. 
Lysosomes are known to travel to plasma membrane disruption sites in 
response to calcium influx (Jaiswal et al., 2002). C2C12 cells double labelled for 
myoferlin and lysosomes showed no colocalisation in uninjured cells, with each 
showing their distinctive staining patterns. However, when cells were wounded, 
myoferlin localised to the same region as the lysosomes i.e. plasma membrane 
disruption site but did not colocalise. This result strongly suggests that myoferlin 
is localised to plasma membrane disruption sites in response to calcium influx 
from a wound site. 
In addition, as explained in chapter 1, AHNAK is also known to undergo calcium 
induced exocytosis (Borgonovo et a!., 2002,Hashimoto et al., 1995). Therefore, 
when the same experiment was repeated with AHNAK and myoferlin each 
showed distinctive staining patterns in uninjured cells but partially colocalising at 
plasma membrane disruption sites. 
In summary, experiments performed in this chapter strongly suggest that 
PERILS is a myoferlin specific antibody and that myoferlin shows calcium 
induced enrichment in response to plasma membrane disruption. 
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4 Chapter Four, Myoferlin & FER1L5 Expression During 
Differentiation 
4.1 Introduction 
At the time this work was conducted, it had been shown that in vitro, the C2A 
domain of dysferlin has a role in Ca^^-dependant phospholipid binding (Davis et 
al., 2002) and that dysferlin deficient muscle fibres are defective in Ca^^-
dependant membrane resealing (Bansai et al. , 2003). All this and other 
indications as discussed in chapter 1 pointed to the involvement of dysferlin in 
muscle membrane fusion. Myoferiin -previously found to be in vesicles (Davis 
et al., 2002)- and FER1L5's high similarity to dysferlin suggested that they might 
have a similar role in aiding membrane repair. 
In addition, evidence from chapter 3 suggested that myoferlin is also enriched at 
plasma membrane disruption sites. Myoferlin may have a role in membrane 
repair since both myogenesis and membrane repair involve the fusion of two 
adjacent lipid bilayers; therefore studying myoferlin expression during 




4.2.1 FER1L5 Analysis & Antibody Immunoadsorption 
In order to prove that the assembled FER1L5 sequence is not a pseudogene, 
one pair of primers were designed within an EST sequence (BY715517 RIKEN 
full-length enriched, adult male testis Mus musculus cDNA clone 4930533D13-
5', mRNA sequence) which mapped to amino acids 5561 to 6182 on the 
XM_136730 locus. The primers were designed to amino acids 5833-5852 
(mFER1L5 _forward) and 5969-5989 (mFER1L5 _reverse) with a product size 
of 157 bp. 
These primers were used for PGR on cDNA extracted from three stages of 
differentiating myoblasts. PGR results suggested a differential expression 
throughout the different stages when compared to a house keeping gene 
(GAPDH) as detailed later in this chapter. 
As for immunoadsorption of FER1L5 serum, samples incubated with 
immunoadsorbed serum showed a complete abolishment of signal (lanes 4, 5 
and 6) when compared to samples incubated with the serum (lanes 1, 2 and 3) 
suggesting the specificity of day 84 FER1L5 serum to the peptides it was 
designed to (Figure 4.1). This experiment was carried out by Dr. K. Saleki 
(University of Durham, UK). 
4.2.2 DysF-Ferlins Expression During Differentiation 
Evidence from chapters 1 and 3 suggested that two out of three (dysferlin and 
myoferlin) DysF ferlins have upregulated expression during repair of damaged 
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Figure 4.1 Immunoadsorption of FER1L5 antibody. 
RlPA lysed C2C12 cells were loaded into a 6% discontinuous SDS-PAGE gel in 
the following order; lanes 1 & 4 (23 |jg), 2 & 5 (35 |jg) and 3 & 6 (57 pg). Lanes 
1, 2 and 3 were incubated with day 84 FER1L5 serum (1:100) while lanes 4, 5 
and 6 were incubated with unbound FER1L5 serum (1:100) from the incubation 
in sepharose beads-peptide bound column. Lanes 4, 5 and 6 show a complete 
abolishment of the FER1L5 antibody. This entire experiment was carried out by 





cells. In order to investigate whether a similar process was occurring during 
myotube neogenesis, the level of protein expression and mRNA in all three 
DysF ferlins was investigated using immunoblotting and RT-PCR respectively. 
Myoblasts were successfully differentiated into myotubes by serum withdrawal 
as explained in the materials and methods chapter. Evidence of differentiation 
as suggested by previously published data (Doherty et al., 2005,Salani et al., 
2004) is the formation of multinucleate myotubes by day 3 of differentiation and 
reaching maximum differentiation (indicated by the proportion of myotubes to 
myoblasts) by day 5 (Figure 4.2). After 5 days of differentiation the number of 
formed myotubes reached a plateau and this stage of myotubes were used for 
immunocytochemistry analysis while two additional stages (day 7 and day 14) 
of myotubes were used for immunoblotting analysis (Salani et al., 2004) in 
addition to DO myoblasts as control cells, D1 myoblasts as early differentiating 
cells, D3 cultures as the start of multinucleate myotube formation (Doherty et 
a l . ,2005,Sa lan ie ta l . , 2004). 
4.2.3 Dysferlin 
Primers designed to the 3' UTR region of dysferlin were used to study dysferlin 
transcript levels during differentiation by PGR on cDNA extracted from DO, D1 
and D5 of differentiating myoblasts. Results from this set of data suggested a 
low but detectable level of dysferlin in control cells after which an increase in 
dysferlin transcripts is seen throughout differentiation (Figure 4.3). 
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Levels of mRNA as determined by PGR may not reflect changes in protein 
expression. In order to demonstrate effects at the protein level, a series of 
western blots was carried out. 
Results obtained from immunoblotting analysis of dysferlin during differentiation 
suggest the low expression of this protein in control cells (DO) followed by a 
constant elevated expression (i.e. during D1 and D3) until the myotube 
formation reaches its maximum (i.e. D5), after that which the level of dysferlin 
expression seems to remain relatively constant at D7 and D14 (Figure 4.4). 
These results suggest that dysferlin expression correlates with the number of 
forming/formed myotubes in the culture and is consistent with the results 
obtained from the PGR. 
Dysferlln's expression during differentiation by immunoblotting has been 
reported previously with similar results. Salani et al. (Salani et al., 2004) 
reported a relatively significant dysferlin expression at DO, and reported the 
proteins expression as constant at D7, D14 and D21. While Doherty et al 
(Doherty et al., 2005) reported almost nil dysferlin expression until later in the 
differentiation when most myotubes were forming or already formed (D5), and 
after that the expression level was reported to be constantly high. 
4.2.4 Myoferlin 
Similar to that of dysferlin, primers designed to the 3' UTR region of myoferlin 
were used to study myoferlin transcript levels during differentiation by PGR on 
cDNA extracted from DO, D1 and D5 of differentiating myoblasts. Results 
strongly suggested a low but detectable level of myoferlin (but relatively higher 
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than that of dysferlin) in control cells after which a constant increase in myoferlin 
transcripts is seen at the remaining two stages studied (D1 and D5) (Figure 
4.3). 
As levels of mRNA determined by PGR may not reflect changes in protein 
expression these results were to be confirmed by western blots. 
Western blot analysis suggested that myoferlin was present already in 
myoblasts (DO). At D1 the start of myoinitiation correlated with an increase in 
myoferlin level and the protein expression continued to rise until most myotubes 
were formed (D5). However, the expression levels did not seem to change after 
7 days (D7) and 14 days (D14) of switching to differentiation media (Figure 4.4) 
also correlating with the number of forming/formed myotubes in the culture and 
is consistent with the results obtained from PGR. 
Changes in levels of message and protein may however reflect global changes 
in transcription/translation, or may be a result of changes in a subpopulation of 
cells. In order to identify those cells which are responsible for the changes, and 
to characterise the subcellular expression in these cells, confocal microscopy 
analysis was carried out using myoferlin antibodies Myof2 and FER1L3. 
Myoferlin expression was found to be notably high in single nucleated 
myoblasts initiating cell to cell fusion (D1) compared to control myoblasts (DO 
C2C12). After that myoferlin expression seems to increase until D5 where the 
majority of the myoblasts have differentiated into myotubes i.e. completion of 
myoinitiation (Figure 4.5). 
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4.2.4.1 Myoferlin Expression During Myotube Injury 
Myotubes wounded in the presence of Oregon green dextran were labelled with 
Myof2 antibody, while myotubes wounded in Texas red dextran were labelled 
with FER1L3 antibody. 
Results obtained from this set of experiments strongly suggest that myotubes 
tend to show enrichment of myoferlin at the wound site (Figure 4.6). These 
results are consistent with results obtained from chapter 3 where an enrichment 
of myoferlin was detected at plasma membrane disruption sites of C2C12 cells. 
4.2.5 FER1L5 
Primers designed to an EST of the assembled FER1L5 gene were used to 
compare FER1L5 transcript levels during differentiation on the cDNA previously 
extracted from DO, D1 and D5 of differentiating myoblasts by PGR. Results from 
this set of data suggested the presence of a very low level of FER1L5 
transcripts in control cells. However, this level seemed to increase dramatically 
during differentiation at the time points studied, D1 and D5 (Figure 4.3). 
In order to investigate if the levels of FER1L5 mRNA detected by PGR correlate 
to changes in FER1L5 protein expression western blot analysis was conducted. 
Results obtained from immunoblotting analysis of FER1L5 during differentiation 
suggest the low expression of this protein in control cells (DO) although 
relatively higher than that of dysferlin and myoferlin. Expression of FER1L5 in 
early stages of differentiation (i.e. D1) is elevated compared to that of control 
cells. However, FER1L5 protein expression seems not to be as high in 
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differentiated myotubes (i.e. D5, D7, and D14) compared to dysferlin and 
myoferlin (Figure 4.4). 
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Figure 4.2 Phase-contrast image of differentiating myoblasts 
C2C12 cells are derived to differentiate by withdrawing growth media and 
replacing it with D-MEM supplemented with 2% (v/v) horse serum. This figure 
shows three stages of myoblast differentiation, Day 0 control myoblasts (A), 






Figure 4.3 Ferlins mRNA profile by RT-PCR during myoblast 
differentiation 
PGR of dysferlin, myoferlin, FER1L5, Otoferlin and GAPDH with cDNA 
extracted from three stages of C2C12 differentiation (control, DO; pre-fusion, 
D1; myotubes, D5). (A) Dysferlin- 150 bp product. (B) Myoferlin- 200 bp 
product. (C) PERILS - 157 bp product. (D) Otoferlin - 130 bp product. (E) 


















Figure 4.4 dysF-ferlins expression profile by immunoblotting during 
myoblast differentiation 
Comparison of dysferlin expression (A), myoferlin (B) and FER1L5 (C) in control 
myoblasts (DO, lanel), pre-fusion (D1, Iane2), and during progressive time 
points in myotube formation (D3, lane 3; D5, lane 4; D7, lane 5; D14, lane 6). 
Protein extracts were prepared from differentiating myoblasts. lOOpg of total 
protein per lane was resolved on 6% SDS-PAGE, transferred to a membrane 
and immunoblotted with monoclonal antibody HCL-Hamlet (1:250) for dysferlin, 
with monoclonal antibody FER1L3 (neat) for myoferlin and polyclonal D84 
serum (1:500) for FER1L5. Molecular weight markers are in KDa. Coomassie 
blue stained protein gels were used to confirm equal loading and no global 
changes in protein expression (data not shown). 
Negative control blots ((D) HRP conjugated Donkey anti-rabbit, IgG; (E) HRP 
conjugated Donkey anti-mouse) blotted against the same samples from six 
stages of differentiating myoblasts. 
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Figure 4.5 Myoferlin expression during myoblast differentiation by 
immunoflorescence 
Differentiating myoblasts were analysed by immunoflorescence using Myof2 (A) 
and FER1L3 (B) antibodies during different stages of differentiation (DO, D1, 
D3, and D5) and imaged by confocal microscopy. Results strongly suggest that 
myoferlin expression increases throughout differentiation with the highest levels 
detected in myotubes. 
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Figure 4.5 (A) 
DO 01 D3 05 
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Figure 4.5 (B) 
DO D1 D3 D5 
Figure 4.6 IVIyoferlin expression in wounded myoblasts during 
differentiation 
Differentiating myoblasts wounded in the presence of dextran (Myof2 (A) and 
FER1L3 (B)) show enrichment of myoferlin at the wound site similar to that seen 
in C2C12 cells, although the enrichment due to wounding is not as obvious as 
in control cells due to the fact that differentiated cells already show an increased 
myoferlin expression. 
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Figure 4.6 (A) 




Figure 4.6 (B) 





In this chapter the expression of DysF ferlins during myoblast differentiation was 
investigated. Dysferlin and myoferlin (i.e. DysF ferlins) mRNA levels were 
analysed by RT-PCR during three stages of differentiation and compared to that 
of otoferlin (i.e. non-DysF ferlins) and a house keeping gene, GAPDH. Results 
suggested that DysF ferlins have elevated mRNA levels during differentiation. 
These results were followed by western blot analysis which confirmed protein 
expression levels of DysF ferlins are higher in later stages of differentiation 
coincided with proportions of myotubes to myoblasts in the studied cultures. 
In addition, myoferlin's expression during differentiation was also analysed by 
immunoflorescence, and results strongly suggested that myoferlin's expression 
was the highest in myotubes confirming the results obtained by PCR and 
immunoblotting. 
Myoferlin's increased expression during differentiation is very significant 
because the process of differentiation involves the fusion of two membranes 
together, similar to that seen in membrane repair following a plasma membrane 
disruption. This supports the hypothesis that myoferlin like dysferlin is involved 
in membrane repair. 
Indeed, after the completion of this project, a recently published study (Doherty 
et al., 2005) used a similar method in understanding myoferlin cellular function. 
In addition, the group generated myoferlin-null mice through homologous 
recombination by inducing a point mutation in the C2A domain of myoferlin, 
which blocked Ca^^'-sensitive phospholipid binding (Doherty et al., 2005) similar 
to that seen in dysferlin (Davis et al., 2002). 
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The myoferlin null mice were used to study myoferlin's significance in cells. 
Myoferlin deficient myoblasts were reported to be defective in myoaugmentation 
but not myoinitiation resulting in smaller muscle area in vivo, in addition to 
defective muscle regeneration post injury associated with upregulation of 
myoferlin (Doherty et al., 2005). 
Also in this chapter the addition of a new member of the ferlin protein family is 
reported. FER1L5 shares the highest homology with dysferlin and myoferlin, in 
addition to possessing a DysF domain which places it in the DysF ferlins 
subgroup. Using SMART analysis, the human FER1L5 is thought to consist of 6 
C2 domains and a C-terminal transmembrane domain. 
In order to prove that FER1L5 is not a pseudogene, one set of primers were 
designed to an EST region of mouse FER1L5 and its expression analysed by 
PGR on cDNA extracted from three stages of myoblast differentiation. The 
resulting expression pattern was compared, to the expression pattern of 
dysferiin, myoferlin, otoferlin and GAPDH. 
As mentioned earlier, dysferlin, myoferlin, and FER1L5 (i.e. DysF ferlins), 
showed an increase in mRNA levels throughout differentiation with the highest 
levels detected in myotubes, while otoferlin (a non-DysF ferlin) and GAPDH 
showed a constant level throughout the studied stages of differentiation. 
Since the increase in mRNA levels detected does not necessarily reflect the 
increase in these protein's expression western blot analysis was conducted to 
investigate whether increased FER1L5 mRNA levels reflect increased levels of 
FER1L5 protein. 
Western blot analysis was conducted on extracts from the same three stages of 
differentiation used in PCRs (DO, D1, D5) in addition to three more stages (D3, 
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D7, D14) of differentiation and results obtained from western blot analysis were 
consistent with those results obtained from PGR suggesting an elevated 
expression of FER1L5 in myotubes compared to control myoblasts. 
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6 Chapter Five, Myoferlin sub-celiular colocalisation 
5.1 Introduction 
The experiments carried out in previous sections of this project may help us in a 
better understanding to myoferlin's expression, localisation and mobilisation of 
myoferlin in C2C12 cells in undisturbed conditions or during significant events of 
a muscle cell's life cycle such as plasma membrane disruptions and 
differentiation. Although myoferlin was suggested to be found in vesicles (Davis 
et al., 2002) of some kind, to date the exact nature of these vesicles is 
ambiguous. We still do not have a clear map of myoferlin's passage in the cell 
once it has left the nucleus post transcription, whether this protein is found 
inside a vesicle or simply attached to it and if so, is this a vesicle of known 
structure and function or a novel vesicle and how this vesicle mobilises inside 
the cell and if the cellular cytoskeleton and cellular ATP levels are involved in 
one way or another in this process and whether myoferlin or its vesicle are 
subjected to conformational changes during myoferlin's mobilisation or not . All 
these questions remain to be answered in order for us to fully understand 
myoferlin's function to use this information further and possibly a therapeutic 
purpose. 
The experiments carried out in this chapter aim at answering some of these 
questions by investigating the possible colocalisation of myoferlin with any other 
cellular structure. Myoferlin's colocalisation with lysosomes and enlargosomes 
was shown in chapter 3. However, since most proteins pass through the TGN 
network at one stage of their cycle or another and ER is known to be 
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responsible for folding of proteins, both the TGN and the ER were investigated 
for a possible colocalisation with myoferlln. Co-immunolabelling of the 
structures of interest with myoferlin followed by confocal imaging was 
performed. 
Next, myoferlin's possible colocalisation with the cytoskeleton or possible 
dependency on the cytoskeleton in its cellular localisation in normal cells and 
how drug induced re-organisation or disruption of the cellular cytoskeleton affect 
this localisation or mobilisation was investigated. Latrunculin B (LA-B) was used 
in this study to investigate the affects of actin re-organisation and disruption on 
myoferlin cellular expression while Nocodazole, a benzimidazole derivative was 
used to study how myoferlin is affected by microtubule re-organisation. 
In the last section of this chapter, myoferlin's possible dependency on ATP in 
cellular mobilisation and localisation In normal and wounded cells was 
examined by drug-induced ATP depletion of the cells. 
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5.2 Results 
5.2.1 Myoferlin Coiocalisation with TGN and ER 
TGN38 is a type 1 membrane protein that cycles between the TGN and the cell 
surface by endosomal intermediates (Ponnambalam et al., 1994). A unique 
motif on the protein's cytosolic domain is responsible for the internalisation from 
the plasma membrane to the TGN through endosomes (Humphrey et al., 1993), 
while its movement back to the cell surface is through exocytotic vesicles 
(Jones et al., 1993). Cells studied for myoferlin coiocalisation with TGN were 
double labelled with TGN38 antibody (1:100, serotec) diluted in FER1L3 
antibody (neat). Alexa 488 and Alexa 546 were used as fluorophores. 
In addition, myoferlin localisation relative to the ER was investigated by labelling 
the ER with the antibody for Protein Disulfide Isomerase (PDI). PDI is a 55 KDa 
ER protein (Brockway et al., 1980). In cells, whether in vivo or in vitro, side 
reactions during folding may lead to inactive protein especially in proteins 
involving disulfide bonds (Buchner & Rudolph, 1991,Hurtley & Helenius, 1989). 
Therefore cells have developed a set of helper proteins like folding catalysts 
and chaperones to guide the polypeptides to a correct structural folding. In this 
context, PDI influences the formation of disulfide bonds in the ER such that PDI 
depleted microsomes in vitro have been shown to accumulate mis-folded 
polypeptides at the translation and translocation of secretory proteins. This 
strongly suggests the role of PDI to be a disulfide bond formation facilitator 
(Bulleid & Freedman, 1988). 
To examine coiocalisation of myoferlin with ER vesicles, cells were labelled with 
PDI antibody (1:750, a kind gift from Dr. A Benham) diluted in FER1L3 antibody 
157 
(neat), and treated with Alexa 488 and 546 as fluorophores. Negative control 
experiments confirmed no cross binding (data not shown). 
TGN38 staining on C2C12 cells resulted in a prominent vesicular staining in 
proximity to the nucleus as reported previously (Roquemore & Banting, 1998), 
while FER1L3 staining was not as vesicular but still present at higher levels 
near the nucleus than the remainder of the cell. Overall, myoferlin staining did 
not substantially colocalise with that of TGN38 (Figure 5.1). Although this 
strongly suggests that myoferlin is not found in or on TGN38 vesicles at the time 
point studied, this study does not rule out other TGN vesicles or the possibility 
of myoferlin being present at a very specific and short time period. 
PDI expression in C2C12 cells was very similar to expression patterns reported 
previously in other cells (Mezghrani et al., 2000). PDI expression, as expected 
from ER distribution in cells, is clustered around the nucleus forming a fine 
network. When images obtained by confocal microscopy of cells double labelled 
with PDI and myoferlin were merged a partial colocalisation of myoferlin and 
PDI was observed in the area surrounding the nucleus. No coiocallsation was 
visible in the rest of the cell (Figure 5.2). These results indicate the presence of 
myoferlin in the ER at one point; however, immunocytochemistry is not an 
accurate enough tool to indicate at which time point of myoferlin's cell cycle this 
protein passes through the ER and how long It resides there. 
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Figure 5.1 Myoferlin colocalisation with TGN38 
C2C12 cells immunolabelled with FER1L3 (neat) and TGN38 (1:100) antibodies 
and imaged by confocal microscopy suggest no substantial colocalisation. 
White arrowheads show TGN38 vesicles which propose no colocalisation when 
merged with that of myoferlin staining. 
159 
Figure 5.1 





Figure 5.2 Myoferlin colocalisation with PDI 
C2C12 cells immunolabelled with FER1L3 (neat) and PDI (1:750). Merged 
confocal images strongly suggest a partial colocalisation at the peri-nuclear 
region (orange colour). 
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Figure 5.2 




5.2.2 Effect of LA-B on Cellular Localisation of Myoferlin 
LA-B is a marine powerful toxin known to inhibit actin polymerisation by forming 
complexes with actin monomers (Specter et al., 1989) therefore resulting in the 
reorganisation of the actin cytoskeleton. Its effects can be seen almost 
immediately after drug application by the disappearance of stress fibres and 
radiating actin fibres. Shortly afterwards, a cloudy, unstructured body thought to 
be short scattered F-actin is reported in treated cells. LA-B is also reported to 
induce a shift of F-actin to G-actin shortly after the introduction of the drug 
(Gronewold et al., 1999). 
Actin destabilising drugs like LA-B are known to result in the production of 
runner-like extensions in addition to resulting in cells losing their mobility and 
polarity at high doses. Although cells stop to divide at this stage, cell growth is 
not affected resulting in large multinucleate cells (Gronewoid et al., 1999). 
The tubulin cytoskeleton is thought not to be affected or destroyed by LA-B but 
rather re-organised at high doses when the cell shape is affected (Gronewold et 
al., 1999). 
In vitro, a narrow range of the toxin (20 nM-200 nM) has been shown to disrupt 
actin filaments resulting in focal aggregates of F-actin (Wakatsuki et al., 2001). 
In this experiment visible changes to the actin cytoskeleton, including focal 
aggregates, were only visible at 150 nM of LA-B or more. 
At 200 nM LA-B, where most but not all of the cellular actin had been 
disintegrated and the appearance of few focal aggregates was visible, 
myoferlin's localisation inside the cell was showing a slightly different pattern to 
that of control cells. At the next higher dose, 250 nM, most cellular actin had 
been broken down and the changes to myoferlin's localisation could be 
examined. 
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Myoferlin appeared to be randomly scattered inside the cell and had lost Its 
distinct pattern of perinuclear subcellular distribution. The subcellular 
distribution of myoferlin also appeared as small aggregates and was grainy in 
texture compared to control cells (Figure 5.3). However, at doses higher than 
250 nM the cells collapsed and the appearance of runner-like extensions was 
visible. 
As a control to myoferlin, Caveolin 3 expression was also investigated in cells 
treated with LA-B. In contrast to myoferlin, Caveolin 3 localisation inside the cell 
did not seem to be affected by the breakdown in the actin cytoskeleton and 
continued to show the regular pattern when compared to control cells. 
Finally, in an attempt to Investigate the affect of the actin cytoskeleton 
breakdown on myoferlin enrichment in response to injury in wounded cells, 
C2C12 cells treated with LA-B were wounded in the presence of dextran. 
Unfortunately, despite repeated attempts this experiment was not successful 
and each time treated cells floated off the coverslips once injured. A possible 
explanation might be that LA-B had resulted in the disintegration of the actin 
cytoskeleton, which in turn resulted in loosening the cell's attachment to the 
growth surface (i.e. coverslip) or that inducing a wound to a cell lacking a 
cytoskeleton might be too much of a stress therefore cells undergo apoptosls. 
5.2.3 Effect of Nocodazole on Cellular Localisation of Myoferlin 
Microtubules are linear protein polymers characterised by their dynamic 
instability (Cassimerls, 1993) and are thought to have a significant role In 
vesicle trafficking (Cole & LIppincott-Schwar, 1995) among other roles. This 
Instability Is divided into two phases: 1) Catastrophe, which Is the switch from 
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elongation to shortening and 2) Rescue, the switch from shortening to 
elongation (Walker et al., 1988). 
Nocodazole was originally developed as a probable anticancer drug, and has 
been shown to induce mitotic arrest in cells and to interfere with dynamic 
instability of microtubules by increasing the time microtubules spend in a 
paused state (Vasquez et al., 1997). 
Visible effects to the tubulin network were slightly noticeable at 25 ng/ml where 
slight aggregates were starting to form. At 50 ng/ml most of the tubulin network 
had broken down and few disoriented tubulin fibres were left. At 60 ng/ml most 
cells had collapsed and rounded up. However, at all the tested doses (< 50 
ng/ml) were cell shape was not affected, myoferlin localisation did not appear to 
be different to that of control cells and continued to show the regular staining 
pattern observed previously (Figure 5.4). 
As a control, similar to that of LA-B experiment, Caveolin 3 localisation was 
investigated in nocodazole treated cells. Caveolin 3 expression did not seem to 
change at the highest doses where cells retained their shape and structure 
when compared to that of control cells. 
5.2.4 Effect of ATP Depletion on Cellular Localisation of Myoferlin 
ATP is known to be involved in several steps of the calcium-dependant 
exocytotic secretion pathway by undergoing hydrolysis to act as a source of 
energy for motor proteins that transport vesicles from the TGN to plasma 
membrane (Martin & Kowalchyk, 1997). Cells were treated with the lowest 
effective dose of ATP depleting reagents ( 0 . 1 % NaNa/ 100 [JM 2-DG) confirmed 
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by the failure to endocytose dextran (Figure 5.5). Unwounded ATP depleted 
cells suggested no evident re-organisation of myoferlin in these cells when 
compared to control cells. However, when ATP depleted cells had plasma 
membrane disruptions induced the confocal images obtained from these cells 
suggested a slight reduction in myoferlin staining in wounded cells when 
compared to control cells and imaged at the same confocal settings (Figure 
5.6). This suggests a possible minor dependency of myoferlin on ATP in its 
mobilisation to sites of plasma membrane disruption. 
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Figure 5.3 Myoferlin expression In LA-B treated cells 
C2C12 cells treated with 0 nM, 150 nM, 200 nM, 250 nM of LA-B were 
immunolabelled with F-actin (1:30) or Myof2 (1:300) or Cav3 (1:300) antibodies. 
At 0 nM i.e. control cells, each of F-actin, myoferlin and Caveolin 3 show normal 
expression patterns. At 150 nM the first visible changes to F-actin is observed 
with the appearance of stress fibres (arrow heads) while myoferlin dramatically 
loses its distinct peri-nuclear staining. At 200 nM more stress fibres are 
prominent in F-actin stained cells and few focal aggregates start to form while 
myoferlin appears grainier in texture. At 250 nM, the highest dose where cells 
retain their shape, focal aggregates (white circles) dominate the cell and very 
few stress fibres remain while myoferlin looses its usual cellular localisation 
pattern and is uniformly distributed. At all four doses Caveolin 3 expression 
seems to be unchanged. 
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Figure 5.4 Myoferlin expression in nocodazole treated cells 
C2C12 cells treated with 0 ng/ml, 25 ng/ml, 35 ng/ml, 50 ng/ml of nocodazole 
were immunolabelied with tubulin (1:100) or Myof2 (1:300) or Cav3 (1:300) 
antibodies. At 0 ng/ml i.e. control cells, tubulin, myoferlin and Caveolin 3 show 
their normal expression patterns. At 25 ng/ml the first visible changes to tubulin 
is seen when tubulin starts to loose its rather spectacular finely weaved 
structure and tubulin appears as short, disorganised strands while no visible 
change in myoferlin and Caveolin 3 expression is observed. At 35 ng/ml the first 
focal aggregates (white circles) start to appear and tubulin starts to breakdown 
while myoferlin and Caveolin 3 seem unchanged. At 50 ng/ml, the highest dose 
where cells retain their shape, very little cellular tubulin remains and tubulin 
focal aggregates dominate the cell. Even at this dose myoferlin and Caveolin 3 
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Figure 5.5 Endocytosis in ATP depleted cells 
C2C12 cells treated with 0.025%-0.2% (w/v) sodium azide (NaNa) and 25 pIVI-
200 [iM 2-deoxyglucose ( 2 - D G ) for 30 minutes were incubated with 5 mg/ml 
Oregon green dextran for a further 30 minutes to study the lowest effective dose 
to inhibit endocytosis here used as an indicator of successful ATP depletion. A) 
Control cells not treated with ATP depleting reagents, B) cells treated with 0 . 1 % 





Figure 5.6 Cell membrane wounding In ATP depleted cells 
A) Cells treated with 0 . 1 % NaNs/100 pM 2-DG and wounded in the presence of 
dextran (here used as an indicator to plasma membrane disruption) show a 
relatively normal enrichment at plasma membrane disruption sites when 
compared to non-ATP depleted and wounded cells (B). 
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Figure 5.6 (A) 
Myoferlin Dextran 
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To summarise this chapter, myoferlin's possible colocalisation with some l<nown 
cytoplasmic vesicles or the cellular cytoskeleton was investigated. Myoferlin 
was analysed for colocalisation with vesicles from the TGN and ER by 
immunocytochemistry using TGN38 and PDI antibodies respectively. TGN38 
and myoferlin did not substantially colocalise with each other giving a distinct 
staining pattern and localisation inside the cell when analysed by 
immunoflorescence and confocal microscopy suggesting that myoferlin is not 
found in or on TGN38 vesicles under the circumstances investigated. However, 
these results do not conclude in any way that myoferlin is not found in the TGN 
at all. Further future experiments can be conducted (see chapter 7) in order for 
myoferlin's presence or absence from the TGN can be concluded. 
ER staining by PDI gave its known distinct pattern in the area adjacent to the 
nucleus as expected from known ER distribution inside the cell and as detailed 
in chapter 3 of this thesis myoferlin also possesses a unique peri-nuclear 
staining in addition to some cytoplasmic staining. Cells double labelled for PDI 
and myoferlin imaged by confocal microscopy showed an overlapping staining 
in the area surrounding the nucleus. This observation suggests that myoferlin 
expressing vesicles do pass through the ER at one stage or another. 
In chapter 3 of this thesis, myoferlin was also shown to partially colocalise with 
AHNAK expressing vesicles at sites of plasma membrane disruption while 
suggesting an independent expression pattern in undisturbed cells. However, 
this was not the case for lysosomes where lysosomes and myoferlin did not 
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seem to colocalise in wild type or wounded cells although both showing an 
increased mobilisation at sites of plasma membrane disruption. 
Although immunocytochemistry is an important tool in investigating the first 
steps of cellular localisation and mobilisation of a protein, it is not the most 
accurate of methods. Deploying more sophisticated methods combined with 
more time and resources can be used to confirm the results observed regarding 
myoferlin possible colocalisation with other cellular vesicles and give better 
details of this process. 
In the second section of this chapter, myoferlin's dependency on two main 
components of the cellular cytoskeleton (actin fi laments and microtubules) for 
its intracellular distribution and localisation was investigated. Results obtained 
from this study strongly suggested that dissociated tubulin network did not seem 
to have any affect on myoferlin's distribution, while in contrast, a dissociated 
actin network seemed to result in the re-distribution of myoferlin inside the cell. 
This was observed as the loss of myoferlin's unique peri-nuclear staining and 
instead a rather uniformly distributed grainy myoferlin staining was seen. These 
results strongly suggest that myoferlin is dependant on actin cytoskeleton for its 
normal cellular distribution. 
Both actin and tubulin cytoskeleton disassembly did not seem to affect the 
cellular localisation of Caveolin 3, which was used as a control in these 
experiments. 
In the last section of this chapter, cells depleted of ATP and wounded were 
used to study whether ATP is a contributing factor to myoferlin's enrichment at 
plasma membrane disruption sites. Although a very slight reduction was 
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observed in cells depleted of their ATP and wounded when compared to control 
cells, these results lack any scientific quantification but most importantly of all it 
is not clear whether the lowest effective dose to inhibit endocytosis has any 
affect on the actin cytoskeleton or not. It is very possible that no noticeable 
difference in myoferlin enrichment at the wound site in ATP depleted cells was 
observed because the lowest effective dose to inhibit endocytosis was not high 
enough to inhibit actins' routine polymerisation and depolymerisation in which 
myoferlin was shown in the previous section of this chapter to be dependant on 
for normal cellular distribution. Further future experiments can be performed to 
confirm these results. 
The work involved in the last three chapters focused on myoferlin and PERILS 
as possible muscular dystrophy associated genes and their possible role in 
membrane resealing post wounding. However, in the next chapter a fresh 
examination of the previously suggested chromosome 10-linked muscular 
dystrophy associated genes is undertaken. 
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6 Chapter Six, Non-dysferlin linked MM 
6.1 Introduction 
In previous chapters, immunoblotting and immunocytochemistry combined with 
confocal microscopy and analysis were used to investigate the distribution and 
expression of myoferlin following membrane injury repair at a cellular level 
which could ultimately give a clue to its possible involvement in muscular 
dystrophy. This approach combined with genetic analysis, resulted in the 
description of a new ferlin protein family member, FER1L5, as reported in 
previous chapters. These two proteins (myoferlin and FER1L5) are closely 
related and their extent of interaction with each other or involvement in 
muscular dystrophy or possibly MM is not fully understood. 
This raises the question of how many more genes are still unidentified that 
might be involved in phenotype variation of muscular dystrophy such of that 
seen in LGMD2B and MM patients or genes that play a role in disease 
progression or genetic modification or even be responsible for non-chromosome 
2-linked MM (i.e. non-dysferlin-linked MM) such as that previously reported by 
Linssen et al (Linssen et al., 1998). 
The number of genes present in the 23cM region that segregated with the 
MMD2 region described in Linssen et al (Linssen et al., 1998) is too many to 
analyse all of them for SSCP, and thus a more rational approach was adopted. 
All of the genes within that region whose known structure or function made 
them strong candidates for analysis were studied. Six genes were selected: 




ARHGAP21 gene was identified by Basseres et al (Basseres et al., 2002). The 
gene consists of 26 exons and is located on the human chromosome 10p12.32. 
Its function is not fully understood but it has been shown to be upregulated in 
brain, muscle and differentiating HL-60 cells and since it belongs to the Rho-
GTPase activating proteins it is thought to have a role as a negative regulator of 
Rho-GTPase signaling pathway related to actin cytoskeleton dynamics, cell 
proliferation, and cell differentiation (Basseres et al., 2002) which makes it a 
strong candidate for SSCP analysis. 
38 out of 40 PGR reactions for this gene were successfully amplified and 
analysed by SSCP (exon 1 and 9d PCR amplifications were not successful). 
Exons 5, 11 , 15, 19, need to be repeated since the number of samples that 
resulted in a clear banding pattern was small compared to the total number of 
samples. For reasons of time and resources, it was only possible that only one 
set of analysis were carried out for each SSCP test. The banding pattern in 
general obtained at the level of analysis adopted seem to be consistent with 
affected and carrier subjects suggesting no polymorphism. 
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Figure 6.1 S S C P gel analysis of ARHGAP21 gene 
Exons 1 and 9d could not be amplified by PGR. However, gel scans of the rest 
of the exons are shown in this figure. From left to right of each gel are two 
affected individuals from family I (lb and Ig) alongside one carrier from family 
one (Id), followed by two affected individuals from family II ( l ib and Ilh) 
alongside one carrier from the same family ( l ie) . In some exons a control 
sample was added. As explained previously both families have been excluded 
from chromosome 2-linked- MM. 
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6.2.2 P R K C Q 
The human PRKCQ gene that encodes PKC-0 (protein kinase C theta) was 
identified by Kofler et a! (Kofler et al., 1998). It is located on the human 
chromosome 10p15 and consists of 18 exons. 
The PRKCQ predominant isotype is expressed in skeletal muscle cells (Osada 
et al., 1992) and was shown to have increased expression in differentiating 
human muscle cells (Chalfant et al., 2000). Its expression in muscle cells and 
elevated expression during differentiation made this gene a strong candidate for 
SSCP screening. 
PRKCQ Is also expressed in haematopoietic tissues, platelets and testis 
(Osada et a!., 1992) and was shown to have a role in T-cell activation and 
regulation of gene expression (Kofler et al., 1998). 
16 out of 17 PCR reactions for this gene were amplified successfully and 
analysed by SSCP (exon 13 PCR amplifications were not successful). 
SSCP analysis of exons 4 and 9 need to be repeated since the exon 4 banding 
pattern was not clear and exon 9 showed some banding inconsistency within 
the panel of samples. In exon 15, the two affected individuals, lib and llh show 
a different banding pattern compared to the carrier, lie, from the same family. 
Repeating this exon in addition to DNA sequencing would clarify if this is a 
polymorphism or not. 
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Figure 6.2 S S C P gel analysis of P R K C Q gene 
Exons 13 could not be amplified by PGR. However, gel scans of the rest of the 
exons are shown in this figure. From left to right of each gel are two affected 
individuals from family I (lb and Ig) alongside one carrier from family one (Id), 
followed by two affected individuals from family II (lib and llh) alongside one 
carrier from the same family (He). In some exons a control sample was added. 
As explained previously both families have been excluded from chromosome 2-
linked- MM. 
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6.2.3 P T P L A 
PTPLA (protein tyrosine phosphatase-like; proline instead of catalytic arginine, 
member A) was first identified by Uwanogho et al (Uwanogho et a!., 1999). It 
maps to human chromosome 10p13-p14 and consists of 7 exons. 
PTPs (Protein tyrosine phosphatises) has three members and are thought to 
mediate the dephosphorylation of phosphotyrosine, to be involved in signal 
transduction, ceil growth, differentiation, and oncogenic transformation. 
PTPLA is expressed in the developing and adult cells of the heart, skeletal 
muscle, liver and lungs. The early expression pattern of this gene and its 
continual expression in adult tissues suggest that it may have an important role 
in the development, differentiation, and maintenance of a number of different 
tissue types (Uwanogho et al., 1999) which made it a strong candidate for 
SSCP screening. 
5 out of 6 PGR reactions for this gene were successfully amplified while exon 1 
PGR amplifications were not possible. Exons 2, 3/4 and 7 need to be repeated 
since some samples show a variable banding pattern while exons 5 and 6 tend 
to show a consistent banding suggesting no polymorphism. 
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Figure 6.3 S S C P gel analysis of PTPLA gene 
Exons 1 could not be amplified by PGR. However, gel scans of the rest of the 
exons are shown in this figure. From left to right of each gel are two affected 
individuals from family I (lb and Ig) alongside one carrier from family one (Id), 
followed by two affected individuals from family II (lib and Ilh) alongside one 
carrier from the same family (lie). In some exons a control sample was added. 
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6.2.4 R A B 1 8 
RAB18 was first identified in humans by Schafer et a! (Schafer et al., 2000). It 
localises to chromosome 10p12.1 and consists of 7 exons. It is a member of a 
family of Ras-related GTPases that regulate membrane trafficking in organelles 
and transport vesicles. 
Rab18 is thought to be a component of Lipid droplets (LDs). Lipid droplets (LDs) 
are organelles that store neutral lipids, but their regulatory mechanism is not 
well understood. The function of RAB18 is still not properly understood but it is 
thought that it might have a role in regulating LD-associated membrane 
formation, that are involved in mobilizing lipid esters stored in LDs (Ozeki et al., 
2005) or may relate to inflammation and some kinds of tumour (Dou et al., 
2005). 
All PGR amplifications for this gene were successful and were subjected to 
SSCP analysis. Out of the 7 exons, two need to be repeated (exon 3 and 6) but 
overall the general banding pattern obtained from these 5 exons indicates no 
evident polymorphism. 
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Figure 6.4 S S C P gel analysis of RAB18 gene 
Gel scans of RAB18 exons analysed by SSCP are shown in this figure. From 
left to right of each gel are two affected individuals from family I (lb and Ig) 
alongside one carrier from family one (Id), followed by two affected individuals 
from family II (lib and llh) alongside one carrier from the same family (lie). In 
some exons a control sample was added. As explained previously both families 
have been excluded from chromosome 2-linked- MM. 
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Ankyrin repeat domain 26 (ANKRD26) or otherwise referred to as KIAA1074 is 
a protein of unknown function. It localises to the human chromosome lOpter-
q22.1 and has 34 exons. It consists of several ankyrin repeat domains, in 
addition to a myosin tail domain. 
Ankyrin repeats are protein-protein interaction motifs composed of tandemly 
repeated modules of amino acids and are mainly found in eukaryotic proteins 
with diverse functions such as transcriptional initiators, cell-cycle regulators, 
cytoskeletal, ion transporters and signal transducers (Bork, 1993). A group of 
muscle ankyrin repeat proteins are thought to be involved in muscle stress 
response pathways (Miller et al., 2003). In addition the ANKRD26 gene is 
thought to contain sequences similar to those found in the myosin tail domain 
and since myosin fibres are basic components of a muscle contractile unit, this 
gene was a strong candidate for the SSCP screening. 
PGR amplifications of exons 11, 12, 13, 14, 15, 18, 19, 20, 30, 31, 32, 33, 34 of 
this gene were not possible but all the rest of the exons were successfully 
amplified and subjected to SSCP analysis. Few exons such as 1,2, 3, 16, 22, 
24a, 26 and 27 need to be repeated to obtain and clear banding profile for these 
exons. Exon 2 in particular shows a different banding pattern for the carrier Id, 
therefore repeating this exons' SSCP analysis along with a control sample 
followed by genetic sequencing can clarify if this is a polymorphism or not. 
Interestingly exon 7 showed variable SSCP banding between the two families 
although within each family there is no evident polymorphism between affected 
and carrier subjects. 
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Figure 6.5 SSCP gel analysis of ANKRD26 gene 
Exons 11, 12, 13, 14, 15, 18, 19, 20 could not be amplified by PGR. However, 
gel scans of the rest of the exons are shown in this figure. From left to right of 
each gel are two affected individuals from family I (lb and Ig) alongside one 
carrier from family one (Id), followed by two affected individuals from family II 
(lib and llh) alongside one carrier from the same family (lie). In some exons a 
control sample was added. As explained previously both families have been 
excluded from chromosome 2-linked- MM. 
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6.2.6 FLJ14813 
MASTL (microtubule associated serine/threonine kinase-like) or FLJ14813 
maps to the human chromosome 10p12.1 and consists of 12 exons. Since this 
work was performed mutations in this gene have been shown to cause 
autosomal dominant thrombocytopenia in humans (Gandhi et al., 2003). The 
function of the protein product of the FLJ14813 gene is still unknown. It belongs 
to the Serine/Threonine protein kinase family which contain the protein kinase C 
(PKC) enzymes and since the expression of nearly all PKC isoforms is known in 
human muscle (Itani et al., 2000) this made it a candidate for the SSCP 
screening in this project. 
All PGR amplifications of this gene were done successfully. However, when 
analysed by SSCP few exons (1, 3, 4, 5,8a, 8c, 10, 11) need to be repeated in 
order to obtain a full SSCP profile but SSCP data obtained from the rest of the 
exons suggest no evident polymorphism. 
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Figure 6.6 SSCP gel analysis of FLJ14813 gene 
Gel scans of FLJ14813 exons analysed by SSCP are shown in this figure. From 
left to right of each gel are two affected individuals from family I (lb and Ig) 
alongside one carrier from family one (Id), followed by two affected individuals 
from family II (lib and Ilh) alongside one carrier from the same family (He). In 
some exons a control sample was added. As explained previously both families 
have been excluded from chromosome 2-linked- MM. 
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6.2.7 Caveolin 3 
As detailed in chapter 1 of this thesis, caveolin 3 is characteristically expressed 
in sarcolemma of muscle cells of all types and its expression is elevated during 
myoblast fusion (Tang et al., 1996), Caveolin 3 is also concentrated in 
developing T-tubule system of developing muscle but expressed at lower levels 
in the T-tubules of mature muscle (Parton et al., 1997). Caveolin 3 null mice are 
deficient in sarcolemmal caveolae but do not show evident clinical symptoms of 
LGMD1C even at old age as seen in humans as a result of caveolin 3 mutation, 
but they reveal variably sized muscle fibres, necrotic fibres and myopathic 
changes, indicating that caveolin 3 is needed in skeletal muscle cells for 
caveolar biogenesis (Razani & Lisanti, 2001) therefore making it a strong 
candidate for SSCP screening in non-dysferlin linked MM patients. Caveolin 3 
was screened on a panel of 19 MM patients that were previously excluded by 
Dr. R. Bashir's group for mutations on chromosome 2 and 10. 
Exon 1 sample panel gave a variable banding pattern which needs to be further 
investigated to exclude polymorphism while samples 4 and 5 from exon 2a 
need to be repeated. All samples from exons 2b showed a consistent banding 
pattern although in some lanes the bands were not reproducible when scanned. 
In exon 3, samples 1-9 PGR amplifications failed to work and again samples 15, 
16 and 17 were not reproducible when gels were scanned 
As explained earlier for reasons of resources and time it was only possible to 
conduct SSCP analysis once for each exon studied but in exons where PCR 
amplifications were not possible, redesign of primers combined with more time 
to optimise the PCR conditions could lead to successful amplification of these 
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exons in the future. However, in few other exons that were successfully 
amplified by PCR and analysed by SSCP, one or more of the samples need to 
be repeated either because their banding pattern was detectable by eye but 
have not been reproduced when the gels were scanned or because some lanes 
appeared to show differences in banding patterns when compared to the rest of 
the samples from the same exon. Although these samples need to be repeated 
because of apparent banding differences but the banding pattern in general 
obtained at the level of analysis adopted seem to be consistent with affected 
and carrier subjects suggesting no evident polymorphism. 
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Figure 6.7 S S C P gel analysis of Caveolin 3 gene 
Caveolin 3 SSCP analysis was carried out on 19 MM patients tiiat were 
excluded for chromosome 2 and 10 mutations. Exon 1 resulted in variable 
banding pattern which needs to be further investigated while samples 4 and 5 
from exon 2a need to be repeated. All samples from exons 2b showed a 
consistent banding pattern although in some lanes the bands were not 
reproducible when scanned. In exon 3, samples 1-9 PGR amplifications failed to 
work and again samples 15, 16 and 17 were not reproducible when gels were 
scanned. 
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The experiments carried out in this chapter aimed to take a further insight to 
previous evidence that suggested the existence of a second gene responsible 
for MM, since not all MM patients showed linkage to chromosome 2. 
In brief six genes located in or near the candidate region on chromosome 10 
where chosen on the basis of their structure or function to be analysed by 
SSCP on affected and carrier individuals from two Dutch families excluded from 
linkage to chromosome 2. 
In addition, 19 patients excluded from linkage to chromosome 2 and 10 were 
screened by SSCP on the caveolin 3 gene. 
At the level of analysis adopted, there was no clear disease associated with 
polymorphism in these genetic loci. There are limitations in this data which 
preclude a definitive conclusion. Our approach was to examine polymorphism in 
the coding regions of the gene, as our hypothesis for disease associated 
mutation would be one of a change in structure of the gene product, but one 
possibility is that mutations in non-coding regions, potentially associated with 
changes in levels of expression or alternative splicing could still be present. In 
addition, although the vast majority of the coding regions of the six genes were 
analysed, there remains a possibility that mutations in those exons which could 
not be amplified remain to be detected. If further time and resource were 
available, the analysis of these exons would be completed. Finally, although 
the rationale for selecting the six candidate genes makes it more likely that they 
would contain the genetic mutations if present, there remain >100 other genes 
in this region of the chromosome, and these await further study. 
219 
7 Chapter Seven, Discussion 
The objectives of this project were to conduct studies on muscular dystrophy 
associated genes. As explained in hypothesis section of chapter one of this 
thesis, one of these genes is myoferlin. Therefore one objective of this study 
was to investigate whether myoferlin might have a role in vesicle fusion 
similar to that of dysferlin and therefore be an essential component in 
membrane repair and other cellular functions of muscle cells such as 
differentiation. Other objectives of this study were to identify the genes that 
are thought to be responsible for MM genetic heterogeneity (i.e. in non-
dysferlin-linked MM) such as that reported by Linssen et al (Linssen et al., 
1998). 
The results in the first part of this thesis have strongly suggested that 
FER1L3 is a myoferlin specific antibody and that myoferlin like dysferlin 
(Bansal et al., 2003) is enriched at plasma membrane disruption sites. 
However, further future experiments can be performed to enforce these 
findings. Although silencing mRNA, for example, to generate myoferlin-null 
cells is an arduous and time consuming method but generating myoferlin-null 
cells in the future and comparing FER1L3 antibody signal in these cells to 
wild type to see whether a total abolishment of signal from FER1L3 is 
observed or not would confirm the specificity of FER1L3 antibody. 
In this project manual cell wounding combined with immunocytochemistry 
and confocal analysis were used to demonstrate myoferlin's enrichment at 
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plasma membrane disruption sites. However, another way to confirm that 
myoferlin's enrichment at the wound site is a specific response is to generate 
a GFP-myoferlin construct. Although GFP tagging has some disadvantages 
including the rate of successful transfection, the issue of GFP fusion proteins 
being generally over-expressed relative to endogenous proteins, or that the 
GFP tag might affect protein function but generating a GFP-myoferlin 
combined with live cell imaging and laser induced wounding could shed more 
light into myoferlin's localisation and mobilisation inside the ceil and paint a 
clearer picture of what happens to myoferiin when plasma membrane 
disruptions are induced. A GFP-myoferlin construct was provided through 
collaborations but achieving a successful transfection level during the limited 
time of this project was not possible. 
Another way of monitoring myoferlin's mobilisation during and after the 
induction of plasma membrane disruptions would be live cell imaging 
combined with laser induced wounding (Bansal et al., 2003) which can be 
used in studying plasma membrane repair or vesicle fusion at the site of 
plasma membrane disruption in cells lacking myoferiin or cells lacking both 
dysferlin and myoferiin. 
As explained earlier in this project cell wounding was induced using a needle 
or glass beads. Therefore, most of the time only wounded cells could be 
distinguished from others rather than the specific site of injury in an individual 
cell. However, laser induced wounding similar to that used in confirming 
dysferlin's localisation to the injury site (Bansal et al., 2003) can give a more 
accurate answer to myoferlin's response to plasma membrane disruptions. 
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This method was successfully used in dysferlin-deficient and wild type 
muscle fibres where individual muscle fibres were injured using a multi-
photon laser and imaged consecutively to show dysferlin enrichment at 
plasma membrane disruption sites (Bansal et al., 2003). 
Immunogold labelling of myoferiin can also be a valuable tool in studying 
myoferlin's localisation and mobilisation, giving a very high resolution and 
accuracy especially compared to immunoflorescence. This method was used 
successfully in localisation of caveolin 1 in vascular smooth muscle cells 
(Robenek et al., 2003). Since it is known that perfecting the method for a 
specific antigen may need considerable time and resources immunogold 
labelling was not an option during this project. However, investing time and 
resources into this method can lead to a better understanding of myoferlin. 
Laser capture micro-dissection in single cells (Benoyahu et al., 2005) or Real 
Time PGR in a group of cells (Sanchez et al., 2006) is another approach for 
future work since in requires a vast amount of time to set up in addition to 
resources. Laser capture micro-dissection has been used to successfully 
used to examine gene expression profiling in individual skeletal muscle cells 
(Benoyahu et al., 2005) suggesting that it could also be applied in future work 
in relation to myoferlin expression. This method will determine if even a 
sudden and one-off cell membrane injury induces the immediate transcription 
and translation of myoferlin therefore resulting in the enrichment seen at the 
site of plasma membrane disruption or if this enrichment is only the result of 
redistribution of the already expressed myoferlin inside the cell since it has 
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been shown that cells that undergo repeated cycles of plasma membrane 
disruption such as cells of mdx mice have upregulated myoferlin expression 
(Davis e ta l . , 2000). 
In a very recent study, Myof2 antibody was used to demonstrate that 
immunoreactivity of this anti-myoferlin antibody in dysferlin deficient muscles 
was only slightly weaker in intensity compared to controls. In addition, 
immunoblot analysis showed that myoferlin expression was similar in 
dysferlin-deficient muscle when compared to normal muscle. These results 
suggest that although myoferlin is upregulated in dystrophin-deficient muscle, 
the compensatory over-expression of myoferlin is not detected in dysferlin-
deficient muscle (Inoue et al., 2006). 
In the second part of this research the addition of a new member of the DysF 
ferlin protein family, named PERILS was reported as a part of this study's 
objective of studying muscular dystrophy associated genes. Although the 
results strongly suggested that PERILS is not a pseudogene and that like the 
other two members of the DysP ferlins its expression is elevated during 
myoblast differentiation, its involvement in muscular dystrophy is unknown 
and needs further investigation. The PERILS antibody used in this study did 
not give positive results by immunocytochemistry at the time these 
experiments were conducted and the results obtained could not be confirmed 
by confocal microscopy analysis. 
Generating another PERILS antibody or the use of in situ hybridization can 
be the first steps in a better understanding of PERILS and to confirm the 
results reported in this project. In addition to similar experiments to those of 
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myoferlin can be carried out to study FER1L5s cellular localisation and 
response to plasma membrane disruptions. In situ hybridisation has been 
successfully used in human skeletal muscle fibres to detect myosin heavy 
chain expression at the protein and mRNA level and could have similar 
implications in myoferlin's study (Serrano et al., 2001). 
Generating a GFP-FER1L5 construct like that of myoferlin can provide a 
useful tool in understanding the role of FER1L5. Generating FER1L5-null 
mice can be problematic in terms of time needed or for example if the 
absence of the FER1L5 gene proves to lack a phenotype or is lethal, but 
either method, if successful, can clarify the role of FER1L5 at cellular and 
muscular function in general and help us understand the need for three 
highly similar proteins and their possible compensatory role in each others 
absence. 
Recently a new sequence, also named FER1L5 was submitted on the 
National Centre for Biotechnology Information website. It is located on the 
human chromosome 8q24.13 and so far nothing is known about its function. 
This opens the possibility to the addition of a sixth member to the ferlin 
protein family and as research continues on this field the addition of more 
members is likely. 
In the third section of this project, myoferlin's possible colocalisation with 
other cellular structures was investigated. Myoferlin was found to be partially 
colocalising with vesicles from the ER. This could not be further investigated 
at the time of this project but future work by immunogold labelling or live cell 
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imaging can help in understanding myoferlin's vesicle circulation inside the 
cell. These techniques can also be used to study what happens to myoferlin 
which is found at the site of plasma membrane disruption post recovery, 
whether these vesicles are degraded, recycled or simply redistributed into the 
cell is still unclear. 
Another experiment for future work would be high resolution fractionation. 
Although density gradient fractionation on cellular membranes was 
performed early in this project, the results did not give conclusive results to 
where exactly myoferlin would be found. A high resolution fractionation 
combined with the use of a cell cracker (Rooney & Meldolesi, 1996) instead 
of homogenising cells using a hand-held homogeniser, such as the one used 
earlier in this project could clarify any possible colocalisation with other 
cellular compartments and confirm the partial colocalisation reported here 
with the ER. 
High resolution fractionation could also be performed on cells pre-treated 
with LA-B and compared to untreated cells to confirm the change in 
distribution of myoferlin seen by immunocytochemistry in cells treated with 
LA-B. 
And finally, the SSCP analysis performed in the last section of this thesis in 
search of MMD2 could benefit from future work. Revisionary work could lead 
to excluding some genes from the MMD2 candidate list and take us a step 
closer to identifying the MMD2 gene. However, a very recent study reported 
the identification and characterisation of a novel dysferlin transcript named 
DYSF_v1. This transcript differs from the currently known dysferlin transcript 
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in the sequence of the entire first exon which spans 232 bases. The first 
exons of DYSF_v1, is 85% homologous with the first exon of the mouse 
dysferlin and is derived from a region within intron 1 of the human dysferlin 
gene, driven by a distinct promoter and therefore has significantly closer 
homology to mouse dysferlin than the currently known human dysferlin. The 
expression of DYSF_v1 transcript appears to be lower than that of the 
currently known transcript of dysferlin in both skeletal muscle (23%) and 
blood (12.6%) (Pramono et al., 2006). The identification of the new dysferlin 
transcript may hold the key to those non-dysferlin MM cases, as all previous 
screenings and genetic analysis focused on the currently known transcript. It 
may be that these non-dysferlin MM patients have a mutation in the new 
dysferlin transcript DYSF_v7. 
Dysferlin associated proteins such as AHNAK and annexins A l and A2 could 
be strong candidates for SSCP screening in MM patients excluded for 
chromosome 2 linkages. AHNAK is thought to be a candidate for SSCP 
screening because of its predominant expression in muscle and contractile 
cells (Gentil et al., 2003) and expression at the plasma membrane and its 
suggested regulatory role in Ca^* homeostasis. Although AHNAK-null mice 
and ES cells showed no difference to wild type mice and cells, leading to the 
conclusion that AHNAK by itself had minimal or no affect on cell adhesion, 
tumorigenisis, proliferation and differentiation or overall mouse development 
(Kouno et al., 2004) but the possibility that this gene could have a role as a 
modifier gene in non-dysferlin MM has not been eliminated yet. 
Annexins A l and A2 are predicted to have a role in fusion and aggregation of 
intracellular vesicles in response to plasma membrane disruptions, and a role 
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in membrane trafficking and transmembrane channel activity (Lennon et al., 
2003) and are therefore candidates for SSCP screening in non-dysferlin MM 
patients. Indeed, a very recent study showed that using an inhibitory 
antibody, a dominant negative mutant protein or a peptide competitor disrupt 
the function of annexin A l , resulting in defective membrane repair. In 
addition annexin A l was found to be upregulated in LGMD2B and MM 
patients. These results suggest that annexin A l is a requirement for 
successful plasma membrane repair by initiating homotypic and exocytotic 
membrane fusion events of resealing (McNeil et al., 2006). 
Overall this project was aimed at studying genes and their proteins that might 
have a role or associated with muscular dystrophy or in specific MM. 
Although the major bulk of this project was focused on myoferlin, its 
expression and role in membrane repair as a consequence of the curiosity 
raised by the attention given to its highly homologous protein, dysferlin which 
had left us with little information about myoferlin, but future work could shed 
more light on the third member of the DysP ferlin, PERILS. 
Identifying the complete set of genes involved in phenotypic variability of MM 
and understanding their role and their protein products in disease 
progression could have future therapeutic implications such as gene therapy 
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DNase Deoxyribonuclease 
EDTA Ethylenediaminetetraacetic acid 
EGTA Ethylene-bis(oxyethylenenitrilo)tetraacetic acid 
ER Endoplasmic Reticulum 
F-actin Filamentous actin 
FBS Foetal Bovine Serum 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
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GFP Green Flourescent Protein 
HDF Human Dermal Fibroblasts 
HEPES N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) 
HMEM HEPES-buffered minimal essential medium 
HRP Horseradish peroxidase 
Kb Kilobase 
KDa KiloDalton 
LA-B Latrunculin B 
LGMD Limb Girdle Muscular Dystrophy 
LGMD2B Limb Gridle muscular dystrophy type 2B 
MM Miyoshi Myopathy 
MP Milk Powder 
mRNA Messenger RiboNucleic Acid 
MW Molecular weight 
NaNs Sodium azide 
NRK Normal Rat Kidney 
oilgo(dT) Oligodeoxythymidylic acid. 
PAC PI derived Artificial Chromosome 
PBS Phosphate buffer saline 
PKA protein Kinase A 
PKC protein Kinase C 
RlPA RadiolmmunoPrecipitation Assay Buffer 
RNA Ribonucleic acid 
RT Room Temperature 











Sodium dodecyl sulfate 
Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis 
Streptolysin O 
Soluble N-ethylmaleimide-sensitive fusion (SNF) 
attachment protein (SNAP) receptors 
Sulforhodamine 101 
Single strand conformational polymorphism 
Tris Buffer Saline 
N,N,N',N'-Tetramethylethylenediamine 
Polyoxyethylene(20) sorbitan monolaurate 
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Mowial 
HES buffer 







2.4 g Mowial 4.88, 6 g glycerol, 6 ml H 2 0 , 12 ml 0.2 M 
tris base pH8.5, 10 pi 2 mg/ml DAPI 
255 mM sucrose, 20 mM HEPES, 1 mM EDTA, pH 7.4. 
1.5 g SDS, 3.75 ml 1 M tris pH6.8, 0.015 g DTT, 7.5 ml 
glycerol, 3.75 ml H 2 0 
23.93 mM Tris, 193.15 mM glycine, 20% Methanol, pH 
9.25. 
1 % powdered milk, 0.2% Tween-20 in PBS. 
5% fat free powdered milk (Tesco), 0.2% Tween-20 
(Sigma) in PBS 
50 mM Tris HCI pH 8, 150 mM NaCI, 1 % NP40, 0.5% 
sodium deoxycholate , 0 . 1 % SDS 
30 ml Hydrolink-MDE (AT Biochem, USA), 3.6 ml lOx 
TBE, 6 ml 50% glycerol, 360 pi 10% APS, 55 pi TEMED, 
20.4 ml H2O 
95% v/v formaldehyde, 5% v/v 20 mM EDTA, 0.05% 
xylene, 0.05% bromophenol blue 
Tank buffer 
10x TBE 
SSCP solut ioni 
SSCP solution2 
3.03 g Tris base, 14.41 g glycine, 1 g SDS in 1 L H2O 
108 g Tris base, 55 g Boric acid, 40 ml of 0.5M EDTA in 
1L H2O 
10% ethanol v/v, 0.5% acetic acid v/v in 1L H2O 
0 . 1 % w/v silver nitrate in H2O 
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SSCP solutions 1.5% w/v sodium hydroxide, 0.15% v/v formaldehyde in 
H2O 
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10 Appendix 2 
Showing primer sequences of GAPDH, dysferlin, myoferlin, Otoferlin and 
FER1L5 sequences used in PGR of cDNA extracted from different stage of 
myoblast differentiation. 
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Primer Sequence Product 
GAPDH _F 5 -AAG GTC ATC CCA GAG CTG AAC GG-3 190bp 
GAPDH _R 5 -ACA ACC TGG TCC TCA GTG TAG CC-3 
Dysferlin_F 5 -CTG GAG AAG GGG GTG CAG -3 150 
Dysferlin_R 5 -TGA AAA TAA CGT GAT TCC CAA G -3 
Myoferlin_F 5 -CAA AGC CAT GGA CCC TCT TA -3 200 
Myoferlin_R 5 -GTC AAG CTT GGG GTT CAT GT -3 
Otoferlin_F 5 -TCT GGT TCC TGA ACC CAC TC -3 130 
Otoferlin_R 5 - AGG CAA AAT ACG CAG CAG-3 
FER1L5_F 5 -ATG ACC CCG AGC TAC CTC CT -3 157 
FER1L5_R 5 - TAG GCC CCA AAT GCT TGT AG -3 
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List of primers used in SSCP screening 
This table shows the list of primers used in PGR amplifications in the seven 
genes screened by SSCP in this study. The primers were designed closely 
flanking each exon using the Primer 3 programme. 
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GENE: ARHGAP21 
EXON PRIMER 5-SEQUENCE-3 
1 F GAG GCG AGG GGA GAG TCC 
1 R TGA GAC GGA AAA GAA ACC AGA 
2 F TATTCCCTGGCACGTTGTCT 
2 R GGTAACCCCCAACTTGCAG 
3 F TATCTTTTCACTTTAGGTCTCAAAAA 
3 R GGAATGGCCTTGTGGTTT 
4 F ATCTGGGGAGGTCGATTTG 
4 R AAAGAAATGGGTAGAAAAACATTCA 
5 F AAAGAAATGGGTAGAAAAACATTCA 
5 R TTTAAAGAAGAATATCAGCACCT 
6 F TAACTTCTCTTTGAAGGTGACCGAAT 
6 R TGCTCTATTGATCTATAAAACCCATC 
7 F ACTTCTGAGTTAACTGTTTTTCCATT 
7 R AAATAAAACTTACCACTTGGAGAATGT 
8 F TTTTAGCTTGCCGTTTCCAG 
8 R AGCAAGGAAATGGCTACTGTG 
ga F CCA GTG ACA CCT TCC TCT CA 
9a R TAG GCC CTA CCA GGT TGT GT 
9b F AGC AAA CAG CAA ACC AGT ACA 
9b R TCT GCT CAC TCA CGC CAT AC 
9c F GTA TGG CGT GAG TGA GCA GA 
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9c R GGG AAT TTG GCG AAT AGT GA 
9d F CAG CAG ATC TCA AGC TGT GG 
9d R TCT GTC GTG CTT TGA GAT GC 
9e F GCA TCT CAA AGC ACG ACA GA 
9e R ATG GAG ACG TCA GTG CTC CT 
9f F AGG AGC ACT GAC GTC TCC AT 
9f R ACG CTT GGA GCC ACA GTA AA 
9g F TGG CTC CAA GCG TTG TTA AT 
9g R CGT GGA AGG AGC TTT CAG AG 
9h F TTC CAC GCA TGT CAC AAA AC 
9h R TAG CAG CGT TTT CAC TCG AC 
gi F AGT CGA GTG AAA ACG CTG GT 
9i R TAG TGT CTG ACC CGG TCT CC 
9j F AAG GCA TCA GTC TTA CAT CTT GG 
9j R TGG CAT ATT AGC CAA TGA CTC T 
10 F GGTCATTGAACATTCTGATTTTCC 
10 R CCTTTAGACGTACCGTGGTCA 
11 F AATCTGTTGGCCCTCCTAGC 
11 R TCAAGGTCATGCTGAACACC 
12 F TTTTTCCCCAACAGGTCCTT 
12 R TCAGAAAAATCAGCACAATGTGTA 
13 F GATCGCAGACAGCCAAAAGT 
13 R CTGACACTCAGGGTGGCTTA 
14 F CGAGTTGGTGGAAGTATTCG 
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14 R TGAACACCCACCTCTTCGTT 
15 F GGACACTGGAGTCACTAACAGG 
15 R TCTTGGAATGTATCCTTGCAAAT 
16 F TTTCCTTCAACAGCAAAGCA 
16 R ACCTCAACGATGCCAATTTT 
17 F TGATACCAGTCCCCCAAAAG 
17 R CTGGTGTCTCCTACCCGATT 
18 F TGTTGCAAATTAGTTGAAGAAAGA 
18 R CATATCCAGTTCCACCAAAGG 
19 F CCCTTTGGTGGAACTGGATA 
19 R TCTGGTATCTTTCACGGGAGTT 
20 F TGTTGTGGTTTAAAATTGATCCT 
20 R TTTTCACAATGGATTCAGAGG 
21 F CAGATTCACGATTTGCCTGA 
21 R CTTTTATTGACTATTTGGCATGAA 
22 F GGCAATTTCAGCCTACTTCC 
22 R TGCTGGATGAGCGTTTCTAC 
23 F AATTTTAGCATGACTGGTTTTTCA 
23 R AGCGGACAATAGCAAAGCAG 
24 F TAGACAACAGTGCAGGAGGAAA 
24 R GCTTTCAGCCTAGAGGTCAAGA 
25 F TTCAGCTACTAGTGACTCAACAAAA 
25 R GGAATGCATTTGTGTATCAACC 
26a F CTC TTG CTT CCC AGG GTT CT 
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26a R CTG TTT TCT GCC CAG TGT CTC 
26b F AAA GCA CAG CCT AGC AGC TC 
26b R CTC TTT CAG GAT GGC AAA GC 
26c F TCA CCA ACT CTC AGC TGT CG 
26c R TCT GAG GTG ATG GTG CTG AC 
26d F TTC CAC CAC ATC GTC TGC TA 
26d R CTC CGG CTG CTC TTA GTC AC 
26e F AGC CGG AGA AAT TCT GAA GG 
26e R GGG TTC CTG TTT TTC GGA TT 
26f F CCC ACA TGG AAA ACG AAA AT 
26f R CTC TGC TCA TGC ACT TTC CA 
26g F TTT GGA AAG TGC ATG AGC AG 
26g R TGG AAG AAC TGC CTG TGT TG 
26h F TGC AAC ACA GGC AGT TCT TC 
26h R GAG TGG ACA TAG CCC CAG TTT 
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GENE: PRKCQ 
EXON PRIMER 5-SEQUENCE-3 
1 F CCCAAACAGCGTTTGTCTTT 
1 R CCTGGAAGACCTTGCTTCAT 
2 F TCCTAGAGAACGGGCAGATG 
2 R TGCAACGTTACCCATATTTCTG 
3 F TTCTCTCCTTCTCCCAACCA 
3 R GGTAAAATAAGCTGCATTTGAGG 
4 F TTCTTCCCCTCTCTCTTCCTG 
4 R CAGACAAACTCGTGGCAGAC 
5/6 F AGGGGCCTGAACAAACAGG 
5/6 R TGCACGTCAAAGAGGAGTGTA 
7 F TGCAAGAACATCCAAAGTCG 
7 R CCACTGGACTCACCATCACA 
8 F ATCCGCAAGGCTCTGTCTTA 
8 R GGCACATGCTCCTACCTGTT 
9 F GGTGGGTGGTCTGACTCTCT 
9 R TGCTGATCAGGACAGCTACC 
10 F CACCAGCTTGCATTTTCAGA 
10 R CTCCCGTGCATTAGCTTACC 
11 F TCTTCCTGGCAGAATTCAAGA 
11 R GAGCAGAAGCCATACCTTGG 
12/13 F CAGAGTGAGACCCTGTCTTGG 
12/13 R AAGCCTCTTACGTCGCTCTG 
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14 F CTTCCCCCAGGTTTTATGCT 
14 R AGCACTCGGTGCAATGATTA 
15 F CTCAGGCTGCAATGAGACAA 
15 R TACCTCTGGGGCGATGTAGT 
16 F TTCCTGTCTGCCTTTTGGTT 
16 R GCTCTTGGCTTCGCTTCTTA 
17 F CTCCCTTTCAGCTCTTCGTG 
17 R GCGAGTCCTTACCACTTTCG 
18 F TGGCTGATTTTTCTTCTCTTTC 
18 R GTCTCTGGAGGGGCAAGATT 
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GENE:PTPLA 
EXON PRIMER 5-SEQUENCE-3 
la F GGT CCT GGA TCC CCA GTG 
la R ATG GCG ATG TCG TAG AAG G 
lb F CCT GGC TCA CCT TCT ACG AC 
lb R GTG CAC CGT ATT AGG CAA TG 
2 F TGG CAT TCA GCA AAT CCA TA 
2 R AAC GCT GCT GTA AAC ACA AA 
3/4 F CCT GCA GGC TCA AGT AGA CA 
3/4 R TGC TGA ATG CCA ATG TTG A 
5 F GTA AAG TAA GTA CCT TCA CTG 
5 R TAA GCA TGC ACA GGA CAA G 
6 F TAG CAA TAG ACC TGC AAT GT 
6 R CTA TCT CCC TTC ACT TTT CC 
7 F GGT TAT TCT GGA AAA AGC ACC TT 
7 R TGC CAC ATT TAA CAG GTT TCA A 
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GENE: RAB18 
EXON PRIMER 5-SEQUENCE-3 
1 F AGG AAG GTG GCA GAG GTG 
1 R CCG CTG CAG TTT ACA GTT CC 
2 F TTC AAG TTC CCA ACC TGT CTT T 
2 R AAG GCC AAA GGC AAG AAA AT 
3 F TCT GGT TTT CTT GGT AAT GGA 
3 R CAA ATT GTT CAT TCA CCA CCT C 
4 F ACT GCT GGT CAA GAG AGG TTT 
4 R TTT CAC AGA CTA GGA CAA TCA GAA A 
5 F TTA ATG CTT ATT TAA CAA ATG ACT CC 
5 R ATG CCA AGT GTC TGC CTT CT 
6 F ACA CTT GGC ATT TTG GTT CT 
6 R TTG GCA AAA ACT CCA TTC AA 
7 F TGA ATG ACC TTT TTC CTT GAA 
7 R TGC AAG GTC CCT AAA ATA GCA 
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GENE: ANKRD26 
EXON PRIIVIER 5-SEQUENCE-3 
1 F GATTTTTAGTAAGAAGGGCGAGTC 
1 R TGCGACGCCTATTACCTG 
2 F CCA TCT GAT GCT GAA AGA GC 
2 R GT TTT GAG ACA GTG CAC TAC AG 
3 F AAA GTT GGT TGA TCT ATA CCT TGT TTT 
3 R ACT CCC AGG CTG TAC AAT GC 
4 F CAG CTA CTG TAC CTT TCC AA 
4 R TTC AGC CGA GAATTA TGT A 
5 F ACC AAG AGA AAT TCA CTA TTG GAA G 
5 R ACA TTT TTC TAT ACA TAG CAG TCA 
6 F GGG ACG ACT ATA TGG AGA AGC A 
6 R TTA ATA GTG GAT GAA AGC TCT GAA 
7 F TTC ATG AGA GAG CAC TTT ACC TTA GT 
7 R TTC TAA AGG CTT TCT GGC AAA 
8 F AGT GAA TAA CAC AAG AAT AAG CAG TTT 
8 R GTT TTC TAG AAT GTC CCA AAA CCA A 
9 F AAA AAC AAC TTA CCT TCA TAA GAC CA 
9 R GTA GTA GAA GCA ACA TAT GGC ACT G 
10 F TTT TTG TGC ACT TCA TCA ACA T 
10 R TTT TAA TAG GAA GAA CCA ACA AAG C 
11 F AAG TCA AAG CAT CTC TTT ATG TTT TA 
11 R ATT TGA TAG ATA TGA TGT CCG CAT T 
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12 F AAA ATG AAA TAT AGC TCT TAC CTT CTG 
12 R AGA AAA TCT TTA GCA ATT CAT TCT TT 
13 F GTG TTC TGA ATT GAT CAG CTT GG 
13 R AGA TGT GTT TTA TAT ACC TTC TTG C 
14/15 F TCA AAA ATT TTA ACG TAC TTC CTT CC 
14/15 R CCC TTT TGG TTT TTA GAG TCT CC 
16 F TGG ACT ATG TTA CAT CAT TAA AGC 
16 R GAC TAT ACC TTT TAC CTA ACT GTT CT 
17 F TCA GCT TAC CTA GCA TAC TCT TTA TTT 
17 R TCA TTA AAG GTT GAA GAA GAA AGG A 
18 F GAT TTT ACC TTC CTT CAT CCT CA 
18 R TGT CAT TTC CCA TGG ATT TTT 
19 F ACT GTG CCC AGC CCA CTT TA 
19 R CAT GTT TAC TAT TTG CCT GAA AGG 
20 F TGC AAT GGT CCT ACC TTT ACA C 
20 R ATT TAT TTC ATA GGT CAA AAA CCA A 
21 F AAA ACT AGG CTATAC CTC AAA GA 
21 R TCT TGT TTT CTT CCT GAT ACA GAT TC 
22 F ACA AAG CGG CAT ATC ACA CA 
22 R CAA AAG GAT GTG ATA ATA GTG ATG AA 
23 F AAG GAA ATA GAA ATA CCT CAG AA 
23 R TGT TTT AAA ATT CTG CTC TTG T 
24A F TTT CTT GAT ACT TAC TTC TCT TTC TGC 
24A R GTA TCA AAA TGA ACA AGT TAA AGT GAA 
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24B F TTA TTC ACT TTA ACT TGT TCA TTT T 
24B R CGT GAT CAA AGT GAG ACA TCA 
24c F ACT TTG ATC ACG ATC ATG TAT AGC 
24c R TTA CTT AGA ATT CTC ATA GTC ATG AAG 
25 F ACA TAC TTG ATT TCT GAT TTG AC 
25 R TAT CAG GTT GTT GTG AGA CA 
26 F TGA CTG TGT TCC GAT AAG GTT 
26 R TGT TTT TCT GTG TGC TGC TTT 
27 F TTA TGC CTT CAG GTG TTT GC 
27 R CGA CAG AAA AGT GGC TGA 
28 F ATG AAT GGT TAA AAT GAT CTG AAA T 
28 R TTT TGT TTC AAA GTC TGA AGA TGA 
29 F CTT TAT TTC ACT GTT CAA AGC A 
29 R TGT TTG CCT TTT TAA AAC TTG 
30 F GCT AAC CTG TAA AAA TAG ATT GAC TTC 
30 R TCA TTC AGA TTG ATG ATC TTA CAG C 
31 F TGA CTT ACT TGG TTA GTT TAC TTG ACA 
31 R TGT TTT AGG CAC AAG CAG CA 
32 F AAC CTT GCT CAA GTA GTT CTC CA 
32 R CTT CTG CAA TCT TCA CAG AAC TAA 
33 F TCA TGA AGT TTG GCA ACA TAC C 
33 R ACA TCA TTT CTA TGT TAA TGT CTC TTG 
34 F AAC AAA ATG TCA CAT AAA CAG C 
34 R TAG CTG CTG CTG AAT TGG 
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GENE: FLJ14813 
EXON PRIMER 5-SEQUENCE-3 
1 F GCC GCT GTA TGC TGT CCA 
1 R CCC TTC CTT GCT ACT CGT TG 
2 F CCT GGG CAA GAG AAT GAG AC 
2 R TTT ACT CAC CAA GTA GAC ATT GTT TG 
3 F TGC CAA ATA TTG TAA CTG TAA TGC 
3 R AAG TGG TTA CTG TGA ATA TCT GAG AC 
4 F TGG TTA TCT AAT ATT TGC CTT TTG T 
4 R CTG GCC TGT TGG ATG TTT TA 
5 F TTT TTA GTC AAT GGG AGG TAA AGG 
5 R TGG TGA TCA TGA AGG GGT ATG 
6 F TGG GGA AGG TAA ACC TGT TG 
6 R GCC TGG CCT ACC TTT TCT TTT 
7 F CAT GGA ATT CAA TAT TGT CTC TTC TC 
7 R CCC TCA AAC CTG GCA ATC TT 
8a F AGG AAA GTG ATG AAG CAT TGG 
8a R CTG CTT CCC AAG AAA CTT CC 
8b F GGA ACT TTC TTG GGA AGC AG 
8b R TTT CTG GTG TTT GTT GTT TAT CAG 
8c F AAG GAG AAC ATT GTC AAT TCT TTT A 
8c R TCG ACA CCT TTT GGT GAG GT 
8d F CCT CAC CAA AAG GTG TCG AG 
8d R GCT TAG AGG CAA ATG TCT GTC TT 
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9 F TTT CAC CAT TTT CTA TTC GGT GT 
9 R CAC TTC AAA AAC TCA AGA CAT GC 
10 F TGC TTG CAA CTT TAG CTG TTT C 
10 R CCA CTA TGC CCA GCC AGT AA 
11 F TTT AGA TAT CCC TTG GCC AGA A 
11 R CCC AGC CAG AAC TTG CTA TT 
12 F AAA ACG TCA TCC TCT CTT CAG TG 
12 R TGC AAG TTC ATT CTA TAA CAC AAG G 
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G E N E : C A V E O L I N 3 
EXON PRIMER 5-SEQUENCE-3 
1 F CTC GGA TCT CCT CCT GTG G 
1 R CTC GCA AAC CTG ACA CTC TC 
2a F CCT GCA GGT GGA TTT TGA AG 
2a R CTC TTA ATG CAT GGC ACC AC 
2b F GGT GGT GCC ATG CAT TAA G 
2b R AGC AGC CCC TGT GAA GAA GT 
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